

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	1.	2155658	04-25-1939	Herrman et al.
	2.	3068188	12-11-1962	Beste et al.
	3.	3121042	02-11-1964	Ercoli
	4.	3218283	11-16-1965	Miller
	5.	3887699	06-03-1975	Yolles
	6.	3888995	06-10-1975	Katz et al.
	7.	3913789	10-21-1975	Miller
	8.	3939111	02-17-1976	Schollenberger et al.
	9.	3989816	11-02-1976	Rajadhyaksha
	10.	4009254	02-22-1977	Renold
	11.	4078060	03-07-1978	Benson
	12.	4083973	04-11-1978	Van der Vies
	13.	4161948	07-24-1979	Bichon
	14.	4197316	04-08-1980	Yu et al.
	15.	4299826	11-10-1981	Luedders
	16.	4346709	08-31-1982	Schmitt
	17.	4424363	01-03-1984	Plath et al.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	18.	4440777	04-03-1984	Zupan
	19.	4442094	04-10-1984	Atkinson et al.
	20.	4447562	05-08-1984	Ivani
	21.	4478822	10-23-1984	Haslam et al.
	22.	4496556	01-29-1985	Orentreich
	23.	4557934	12-10-1985	Cooper
	24.	4563473	01-07-1986	Hofman et al.
	25.	4631188	12-23-1986	Stoy et al.
	26.	4663157	05-05-1987	Brock, ED
	27.	4690775	09-01-1987	Schott et al.
	28.	4695465	09-22-1987	Kigasawa et al.
	29.	4699779	10-13-1987	Palinczar, V.
	30.	4704282	11-03-1987	Campbell et al.
	31.	4725439	02-16-1988	Campbell et al.
	32.	4745160	05-17-1988	Churchill et al.
	33.	4767627	08-30-1988	Caldwell et al.
	34.	4780320	10-25-1988	Baker
Examiner Signature			Date Considered	

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	35.	4788062	11-29-1988	Gale et al.
	36.	4791099	12-13-1988	Aroonsakul
	37.	4820724	04-11-1989	Nimni
	38.	4855305	08-08-1989	Cohen
	39.	4863911	09-05-1989	Anderson et al.
	40.	4863970	09-05-1989	Patel et al.
	41.	4906169	03-06-1990	Chien et al.
	42.	4920203	04-24-1990	Tang et al.
	43.	4946870	08-07-1990	Partain et al.
	44.	4954487	09-04-1990	Cooper et al.
	45.	4981696	01-01-1991	Loomis et al.
	46.	5013553	05-07-1991	Southard et al.
	47.	5023252	06-11-1991	Hsieh, D.
	48.	5026692	06-25-1991	Jubo et al.
	49.	5036100	07-30-1991	Deboeck et al.
	50.	5053227	10-01-1991	Chiang et al.
	51.	5059603	10-22-1991	Rubin

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	52.	5071657	12-10-1991	Oloff et al.
	53.	5073545	12-17-1991	Arima et al.
	54.	5116828	05-26-1992	Miura et al.
	55.	5122519	06-16-1992	Ritter
	56.	5208013	05-04-1993	Klein
	57.	5231382	07-27-1993	Tanaka
	58.	5238933	08-24-1993	Catz et al.
	59.	5256652	10-26-1993	El-Rashidy
	60.	5324521	06-28-1994	Gertner et al.
	61.	5326566	07-05-1994	Thornfeldt
	62.	5326790	07-05-1994	Thornfeldt
	63.	5332577	07-26-1994	Gertner et al.
	64.	5340584	08-23-1994	Spicer et al.
	65.	5340585	08-23-1994	Pike et al.
	66.	5340586	08-23-1994	Pike et al.
	67.	5346901	09-13-1994	Bell et al.
	68.	5362497	11-08-1994	Yamada et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/829,618
Filing Date	April 20, 2004
Inventor(s)	Dudley et al.
Art Unit	1627
Examiner Name	Jean-Louis, Samira
Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	69.	5362886	11-08-1994	Berglund
	70.	5413794	05-09-1995	Suzuki et al.
	71.	5436634	07-25-1995	Kanazawa
	72.	5446025	08-29-1995	Lu, M.F.
	73.	5446070	08-29-1995	Mantelle
	74.	5460820	10-24-1995	Ebert et al.
	75.	5482970	01-09-1996	Kim et al.
	76.	5487898	01-30-1986	Lu et al.
	77.	5589498	12-31-1996	Mohr
	78.	5607691	03-04-1997	Hale et al.
	79.	5610150	03-11-1997	Labrie
	80.	5629019	05-13-1997	Lee et al.
	81.	5629021	05-13-1997	Wright
	82.	5639743	06-17-1997	Kaswan et al.
	83.	5641504	06-24-1997	Lee et al.
	84.	5648350	07-15-1997	DeLignieres
	85.	5651973	07-29-1997	Moo-Young et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	86.	5654337	08-07-1997	Roentsch et al.
	87.	5656286	08-12-1997	Miranda et al.
	88.	5662925	09-02-1997	Ebert et al.
	89.	5665377	09-09-1997	Gonella
	90.	5676956	10-14-1997	Duffy et al.
	91.	5686112	11-11-1997	Liedtke Rainer
	92.	5708038	01-13-1998	Davis
	93.	5716638	02-10-1998	Touitou
	94.	5719197	02-17-1998	Kanios et al.
	95.	5725874	03-10-1998	Oda et al.
	96.	5731303	03-24-1998	Hsieh, D.
	97.	5731339	03-24-1998	Lowrey
	98.	5744162	04-28-1998	Okabe et al.
	99.	5770606	06-23-1998	El Rashidy et al.
	100.	5776923	07-07-1998	Labrie
	101.	5788984	08-04-1998	Guenther et al.
	102.	5780050	07-14-1998	Jain et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	103.	5783208	07-21-1997	Venkateshwaran et al.
	104.	5785991	07-28-1998	Burkoth et al.
	105.	5807568	09-15-1998	Cody et al.
	106.	5807849	09-15-1998	Labrie
	107.	5807957	09-15-1998	Samour et al.
	108.	5837289	11-17-1998	Grasela et al.
	109.	5844103	12-01-1998	Au et al.
	110.	5847128	12-08-1998	Martin et al.
	111.	5849729	12-15-1998	Zoumas et al.
	112.	5855905	01-05-1999	Oettel et al.
	113.	5855920	01-05-1999	Chein
	114.	5863560	01-26-1999	Osborne
	115.	5874074	02-23-1999	Smith
	116.	5877216	03-02-1999	Place et al.
	117.	5880117	03-09-1999	Arnold
	118.	5881926	03-16-1999	Ross
	119.	5882676	03-16-1999	Lee et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	120.	5891462	04-06-1999	Carrara D.
	121.	5902603	05-11-1999	Chen et al.
	122.	5906830	05-25-1999	Farinas et al.
	123.	5908619	06-01-1999	Scholz
	124.	5908638	06-01-1999	Huber et al.
	125.	5932227	08-03-1999	Higo et al.
	126.	5935949	08-10-1999	White
	127.	5942545	08-24-1999	Samour et al.
	128.	5952000	09-14-1999	Venkateshwaran et al.
	129.	5962021	10-05-1999	Hughes, Jr. et al.
	130.	5972377	10-26-1999	Jona et al.
	131.	5981542	11-09-1999	Bigg et al.
	132.	6010716	01-04-2000	Saunal et al.
	133.	6019988	02-01-2000	Parab et al.
	134.	6024974	02-15-2000	Li
	135.	6036977	03-14-2000	Drizen et al.
	136.	6037346	03-14-2000	Doherty, Jr. et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	137.	6046244	04-04-2000	Buyuktimkin et al.
	138.	6051555	04-18-2000	Hadley
	139.	6071531	06-06-2000	Jona et al.
	140.	6075028	06-13-2000	Graham
	141.	6077841	06-20-2000	Sui et al.
	142.	6087362	07-11-2000	EI-Rashidy
	143.	6087368	07-11-2000	Macor et al.
	144.	6103765	08-15-2000	Neal
	145.	6117446	09-12-2000	Place
	146.	6124461	09-26-2000	Shoemaker
	147.	6127363	10-03-2000	Doherty et al.
	148.	6132760	10-17-2000	Hedenstrom et al.
	149.	6133320	10-17-2000	Yallampalli et al.
	150.	6139873	10-31-2000	Hughes, Jr. et al.
	151.	6143746	11-07-2000	Daugan et al.
	152.	6146662	11-14-2000	Jao et al.
	153.	6156753	12-05-2000	Doherty et al.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	154.	6165491	12-26-2000	Grasset et al.
	155.	6172088	01-09-2001	Simpkins et al.
	156.	6187750	02-13-2001	Chein
	157.	6190693	02-20-2001	Kafrissen et al.
	158.	6200593	03-13-2001	Place
	159.	6207694	03-27-2001	Murad
	160.	6214374	04-10-2001	Schmirler et al.
	161.	6221379	04-24-2001	Place
	162.	6224573	05-01-2001	Yeager et al.
	163.	6225299	05-01-2001	Golbs et al.
	164.	6228852	05-08-2001	Shaak
	165.	6238284	05-29-2001	Dittgen et al.
	166.	6241529	06-05-2001	Place
	167.	6248363	06-19-2001	Patel et al.
	168.	6251436	06-26-2001	Drizen et al.
	169.	6266560	07-24-2001	Zhang et al.
	170.	6267984	07-31-2001	Beste et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	171.	6267985	07-31-2001	Chen et al.
	172.	6277884	08-21-2001	de Tejada
	173.	6284234	09-04-2001	Niemiec et al.
	174.	6284263	09-04-2001	Place
	175.	6294192	09-25-2001	Patel et al.
	176.	6294550	09-25-2001	Place et al.
	177.	6299900	10-09-2001	Reed et al.
	178.	6306841	10-23-2001	Place et al.
	179.	6309663	10-30-2001	Patel et al.
	180.	6323242	11-27-2001	Mueller
	181.	6331543	12-18-2001	Garyey et al.
	182.	6342246	01-29-2002	Johnson et al.
	183.	6342250	01-29-2002	Masters
	184.	6395744	05-28-2002	Adams et al.
	185.	6436950	08-20-2002	Achari et al.
	186.	6469016	10-22-2002	Place et al.
	187.	6472425	10-29-2002	Garvey et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS				
Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	188.	6506765	01-14-2003	Gupta et al.
	189.	6579865	06-17-2003	Mak et al.
	190.	6582724	06-24-2003	Hsu et al.
	191.	6593313	07-15-2003	Place et al.
	192.	6980566	12-27-2005	Melick et al.
	193.	7611727	11-03-2009	Taravella et al.
	194.	RE36138	03-09-1999	Suzuki et al.
	195.	2001036483	11-01-2001	Luo et al.
	196.	2002004065	01-10-2002	Kanios
	197.	20010018073	08-30-2001	Dittgen et al.
	198.	20010023261	09-20-2001	Ryoo et al.
	199.	20010033870	10-25-2001	Luo et al.
	200.	20010036183	11-01-2001	Melick et al.
	201.	20010036483	11-01-2001	Luo et al.
	202.	20010051166	12-13-2001	Luo et al.
	203.	20010051656	12-13-2001	Place et al.
	204.	20020013304	01-01-2002	Wilson et al.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	205.	20020034554	03-21-2002	Hsu et al.
	206.	20020183296	12-05-2002	Dudley et al.
	207.	20030018085	06-23-2003	Raoof
	208.	20030050292	03-13-2003	Dudley et al.
	209.	20030087885	05-08-2003	Masini-Eteve et al.
	210.	20030139384	07-24-2003	Dudley
	211.	20030175329	09-2003	Azarnoff et al.
	212.	20030232072	12-18-2003	Dudley et al.
	213.	20040001881	01-2004	Selzer et al.
	214.	20040002482	01-01-2004	Dudley et al.
	215.	20040044086	03-04-2004	Schulze
	216.	20040110732	06-2004	Masini-Eteve et al.
	217.	20050025833	02-03-2005	Aschkenasy et al.
	218.	20050042268	02-24-2005	Aschkenasy et al.
	219.	20050049233	03-03-2005	Dudley
	220.	20050054623	03-10-2005	Dudley
	221.	20050112181	05-26-2005	Dudley et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	222.	20050113353	05-26-2005	Dudley et al.
	223.	20050118242	06-02-2005	Dudley et al.
	224.	20050142173	06-30-2005	Dudley et al.
	225.	20050152956	07-14-2005	Dudley
	226.	20050276842	12-15-2005	Zhang et al.
	227.	20060211664	09-21-2006	Dudley
	228.	20070088012	04-19-2007	Seo
	229.	20070154533	07-05-2007	Dudley
	230.	20070189977	08-16-2007	Zhang et al.
	231.	20070190124	08-16-2007	Zhang et al.
	232.	20070196323	08-23-2007	Zhang et al.
	233.	20070196453	08-23-2007	Zhang et al.
	234.	20070237822	10-11-2007	Malladi
	235.	20070254036	11-01-2007	Brennan et al.
	236.	20080058299	03-06-2008	Dudley
	237.	20080220068	09-11-2008	Masini-Eteve et al.
	238.	20080261937	10-23-2008	Dudley et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Issue/Publication Date	Applicant(s)
	239.	20080317844	12-25-2008	Dudley
	240.	20090258063	10-15-2009	Udagawa et al.
	241.	20100048526	02-25-2010	Taravella et al.

FOREIGN PATENT DOCUMENTS

Exam Initial	No.	Document No.	Publication Date	Country
	242.	AU4998490	09-20-1990	Amway Corp.
	243.	AU9141391	06-25-1992	Theratech Inc.
	244.	CA2419573	03-07-2002	Dudley
	245.	CA2420895	03-07-2002	Dudley
	246.	CA2451725	01-09-2003	van der Hoop
	247.	CA2502607	05-06-2004	Dudley
	248.	CA2624788	04-19-2007	Malladi et al.
	249.	CN100349572C	01-07-2004	Unimed Pharmaceuticals
	250.	DE19517145.4	11-28-1996	Fischer et al.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

251.	DE3238984	10-21-1982	Besins
252.	DE3836862	05-03-1990	Gunther et al.
253.	EP0183492	06-04-1986	Karjalainen et al.
254.	EP0189861	08-06-1986	Showa Denko
255.	EP0196769B1	07-08-1992	University of Rutgers
256.	EP0197753	10-15-1996	Baylor College Medicine
257.	EP0248885	12-16-1987	Hsieh, D.
258.	EP0271983	06-22-1988	Francoeur et al.
259.	EP0332147	09-13-1989	Warner-Lambert
260.	EP0364211	04-18-1990	Azuma et al.
261.	EP0386960	09-12-1990	American Cynamid Co.
262.	EP0483105B1	06-28-1995	Cygnus Therapeutic Systems
263.	EP0491076	06-24-1992	Patel et al.
264.	EP0513832	11-19-1992	Parab
265.	EP0552405	11-25-1998	Lintec Corp.
266.	EP0563813B1	12-01-1999	Hoechst Roussel Pharma
267.	EP0581587A2	02-02-1994	Kobayashi, et al.
268.	EP0672422	09-20-1995	Chi et al.
269.	EP0698393	02-28-1996	Hisamitsu Pharmaceutical Co.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

	270.	EP0737477	10-16-1996	Kuroda et al.
	271.	EP0804926	04-19-1997	Jenapharm Gmbh
	272.	EP0811381	05-02-2003	Carrara, D.
	273.	EP0811381	05-02-2003	Permatech N.V.
	274.	EP0815871B1	07-17-2002	Lintec Corp.
	275.	EP0857488	08-12-1998	Squibb Bristol Myers Co.
	276.	EP1043020	01-11-2000	Daiichi PharmaceuticalCo. Ltd.
	277.	EP1317921	06-11-2003	Besins Intrant Belgique
	278.	EP2004199	12-24-2008	Brennan et al.
	279.	FR2515041	04-29-1983	Besins
	280.	FR2518879	07-01-1983	Besins
	281.	FR2519252	07-08-1983	Besins
	282.	FR2705572	12-02-1994	De Lignieres
	283.	FR2814074	03-22-2002	Gray et al.
	284.	FR8124481	07-01-1983	Besins
	285.	GB1158283	07-16-1969	Foster-Milburn
	286.	GB2109231	06-02-1983	Besins
	287.	GB916778	01-30-1963	Vismara Francesco Spa
	288.	GB941634	01-13-1963	Upjohn Co.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

289.	IL154693	04-15-2010	Unimed; Besins
290.	JP01138288 English Abstract	05-31-1989	Nonogawa
291.	JP08-501529	02-20-1996	Theratech et al.
292.	JP2001-163783	06-19-2001	Shoei Co Ltd
293.	JP2001-522804	11-20-2001	Cellegy Pharmaceuticals Inc.
294.	JP2002212105 (English translation)	07-31-2002	Lion Corp.
295.	JP2002-249425	09-06-2002	Theratech Inc.
296.	JP62011675	08-02-1994	Tezuka
297.	JPH10-87488	06-09-1989	N/A
298.	JPH7-82147	03-28-1995	Dot KK
299.	KR2002013248	05-20-1999	Cellegy Pharma., Inc.
300.	RU2003108500	08-10-2007	Junimed Farmas Jutikals Ink
301.	RU2004112473	05-10-2006	Smirnova et al.
302.	RU2114621	07-10-1998	Majkl
303.	RU2122396	11-27-1998	Andrushina et al.
304.	WO0001351	01-13-2000	Transdermal Technologies Inc.
305.	WO0006144	02-10-2000	Murad
306.	WO0024362	05-04-2000	Univ Virginia Commonwealth

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

307.	WO0040230	07-13-2000	Cedars-Sinai Medical Center
308.	WO0045795	08-10-200	CIPLA Limited et al.
309.	WO0066870	08-10-2000	Lulla et al.
310.	WO0067708	11-16-2000	Univ Texas
311.	WO0074684	12-14-2000	The General Hospital Corporation et al.
312.	WO0076522	12-21-2000	Watson Pharmaceuticals, Inc.
313.	WO0143775	06-21-2001	Luo et al.
314.	WO0151053	07-19-2001	Nexmed Holdings Inc.
315.	WO0152823	7-26-2001	Kanios
316.	WO0154699	08-02-2001	Endorech Inc.
317.	WO0164146	09-07-2001	Radiant Medical Inc.
318.	WO0164167	09-07-2001	Henkel KGAA
319.	WO0172307	10-04-2001	David Gladson Inst.
320.	WO0176608	10-18-2001	Lipp et al.
321.	WO0211768	02-14-2002	Antares Pharma IPL AG
322.	WO0217927	03-07-2002	Unimed Pharmaceuticals
323.	WO0222132	03-21-2002	Gray et al.
324.	WO0251421	07-04-2002	Schulze
325.	WO0347548	06-12-2003	Masini-Eteve et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

326.	WO0623526	03-02-2006	Waters Investments Limited et al.
327.	WO2002017967	03-07-2002	Dudley et al.
328.	WO2003002123	01-09-2003	Solvay Pharmaceuticals
329.	WO2003088974	10-30-2003	Bentley Pharmaceuticals
330.	WO2004037173	05-06-2004	Dudley
331.	WO2005076899	08-25-2005	Amory et al.
332.	WO2006113505	10-26-2006	Clarus Therapeutics
333.	WO2007044976	04-19-2007	Unimed Pharmaceuticals Inc.
334.	WO2007119151	10-25-2007	Besins Healthcare Inc.
335.	WO8703473	06-18-1987	Hsieh, D.
336.	WO9207586	05-14-1992	Beecham Group PLC
337.	WO9207590	05-14-1992	Alza Corp.
338.	WO9215289	09-17-1992	Mantelle
339.	WO9404157	03-03-1994	Lipp et al.
340.	WO9408590	04-28-1994	BTG Pharma Corp
341.	WO9409778	05-11-1994	Merck & Co., Inc.
342.	WO9421230	09-29-1994	Ellis, et al.
343.	WO9421271	09-29-1994	Cellegy Pharma Inc
344.	WO9424125	10-27-1994	Boehringer Ingelheim Italia SPA

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

	345.	WO9427609	12-08-1994	De Lignieres
	346.	WO9428902	12-22-1994	Pfizer Limited et al.
	347.	WO9517896	07-06-1995	Kuroda et al.
	348.	WO9519978	07-27-1995	Laboratories Glaxo Wellcome SA et al.
	349.	WO9616644	06-06-1996	Pfizer Limited et al.
	350.	WO9616657	06-06-1996	Cambell et al.
	351.	WO9620699	07-11-1996	Noven Pharmaceuticals, Inc., et al.
	352.	WO9629056	09-26-1996	Gebro Broschek GMBH
	353.	WO9629988	03-10-1996	Roentsch et al.
	354.	WO9636339	11-21-1996	Beth Israel Hospital
	355.	WO9703985	02-06-1997	Daugan, et al.
	356.	WO9724148	07-10-1997	Chen, et al.
	357.	WO9739743	10-30-1997	Chien et al.
	358.	WO9740792	11-06-1997	Theratec Inc.
	359.	WO9741865	11-13-1997	Azumpharma GMBH
	360.	WO9743989	11-27-1997	Portman, et al.
	361.	WO9806404	02-19-1998	Carey et al.
	362.	WO9808547	03-05-1998	Seikisui Chemical Co. Ltd.
	363.	WO9817215	04-30-1998	Sherwood Medical Co.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

364.	WO9818417	05-07-1998	Venkateshwaran et al.
365.	WO9824451	06-11-1998	Biotechnology General Corp.
366.	WO9832465	07-30-1998	Moon et al.
367.	WO9834621	08-13-1998	Rako
368.	WO9837871	09-03-1998	Minnesota Mining & Mfg
369.	WO9840076	09-17-1998	Sschering AG
370.	WO9850016	11-12-1998	Galen Chemicals Ltd
371.	WO9855076	12-10-1998	Jedco Products LLC
372.	WO9913812	03-25-1999	Population Council Inc.
373.	WO9920257	04-29-1999	Marochem Corporation
374.	WO9921558	05-06-1999	Vivus, Inc.
375.	WO9932107	07-01-1999	Danbiosyst UK
376.	WO9933458	07-08-1999	Daiichi Seiyaku Co.
377.	WO9933859	07-08-1999	Tanabe et al.
378.	WO9966870	12-29-1999	Lavipharm Laboratories, Inc.
379.	WO9966909	12-29-1999	Queens University at Kingston

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

OTHER DOCUMENTS (Non-patent literature)

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	380.	Abbasi A, Mattson DE, Cuisinier M, Schultz S, Rudman I, Drinka P, Rudman D: Hyposomatotropinemia and hypogonadism in hemiplegic men who live in nursing homes. Arch Phys Med Rehabil 75:594-9, 1994.	
	381.	Abbasi AA, Drinka PJ, Mattson DE, Rudman D: Low circulating levels of insulin-like growth factors and testosterone in chronically institutionalized elderly men. J Amer Geri Soc 41:975-82, 1993.	
	382.	ABCNews.com: Testosterone Patch Increases Women's Sex Drive, http://abcnews.go.com/sections/living/DailyNews/testosterone990615.html . September 8, 2000.	
	383.	ABDU, et al., Coronary Risk in Growth Hormone Deficient Hypopituitary Adults: Increased Predicted Risk is Due Largely to Lipid Profile Abnormalities, Clinical Endocrinology, Vol. 55, pp. 209-216 (2001).	
	384.	Abitbol, et al., Sex Hormones and the Female Voice, J Voice, Sep. 1999; 13(3): 424-46.	
	385.	Abraham G. E., Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle, J. Clin. Endocrinol. Metab. 1974; 39:340-346.	
	386.	Acrux -Axiron, a 2% testosterone solution, Executive Summary. No date available.	
	387.	Adami, et al., Effect of Hyperandrogenism and Menstrual Cycle Abnormalities Bone Mass and Bone Turnover in Young Women, Clinical Endocrinology (OXF), Vol. 48, No.2, 169-173 (February 1998).	
	388.	Additional Experimental Results Clinical Data, filed as Annex 2 in GE10611/01	
	389.	ADESUYI, et al., Coronary Heart Disease/Myocardial Infarction: Testosterone Increases Human Platelet Thromboxane A ₂ Receptor Density and Aggregation Responses, Circulation, Vol. 91, No. 11, pp. 2742-2747 (June 1, 1995).	
	390.	Adult female postmenopausal subject. Stedman's Medical Dictionary, 25th Edition.	
	391.	Adult female premenopausal subject. Stedman's Medical Dictionary, 25th Edition.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	392.	ADVANCE Collaborative Group, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. <i>N Engl J Med.</i> 2008 Jun 12;358(24):2560-72. <i>Epub</i> 2008 Jun 6.	
	393.	AGARWAL, et al., Differential Response of Prostate Specific Antigen to Testosterone Surge after Luteinizing Hormone-Releasing Hormone Analogue in Prostate Cancer and Benign Prostatic Hyperplasia, <i>BJU Intl.</i> , Vol. 85, pp. 690-695 (2000).	
	394.	Ahmed, et al., Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism, <i>J Clin Endocrinol Metab</i> , Mar. 1988; 66(3): 546-51.	
	395.	Buhling et al., AIPPI Summary Report on Selection Inventions - The Inventive Step Requirement, Other Patentability and Scope of Protection (2009).	
	396.	Akimoto, et al., Relationship Between Diurnal Rhythm of Serum Testosterone and Prostatic Markers (PSA and PAP) in Untreated Prostate Cancer, <i>Urology</i> , Mar. 1994; 43(3): 337-41.	
	397.	Albertson's, Inc. Enters Agreement with Men's Health Network to Support National Men's Health Awareness Campaign: 'Time Out for Men's Health' Encourages Men to be Checked by a Doctor More Regularly, <i>Yahoo!Finance.com</i> (August 29, 2002).	
	398.	Alexander, et al., Testosterone and Sexual Behavior in Oral Contraceptive Users and Nonusers: A Prospective Study, <i>Hormones and Behavior</i> , Vol. 24, No.3, pp. 388-402 (September 1990).	
	399.	ALEXANDER, et al., Androgen-Behavior Correlations in Hypogonadal Men and Eunuchal Men, <i>Hormones and Behavior</i> , Vol. 33, pp. 85-94 (1998).	
	400.	Alexander, et al., Sex Steroids, Sexual Behavior, and Selection Attention for Erotic Stimuli in Women Using Oral Contraceptives, <i>Psychoneuroendocrinology</i> , 1993; 18(2): 91-102.	
	401.	Alivizatos, et al., Update of Hormonal Treatment in Cancer of the Prostate, <i>Anticancer Drugs</i> , Jun. 1993; 4(3):301-9.	
	402.	Allen, Methyltestosterone 6-mg/g Gel, <i>Int'l J. Pharm. Compounding</i> , Vol. 2(1), pg. 52 (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	403.	Allen, Testosterone Topical Vaginal Cream, U.S. Pharmacist, pp. 54, 56, 58, (January 22 2000).	
	404.	Almeida, Sex Playing with the Mind. Effects of Oestrogen and Testosterone Mood and Congition, Arq Neuropsiquiatr, Sep. 1999; 57(3A): 701-6.	
	405.	Alternative to Viagra For Women!, www.mdhealthline.com (Downloaded Aug. 7, 2000).	
	406.	American association of Clinical Endocrinologies (AACE) medical guidelines for clinical practices for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract 2002; 8(6):439-456	
	407.	Anabolic Steroid Boosts Weight, GMHC Treatment Issues, vol. 10, No. 9 (Sep. 1996) (no authors listed)	
	408.	Anabolic Steroids, Project Inform Hotline Handout, www.projinf.org. (Downloaded Oct. 8, 1998).	
	409.	Anabolic Steroids, Project Inform, Anabolic Steroids Quick Sheet (Dec. 1997).	
	410.	Anabolic Steroids--A Simple Facts Sheet From The Network, www.network/simple/steroids (Downloaded Oct. 27, 1998).	
	411.	Anawalt, Potential Expanded Indications for Androgen Treatment, The Endocrine Society, No. 166 (ENDO 2000).	
	412.	Anderson et al., The effects of exogenous testosterone on sexuality and mood of normal men, J. Clin. Endocrinol. Metab., 1992, 75(6):1503-7	
	413.	ANDERSON, et al., Haemostatic Effects of Supraphysiological Levels of Testosterone in Normal Men, pp. 693-697 (1995).	
	414.	Andro Gel, Netrition, http://www.netrition.com/andro_gel_page.html (1997-1998).	
	415.	Androgel (testosterone gel 1%), A Double-Blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of AndroGel, as and Adjunct to Hypoglycemic Therapy, in the Treatment of Hypogonadal and Low Testosterone Men with Type 2 Diabetes. Solvay Pharmaceuticals. 20 Jun 2008.	
	416.	Androgel 1% (testosterone gel) CIII.; www.Androgel.com , pp. 1-2.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	417.	Androgel 1.62% Volume Pump Patient IDI, Q2 Marketing Research, June 2008.
	418.	AndroGel Trademark Application Serial No. 74721663]
	419.	Androgel, The Medical Letter on Drugs and Therapeutics, Vol. 42 (Issue 1080), pp. 49-52 (June 12, 2000).
	420.	Androgel, The Medical Letter On Drugs And Therapeutics, vol. 42 (Issue 1080), pp. 49-52 (Jun. 12, 2000).
	421.	AndroGel® (Testosterone Gel). CIII Physicians Desk Reference, Issued 12/00.
	422.	Androgel® 1% (Testosterone Gel). Physicians Desk Reference, pp. 3239-3241 (2004).
	423.	Androgel® 1% (Testosterone Gel). Physician's Package Insert, pages 1 and 11 (2004).
	424.	Androgel--Phase III Clinical Trial, Gynecology, (Undated).
	425.	Andropausal, Los Gatos Longevity Institute, http://www.antiaging.com/andropause.html (1998).
	426.	Andropause Added to Men's Health Risk Assessment Tool, America's Pharmacist (Alexandria, VA), January 2002.
	427.	Andropause, National Public Radio The Connection Online (July 29, 2003).
	428.	AndrosteDERM, http://www.gethuge.net/androderm1.htm .
	429.	Angold, et al., Pubertal Changes in Hormone Levels and Depression in Girls, <i>Psychol Med</i> Sep. 1999; 29(5): 1043-53.
	430.	Ansel et al., Transdermal Drug Delivery Systems, <i>Pharmaceutical Dosage Forms and Drug Delivery Systems</i> , pp. 263-278 (1999).
	431.	Ansel, H. Introduction to Pharmaceutical Dosage Forms. <i>Psychiatry</i> . 43(12):279-308 (1981) (June 15 1998).
	432.	Approved Products: From Pipeline to Market, R&D Directions (West Trenton, NJ), June 2002.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02-698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	433.	Arisaka et al., Systemic effects of transdermal testosterone for the treatment of microphallus in children. Pediatrics International: Official Journal of the Japan Pediatric Society APR, 43(2):134-136 (2001).	
	434.	Arseneva, Treatment of menpausal neurosis with androgens. Sov Med. 1964 Nov;27:116-21. [Article in Russian].	
	435.	Arver et al., Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men, Clinical Endocrinology, Vol. 47, pp. 727-737 (1997).	
	436.	Arver, et al., Improvement of Sexual Function in Testosterone Deficient Men Treated for 1 Year with a Permeation Enhanced Testosterone Transdermal System, J Urol, May 1996; 155(5): 1604-8.	
	437.	Asscheman H. Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men. Ned Tijdschr Geneesk. 2000 Apr 29;144(18):847-50.	
	438.	AVERSA, et al., Androgens and Penile Erection: Evidence for a Direct Relationship Between Free Testosterone and Cavernous Vasodilation in Men with Erectile Dysfunction, Clinical Endocrinology, Vol. 53, pp. 517-522 (2000).	
	439.	Baarends, E. M., A. M. W. J. Schols, W. D. van Marken Lichtenbelt, and E. F. M. Wouters. Analysis of body water compartments in relation to tissue depletion in clinically stable patients with chronic obstructive pulmonary disease. Am. J. Clin. Nutr. 65: 88-94 (1997).	
	440.	BABA, et al., Delayed Testosterone Replacement Restores Nitric Oxide Synthase-Containing Nerve Fibres and the Erectile Response in Rat Penis, BJU Intl., Vol. 85, pp. 953-958 (2000).	
	441.	Bachmann et al., Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment, Fertility and Sterility, Vol. 77, No. 4, April 2002, pp 660-665.	
	442.	Bagatell et al., Metabolic & Behavioral Effects of High-Dose, Exogenous Testosterone in Healthy Men, J. CLINICAL METABOLISM & ENDOCRINOLOGY 79:561-567 (1994)	
	443.	Bagatell et al., Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men, Journal Of Clinical Endocrinology And Metabolism, Vol. 78, No.3, pp. 711-716 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/829,618
Filing Date	April 20, 2004
Inventor(s)	Dudley et al.
Art Unit	1627
Examiner Name	Jean-Louis, Samira
Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	444.	Bagatell et al. Androgens in Men - Uses and Abuses. New England Journal of Medicine. 334(11):707-714 (1996).
	445.	Baillie et al. Pathogenesis of vertebral crush fractures in men. Age and Aging 21:139 (1992).
	446.	Baker et al. Changes in the pituitary-testicular system with age. Clin. Endocrinol. 5:349 (1976).
	447.	Balagopal P, Rooyackers OE, Adey DB, Ades PA, Nair KS: Effects of aging on <i>in vivo</i> synthesis of skeletal muscle myosin heavy-chain and sarcoplasmic protein in humans. Am J Physiol 273 :E790-800, 1997.
	448.	Bals-Pratsch et al., Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year, ACTA Endocrinologica (COPENH), Vol. 118, pp. 7-13 (1988).
	449.	Bals-Pratsch, et al., Transdermal Testosterone Substitution Therapy for Male Hypogonadism, Lancet, Oct. 25, 1986; 2(8513): 943-6.
	450.	Bancroft, Endocrinology of Sexual Function, Clinics In Obstetrics And Gynecology, Vol. 7, No.2, pp. 253-281 (August 1980).
	451.	Bancroft, et al., Androgens and the Menopause; a Study of 40-60-Year-Old Women, Clin Endocrinol (Oxf), Nov. 1996; 45(5): 577-87.
	452.	Bancroft, et al., Mood, Sexuality, Hormones, and the Menstrual Cycle. III. Sexuality and the Role of Androgens., Psychosom Med, Dec. 1983; 45(6): 509-16.
	453.	Bardin et al. Androgens: Risks and benefits. J. Clin. Endocrinol. Metab. 73:4 (1991).
	454.	Barlow et al., In Vivo Observations on Testosterone and Estradiol-17beta Protein Binding in Women, Journal of Clinical Endocrinology and Metabolism, Vol. 29 (No.6), p. 767-776, (January 22, 1969).
	455.	Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin dependent diabetes mellitus. Ann. Int. Med. 12/92 (1992).
	456.	Barrett-Connor, E., et al., Endogenous sex hormone levels in older adult men with diabetes mellitus. Am. J. Epidemiol., 132(5):895-901 (1990)
	457.	Barrett-Connor, et al., Cognitive Function and Endogenous Sex Hormones in Older Women, J. Am. Geriatr. Soc., Vol. 47, No. 11, pp.1289-93 (November 1999).
	458.	Barrett-Connor, et al., A Two-Year, Double-Blind Comparison of Estrogen-Androgen and Conjugated Estrogens in Surgically Menopausal Women. Effects Bone Mineral Density, Symptoms and Lipid Profiles, J Reprod Med, Dec. 1999; 44(12):

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		1012-20.	
	459.	BARRY, Dermatological Formulations, Percutaneous Absorption, Marcel Dekker (1983)	
	460.	BARRY, Low Testosterone Can Trigger Male Depression, Atlanta Business Chronicle, February 14, 2002.	
	461.	BARRY, Prostate-Specific-Antigen Testing for Early Diagnosis of Prostate Cancer, N. Engl. J. Med., Vol. 344, No. 18, pp. 1373-1377 (May 23, 2001).	
	462.	Bartnof, Testosterone Therapy Causes Menstruation to Return in Women with AIDS-Related Wasting, www.hivandhepatitis.com (Oct. 12, 1999).	
	463.	BARTSCH, et al., Sex Hormone Binding Globulin Binding Capacity, Testosterone, 5alpha-Dihydrotestosterone, Oestradiol and Prolactin in Plasma of Patients with Prostatic Carcinoma Under Various Types of Hormonal Treatment, ACTA Endocrinologica (COPENH), Vol. 85, No. 3, pp. 650-664 (July 1977).	
	464.	Bartsch, et al., Interrelationships Between Sex Hormone-Binding Globulin and 17 beta-Estradiol, Testosterone, 5 alpha-Dihydrotestosterone, Thyroxine, and Triiodothyronine in Prepubertal and Pubertal Girls, J Clin Endocrinol Metab, Jun. 1980; 50(6): 1053-1056 (June 1980)	
	465.	Bartsch, Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-dihydrotestosterone and Oestradiol-17 beta in Blood of Normal Men, Maturitas, Jul. 1980; 2(2): 109-118.	
	466.	Barzel, Uriel S., Recommended Testing Patients with Low Bone Density. J Clin Endocrinol Metab 88(3): 1403-1404(2003)	
	467.	Basson, et al., Androgen Replacement for Women, Canadian Family Physician, Vol. 45, pp. 2100-2107 (Sep. 1999).	
	468.	BAUM, ET AL., Effects of Testosterone, Dihydrotestosterone, or Estradiol Administered Neonatally on Sexual Behavior of Female Ferrets, Endocrinology, Vol. 111 (No.3), p. 773-780, (January 22 1982).	
	469.	Baumgartner, et al., Predictors of Skeletal Muscle Mass in Elderly Men and Women, Mech Ageing Dev, Mar. 1, 1999; 107(2): 123-36.	
	470.	BAZELL, Male Hormone Gel May Pose Risks: Testosterone Therapy Promises Renewed Vigor, but Some Experts are Skeptical, NBC-TV NBC Nightly News	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Online (July 31, 2002).	
	471.	BEASLEY, Hormone Replacement Therapy for Men Gains Ground, Reuters, June 21, 2002.	
	472.	Behre HM, et al., Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body Proportion with AndroGel, Testosterone 1% gel therapy, in hypogonadal men, Aging Male. 2008 Jun;11(2):101-6.	
	473.	Behre, et al., Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester, Journal Of Endocrinology And Metabolism, Vol. 75, No.5, pp. 1204-1210 (1992).	
	474.	Behre, et al., Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men, Journal of Clinical Endocrinology and Metabolism, vol. 82, No. 8, pp. 2386-90 (1997).	
	475.	Behre, et al., Long-Term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years, Clinical Endocrinology (1999) Vol. 50, 629-635.	
	476.	Behre, et al., Prostate Volume in Testosterone-Treated and Untreated Hypogonadal Men in Comparison to Age-Matched Normal Controls, Clin Endocrinol (Oxf), Mar. 1994; 40(3): 341-9.	
	477.	Behre, et al., Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies, European Journal of Endocrinology (1999);140:414-419.	
	478.	Belgorosky, et al., Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones, J. Steroid Biochem., Vol. 18, No.6, pp. 783-787 (June 1983).	
	479.	Belgorosky, et al., Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys, J Steroid Biochem, 1987; 27(1-3): 291-295.	
	480.	Belgorosky, et al., Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Prepuberty in Boys, J Clin Endocrinol Metab, Aug. 1986; 63(2): 510-512.	
	481.	Belgorosky, Sex Hormone Binding Globulin Response to Testosterone. An Androgen Sensitivity Test, Acta Endocrinol (Copenh), May 1985; 109(1): 130-138.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	482.	Bentley Pharmaceuticals Announces License Agreement for Its Topical Testosterone Gel Formulation; Li, www.UVentures.com (Dec. 18, 2000).	
	483.	Bentley Pharmaceuticals Announces Research and Licensing Agreements For Intranasal Pain Management and Topical Hormone Replacement Therapy, www.bentleypharm.com (downloaded Nov. 17, 2001).	
	484.	Benzoyl peroxide. Wikipedia. http://en.wikipedia.org/wiki/Benzoyl_peroxide . Pages 1-3. Downloaded on 10/13/2009. Exhibit to the Declaration by Norman Weiner filed 10-13-2009 in U.S. Ser. No. 11/549083.	
	485.	Berger, RS et al. A reappraisal of the 21-day cumulative irritation test in man. J. Toxicol. Cut. And Ocular Toxicol. (1982) 1:109-115.	
	486.	Berner, et al., Pharmacokinetic Charactierisation of Transdermal Delivery System, Clin Pharmacokinet, Feb. 1994; 26(2): 121-34.	
	487.	Bernini, et al., Endogenous Androgens and Carotid Intimal-Medical Thickness in Women, J Clin Endocrinol Metab, Jun. 1999; 84(6): 2008-12.	
	488.	Besins International Licenses Testogel to Schering, In Vivo: The Business & Medicine Report (Norwalk, CT), September 2002.	
	489.	Betamethasone dipropionate (Disprosone, Diprolene) MedicineNet.com. http://www.medicinenet.com/betamethasone_dipropionate/article.htm . pages 1-3. Downloaded 10/13/2009. Exhibit to the Declaration by Norman Weiner filed 10-13-2009 in U.S. Ser. No. 11/549083	
	490.	Bevier W, Pyka G, Kozah (1989) Aerobic capacity, muscle strength and bone density in elderly men and women. J. Bon. Miner. Res. 4:421.	
	491.	Bhasin et al. The effects of supraphysiologic doses of testosterone on muscle size and strength. N. Eng. J. Med. 335: 1-7 (1996).	
	492.	Bhasin S, Storer TW, Berman. N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R Testosterone replacement increases fat-free mass and muscle size in hypogonadal men J Clin Endocrinol Metab 82(2):407-13, 1997.	
	493.	Bhasin S. et al. Editorial Commentary: Testosterone Supplementation for Cognitive Loss. J. Androl.: 45-46 (Jan/Feb 2002)	
	494.	Bhasin, Clinical Review 34--Androgen Treatment of Hypogonadal Men, Journal of Clinical Endocrinology and Metabolism, vol. 74, No. 6, pp. 1221-1225 (1992).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	495.	BHASIN, et al., Can Androgen Therapy Replete Lean Body Mass and Improve Muscle Function in Wasting Associated with Human Immunodeficiency Virus Infesction?, <i>J. of Parental and Enteral Nutrition</i> , Vol. 23, pp. S195-S201 (1999).
	496.	BHASIN, et al., Effects of Testosterone Replacement with a Nongenital, Transdermal System, Androderm, in Human Immunodeficiency Virus-Infected Men with Low Testosterone Levels, <i>J. of Clinical Endocrinology and Metabolism</i> , Vol. 83, No. 9, pp. 3155-3162 (1998).
	497.	BHASIN, et al., Testosterone Supplementation in Older Men: A Rational Idea Whose Time Has Not Yet Come, <i>J. of Andrology</i> , Vol. 22, No. 5, pp. 718-731 (2001).
	498.	Bhasin, et al., A Biodegradable Testosterone Microcapsule Forumlation Providing Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men, <i>J Clin Endocrinol Metab</i> , Jan. 1992; 74(1): 75-83.
	499.	Bhasin, et al., Therapeutic Perspective--Issues in Testosterone Replacement in Older Men, <i>Journal of Clinical Endocrinology and Metabolism</i> , vol. 83, No. 10, pp. 3435-3448 (1998).
	500.	Bhowmick et al., Sexual Precocity in a 16-Month-Old Boy Induced by Indirect Topical Exposure to Testosterone, <i>Clinical Pediatric</i> , Vol. 46(6), pp. 540-543 (2007).
	501.	Biopharmaceutical Firm Launched in Northbrook, Northbrook Star (Northbrook, IL), August 29, 2002.
	502.	Bisschop, et al., Effects of Nandrolone Decanoate on Respiratory and Peripheral Muscles in Male and Female Rats, www.uth.tms.edu . (1996, Downloaded Oct. 8, 1998).
	503.	Bloch, et al. Pituitary-Adrenal Hormones and Testosterone Across the Menstrual Cycle in Women with Premenstrual Syndrome and Controls, <i>Biol Psychiatry</i> , Jun. 15, 1998; 43(12): 897-903.
	504.	Bocchinfuso, et al., Expression and Differential Glycosylation of Human Sex Hormone-Binding Globulin by Mammalian Cell Lines, <i>Mol Endocrinol</i> , Nov. 1991; 5(11): 1723-1729.
	505.	BOCKSERMAN, Med. Plastics and Biomaterials Mag., pp. 26-33 (July 1996)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	506.	Bond, et al., Sex Hormone Binding Globulin in Clinical Perspective, <i>Acta Obstet. Gynecol. Scand.</i> , Vol. 66, pp. 255-262 (1987). [Abstract]	
	507.	BONITHON-KOPP, et al., Relationship Between Sex Hormones and Haemostatic Factors in Healthy Middle-Aged Men, <i>Atherosclerosis</i> , Vol. 71, pp. 71-76 (1988).	
	508.	BONNEY, Hormone Replacement Therapy for Men, American Clinical Laboratory, http://iscpubs.com/pubs/acl1197.html (November/December 1997).	
	509.	Booji, et al., Androgens as Adjuvant Treatment in Postmenopausal Female Patients with Rheumatoid Arthritis, <i>Ann Rheum Dis</i> , Nov. 1996; 55(11): 811-5.	
	510.	Boots, et al., Measurement of Total Serum Testosterone Levels Using Commercially Available Kits: High Degree of Between-Kit Variability, <i>Fertil Steril</i> , Feb. 1988; 69(2): 286-292.	
	511.	Borah et al., Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. <i>Bone</i> , 34:736-46 (2004).	
	512.	Boyle, et al., Serum Testosterone Measurements, <i>Am J Clin Pathol</i> , Jun. 1984; 81(6): 754-761.	
	513.	Brachet et al., Children's virilization and the use of a testosterone gel by their fathers, <i>Eur J Pediatr</i> , Vol. 164, pp. 646-647 (2005).	
	514.	Braunstein G., et al., Fertility and Sterility, Vo. 77, No. 4, April 2002, pp 660-665	
	515.	BRAUNSTEINER, et al., Essential Role of Post-Heparin Lipoprotein Lipase Activity and of Plasma Testosterone in Coronary Artery Disease, <i>The Lancet</i> , pp. 1242-1244 (June 1, 1985).	
	516.	Brawer MK, et al. Screening for prostatic carcinoma with prostate-specific antigen. <i>J. Urol</i> 147:841 (1992).	
	517.	BRILL, et al., Single and Joint Impact on One-Month of Transdermal Testosterone (T) and/or Recombinant Human Growth Hormone (rhGH) Supplementation on Body Composition, Strength, Balance, Function and Muscle IGF-1 and Androgen Gene Expression in Healthy Older Men: A Prospective Randomized Double-Blind Crossover, <i>The Endocrine Society</i> , No 1647 (ENDO 2000)	
	518.	Brocks, et al., Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose, <i>Journal of Clinical Pharmacology</i> , Vol. 36,	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		pp. 732-739 (1996).	
	519.	Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men. <i>J Clin Endocrinol Metab</i> 1996;81(10) 3469-3475.	
	520.	Brokaw, T NBC-TV NBC Nightly News Online (November 7, 2002)	
	521.	BRONAUGH et al., Vehicle effects on percutaneous absorption: in vivo and in vitro comparison with human skin, <i>Br. J. Dermatol.</i> , Vol. 11, pp. 1-11 (1986)	
	522.	BRONIARCZYK-DYLA, ET AL., Aging of the Skin During Menopause, <i>Medical Science Monitor</i> Vol. 5 (No.5) 1024-1029. (January 22, 1999).	
	523.	Bross, R., R. Casaburi, T. W. Storer, and S. Bhasin. Androgen effects on body composition and muscle function: implications for the use of androgens as anabolic agents in sarcopenic states. <i>Baillieres Clin. Endocrinol. Metab</i> 12: 365-378 (1998).	
	524.	Bruun, et al., Dihydrotestosterone Measured in Core Biopsies from Prostatic Tissues, <i>Am J Clin Oncol</i> , 1988; 11 Suppl 2:S27-9.	
	525.	Buckler, et al., The Effects of Low-Dose Testosterone Treatment on Lipid Metabolism, Clotting Factors and Utrasonographic Ovarian Morphology in Women, <i>Clinical Endocrinology</i> , Vol. 49, pp. 173-178 (1997).	
	526.	BUCKLER, ET AL., Pharmacokinetics of a Novel Transdermal Delivery System For Testosterone in Women <i>Journal of Endocrinology</i> , Vol. 144 pg. P329 (1995)	
	527.	Buckler, et al., Which Androgen Replacement Therapy for Women?, <i>J Clin Endocrinol Metab</i> , Nov. 1998; 83(11):3920-4.	
	528.	BUNCH, et al., Pituitary Radiographic Abnormalities and Clinical Correlates of Hypogonadism in Elderly Males Presenting with Erectile Dysfunction, <i>The Aging Male</i> , Vol. 5, pp. 38-46 (2002).	
	529.	Burdet, L., B. de Muralt, Y. Schutz, C. Pichard, and J. W. Fitting. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. <i>Am. J. Respir. Crit Care Med.</i> 156: 1800-1806 (1997).	
	530.	Burger H. G. et al., The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results, <i>Maturitas</i> 1984; 6:351-358	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	531.	BURGER, et al., Effect of Combined Implants of Oestradiol and Testosterone on Libido in Postmenopausal Women, British Medical Journal (Clin. Res. Ed.), Vol. 294, No. 6577, pp. 936-937 (April 11, 1987).
	532.	BUVAT, et al., Endocrine Screening in 1,022 Men with Erectile Dysfunction: Clinical Significance and Cost-Effective Strategy, The J. of Urology, Vol. 158, pp. 1764-1767 (November 1997).
	533.	Calendar – It's a Guy Thing, Houston Chronicle, September 11, 2002.
	534.	Calendar – Men's Health, Atlanta Journal-Constitution, October 29, 2002.
	535.	Capaldini L. Fatigue and HIV: Interview with Lisa Capaldini, M.D. Part II. Interview by John S. James. AIDS Treat News. 1998 Mar 20;(No 291):1-6 contd.
	536.	Carey et al., Transdermal Testosterone Treatment of Hypogonadal Men, The Journal of Urology, Vol. 140, pp. 76-79, (July 1988).
	537.	CAREY, et al., A Study to Evaluate Serum and Urinary Hormone Levels Following Short and Long Term Administration of Two Regimens of Progesterone Cream in Postmenopausal Women, British Journal of Obstetrics and Gynaecology, p. 722-726, (June 22, 2000).
	538.	Carlstrom et al., Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function, International Journal Of Andrology, Vol. 13, pp. 67-73 (1990).
	539.	Carter HB. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215 (1992).
	540.	Casaburi, R, Anabolic therapies in chronic obstructive pulmonary disease. Monaldi Arch. Chest Dis. 53: 454-459 (1998).
	541.	Cascione, Evaluation of the use of a unique testosterone topical gel formulation and a transdermal testosterone patch (Androderm), Department of Veterans Affairs (Research in Progress)
	542.	Cashdan, Hormones, Sex and Status in Women, Hormones And Behavior, Vol. 29, pp. 354-366 (September 1995).
	543.	CASSON, ET AL., Testosterone Delivery Systems for Women: Present Status and Future Promise, Seminars in Reproductive Endocrinology, Vol. 16 (No.2). P. 153-

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		159 (January 22 1998).	
	544.	Casson, et al., Androgen Replacement Therapy in Women: Myths and Realities, Int J Fertil Menopausal Stud; Jul.-Aug. 1996; 41(4):412-22.	
	545.	CASTELO-BRANCO, ET AL., Circulating Hormone Levels in Menopausal Women Receiving Different Hormone Replacement Therapy Regimens, Journal of Reproductive Medicine, Vol. 40 (No.8), p. 556-560, (August 22, 1995).	
	546.	Catalona W. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J. Med 324:1156 (1991).	
	547.	CBS Evening News, More Men Take Testosterone, (CBS television broadcast August 25, 2002).	
	548.	Cellegy Pharmaceuticals Market Opportunities, CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market.html (1997).	
	549.	CELLEGY PHARMACEUTICALS, INC. Annual Report (Form 10-K) pursuant to The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 1998, filed on March 22, 1999.	
	550.	CELLEGY PHARMACEUTICALS, INC. Annual Report (Form 10-K) pursuant to The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 1999, filed on March 14, 2000.	
	551.	CELLEGY PHARMACEUTICALS, INC. Annual Report (Form 10-KSB) pursuant to The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 1997, filed on March 31, 1998.	
	552.	CELLEGY PHARMACEUTICALS, INC. Annual Report (Form 10-KSB) pursuant to The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 1996, filed on March 28, 1997.	
	553.	CELLEGY PHARMACEUTICALS, INC.: INVESTORS: PRESS RELEASES, Cellegy Pharmaceuticals Receives FDA Nonapproval Letter for Fortigel, July 7, 2003, www.cellegy.com .	
	554.	CENTER, et al., Mortality After All Major Types of Osteoporotic Fracture in Men and Women: An Observational Study, The Lancet, Vol. 353, pp. 878-882 (March 13, 1999).	
	555.	Chakravarti, et al., Endocrine Changes and Symptomatology After Oophorectomy in Premenopausal Women, Br J Obstet Gynaecol, Oct. 1977; 84(10): 769-75.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	556.	Chan, TC. Percutaneous penetration enhancers: An update. Procdgs of 9th Biennial Intl Conf of Perspectives in Percutaneous Penetration, La Grand Motte, France, April 13, 2004; published January 2005	
	557.	Chemana et al., Percutaneous absorption of 5-alpha-dihydrotestosterone in Man II. Percutaneous administration of 5-alpha-dihydrotestosterone in hypogonadal men with idiopathic haemochromatosis; clinical, metabolic and hormonal effectiveness. International Journal of Andrology 5:595-606 (1982).	
	558.	CHEN, et al., The Correlation Between Pretreatment Serum Hormone Levels and Treatment Outcome for Patients with Prostatic Cancer and Bony Metastasis, BJU Intl., Vol. 89, pp. 710-713 (2002).	
	559.	CHEN, et al., Therapeutic Patents for Topical and Transdermal Drug Delivery Systems, Expert Opinion on Therapeutic Patents, Vol. 10 (No. 7, pp. 1035-1043 (2000).	
	560.	Cheng, R. Columbia Labs Reports Data on Testosterone Buccal Pdt, Dow Jones News Service, June 20, 2002.	
	561.	CHERRIER, et al., Testosterone Supplementation Improves Spatial and Verbal Memory in Healthy Older Men, Neurology, Vol. 57, pp. 80-88 (2001).	
	562.	CHERRIER, et al., 'T-Gel Study: Cognitive Effects of Exogenous Testosterone Manipulation in Hypogonadal Men, (6/7/99), University of Washington.	
	563.	CHEVALLIER, et al., A double-blind, placebo-controlled study on the effects of transdermal testosterone replacement in hypogonadal men with type 2 diabetes or metabolic syndrome: the TIMES2 study, European Association of Urology, PosterSessionOnline.com (2008).	
	564.	Chiang HS, et al., Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology. 2009 Apr;73(4):762-6. Epub 2009 Jan 1.	
	565.	Chik Z, et al., Correcting endogenous concentrations of testosterone influences bioequivalence and shows the superiority of TDS(R)-testosterone versus Androgel(R), Int J Clin Pharmacol Ther. 2009 Apr;47(4):262-8.	
	566.	Chilcott et al., Transepidermal Water Loss Does not Correlate with Skin Barrier Function In Vitro, The Journal of Investigative Dermatology, Vol. 118, No.5, pp.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		871-875, May 2002.
	567.	Choi, et al., Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus, J Urol, Aug. 1993; 150(2 Pt 2): 657-660.
	568.	Christiansen, Behavioral Correlates of Testosterone, Testosterone: Action, Deficiency, Substitution, 109-111 (1998).
	569.	Chudakov B, et al., Transdermal testosterone gel prn application for hypoactive sexual desire disorder in premenopausal women: a controlled pilot study of the effects on the arizona sexual experiences scale for females and sexual function questionnaire, J Sex Med. 2007 Jan;4(1):204-8.
	570.	CITRON, et al., Prevalence of Hypothalamic-Pituitary Imaging Abnormalities in Impotent Men with Secondary Hypogonadism, The J. of Urol., Vol. 155, pp. 529-533 (February 1996).
	571.	Cleary et al., The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006 Dec;55(12):3556-65.
	572.	CLIFT, Let Us Pause, Brattleboro Reformer (Brattleboro, VT), August 17, 2002.
	573.	CLIFT, Medicalizing Middle Age: Now Drug Companies Go After Men, The Keene Sentinel (Keene, NH), August 18, 2002.
	574.	Cofrancesco, Jr., et al., Transdermal Testosterone Delivery Systems, The Endocrinologist, Vol. 6, No.3, pp. 207-213 (1996).
	575.	Cohan GR, et al. A prospective study of the safety and efficacy of a topical transdermal testosterone gel versus intramuscular injections of testosterone for the treatment of testosterone deficiency in male HIV-infected patients. Poster presentation #H-1912 at the Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, October 2002, Chicago, IL.
	576.	COLAO, et al., Effect of GH and/or Testosterone Deficiency on the Prostate: An Ultrasonographic and Endocrine Study in GH-deficient Adult Patients, Euro. J. of Endocrinology, Vol. 143, pp. 61-69 (2000).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	577.	COLKER, Q and A: Ask Dr. Colker, Muscular Development (Setauket, NY), August 2002.	
	578.	Columbia Laboratories Announces European Marketing Partnership With Ardana Bioscience for Testosterone Buccal Bioadhesive Product, www.bioexchange.com (October 17,2002).	
	579.	Colvard DS et al. Identification of androgen receptors in nonnal human osteoblast-like cells. Proc Natn Acad Sci 86:854 (1989).	
	580.	Company Interview: MacroChem Corporation (MCHM), The Wall Street Transcript (New York, NY), July 8, 2002 at 201-205.	
	581.	Conan, N. Men's Health Series, Part II: Male Menopause, National Public Radio Talk of the Nation Online (October 15, 2002).	
	582.	CONFRANCESO JR., et al., Testosterone Replacement Treatment Options for HIV-Infected Men, J. of AIDS and Human Retrovirology, Vol. 16, pp. 254-265 (1997).	
	583.	Conway, et al., Randomized Clinical trial of Testosterone Replacement Therapy in Hypogonadal Men, Int J Androl, Aug. 1988; 11(4): 247-64.	
	584.	COOPER, et al., Epidemiology of Osteoporosis, Trends Endocrinol. Metab., Vol. 3, pp. 224-229 (1992).	
	585.	Cooper, et al., Effect of Fatty Acids and Alcohols on the Penetration of Acyclovir Across Human Skin in Vitro, Journal of Pharmaceutical Sciences, vol. 74, No. 6, pp. 688-689 (Jun. 1985).	
	586.	Corona G, et al., Six-month administration of 1% testosterone gel is able to restore erectile function in hypogonadal patients with erectile dysfunction, Arch Ital Urol Androl. 2008 Sep;80(3):103-8.	
	587.	Corrales, et al., Partial Androgen Deficiency in Aging Type 2 Diabetic Men and Its relationship to Glycemic Control, Metabolism 53(5):666-72 (May 2004).	
	588.	Correspondence to FDA from Testocreme® and Citizen Petition (July 3, 2001).	
	589.	Correspondence to Testocreme® from FDA regarding response to Citizen's Petition	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		(April 12, 2002).	
	590.	Cortaid. RxList.com. http://www.rxlist.com/cortaid-drug.htm . Pages 1-2. Downloaded on 10/13/2009. Exhibit to the Declaration by Norman Weiner filed 10-13-2009 in U.S. Ser. No. 11/549083.	
	591.	CROLS, Solvay Sees 2 Bln Euros in Drug Sales in 2002, Reuters, July 5, 2002.	
	592.	Cunningham, et al., Testosterone Transdermal Delivery System, Pharmacology, Biology, and Clinical Applications of Androgens. Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc).	
	593.	Cunningham, et al, Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irresponsive of Pubertal Status, Journal of Clinical Endocrinology and Metabolism, vol. 58, No. 5, pp. 915-918 (1984).	
	594.	Cunningham, et al, Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men, Journal of Clinical Endocrinology and Metabolism, vol. 70, No. 3, 792-797.	
	595.	Cunningham, et al., Testosterone Replacement with Transdermal Therapeutic System, Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels, JAMA, May 5, 1989; 261(17): 2525-30.	
	596.	CUTOL.O, et al., Androgen Replacement Therapy in Male Patients with Rheumatoid Arthritis, Arthritis and Rheumatism, Vol. 34, No. 1, pp.1-5 (January 1991).	
	597.	Cutolo, et al., Hypothalamic-Pituitary-Adrenocortical Axis Function in Premenopausal Women with Rheumatoid Arthritis Not Treated with Glucocorticoids, J Rheumatol, Feb. 1999; 26(2): 282-8.	
	598.	CUTTER, Christopher, Compounded Percutaneous Testoterone Gel: Use and Effects in Hypogondal Men, JABFP, Col. 14(1), pp. 22-32 (2001).	
	599.	d'A Semple, P., W. S. Watson, R. Hume, and G. R Sutherland. Potassium studies in chronic obstructive airways disease. Thorax 33: 734-739 (1978).	
	600.	Daly, R.C. et al. Testoterone's Effects Not Limited to Mood. Arch Gen Psychiatry 57: 403-404(Apr 2001)	
	601.	Damassa, et al., Sex Hormone-Binding Globulin and Male Sexual Development, Neuroscience And Biobehavioral Reviews, Vol. 19, No.2, pp. 165-175 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	602.	Data Supports Safety of Estratest For Men, Doctor's Guide, www.psigroup.com (Mar. 9, 1998).	
	603.	Davidson JM. et al. Effects of androgens on sexual behavior in hypogonadal men. <i>J. Clin. Endocrinol. Metab.</i> 48:955 (1979).	
	604.	Davidson, et al., Hormonal Changes and Sexual Function in Aging Men, <i>Journal Of Clinical Endocrinology And Metabolism</i> , Vol. 57, No.1, pp. 71-77 (1983).	
	605.	Davidson, et al., Hormonal Replacement and Sexuality in Men, <i>Clinics in Endocrinology and Metabolism</i> , vol. 11, No. 3, pp. 599-623 (Nov. 1982).	
	606.	Davis et al., Testosterone Enhances Estradiol's Effects on Postmenopausal Bone Density and Sexuality, <i>Maturitas</i> , Vol. 21, No.3, pp. 227-36 (April 1995).	
	607.	DAVIS, Androgen Treatment in Women, <i>Medical Journal of Australia</i> , Vol. 170 (No. 11), p. 545-549. (June 7 1999),	
	608.	Davis, The Clinical Use of Androgens in Female Sexual Disorders, <i>Journal of Sex & Marital Therapy</i> , Vol. 24, pp. 153-163 (1998).	
	609.	Davis, Androgen Replacement in Women: A Commentary, <i>J Clin Endocrinol Metab</i> , Jun. 1999; 84(6): 1886-91.	
	610.	Davis, et al., Clinical Review 82: Androgens and the Postmenopausal Woman, <i>J. Clin Endocrinol Metab</i> , Aug. 1996; 81(8): 2759-63.	
	611.	Davis, et al., Use of Androgens in Postmenopausal Women, <i>Curr Opin Obstet Gynecol</i> , Jun. 1997; 9(3): 177-80.	
	612.	De Boer et al., Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. <i>Arch Intern Med.</i> 2008 Sep 22;168(17):1867-73.	
	613.	De Lignieres et al., Treatment of Male Hypogonadism by Topical Administration of Androgens. In: Mauvais-Jarvis et al. Eds. <i>Percutaneous Absorption of Steroids</i> , pp. 273-283 (1980).	
	614.	de Lignieres, Transdermal Dihydrotestosterone Treatment of Andropause, <i>Annals of Medicine</i> 25: 235-241, 1993.	
	615.	De Lunardo, et al., Determination of Acceptability of 2 Cutaneous Estradiol Gels, In A Dose of 1.5 mg Daily, <i>J. Gynecol. Obstet. Biol. Reprod. (Paris)</i> , Vol. 29, No. pp. 509-516, (September 2000). [Abstract]	
	616.	De Ronde, Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies, <i>Human Reproduction</i> , Vol. 24(2), pp. 425-428 (2008).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02-698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	617.	DE RONDE, Willem, Testosterone Gel for the Treatment of Male Hypogonadism, Expert Opin. Biol. Ther., Vol. 9(2), pp. 249-253 (2009)
	618.	DE ROSE, et al., Combined Oral Therapy with Sildenafil and Doxazosin for the Treatment of Non-Organic Erectile Dysfunction Refractory to Sildenafil Monotherapy, Intl. J. of Impotence Research, Vol. 14, pp. 50-53 (2002).
	619.	Definition of Isopropyl Myristate (5103), The Merck Index – An Encyclopedia of Chemicals, Drugs, and Biologicals, 11th edition, pg. 821 (1989)
	620.	DELANOE et al., Androgenisation of Female Partners of Men on Medroxyprogesterone Acetate/Percutaneous Testosterone Contraception, The Lancet (Feb 1984), p. 276.
	621.	DELATESTRYL BTG (testosterone cypionate), USP
	622.	DEMERY, A. Contraception Masculine Soins Gyn.-Obs.-Puer,-Ped No, 72 (May 1987) pp.33-38.
	623.	Denis, Future Implications for the Management of Benign Prostatic Hyperplasia, Eur Urol, 1994; 25 Suppl 1:29-34.
	624.	DEPO-TESTOSTERONE (testosterone cypionate), USP
	625.	Derogatis, The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): an introductory report, J Sex Marital Ther. 1997 Winter;23(4):291-304.
	626.	Deslypere JP et al. Influence of age on pulsatile luteinizing hormone release and responsiveness of the gonadotrophs to sex hormone feedback in men. J. Clin. Endocrinol. Metab. 64:68 (1987).
	627.	Deslypere JP. et al. Leydig cell function in normal men: effect of age, life-style, residence, diet and activity. J. Clin. Endocrinol. Metab. 59:955-962 (1984).
	628.	Devogelaer et al., Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. Maturitas. 1992 Aug;15(1):17-23.
	629.	Diamond T. et al. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J. Bone Min Res 6:39 (1991).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	630.	Ding, et al., Sex Hormone-Binding Globulin Mediates Prostate Androgen Receptor Action via a Novel Signaling Pathway, <i>Endocrinology</i> , Vol. 139, No.1, pp. 213-218 (January 1998).	
	631.	DISSEMOND, et al., Venous Leg Ulcers in a Patient with Klinefelter's Syndrome and Increased Activity of Plaminogen Activator Inhibitor-1, <i>Acta. Derm. Venerol.</i> , Vol. 83, pp. 149-150 (2002).	
	632.	Dobs A, Clinical Trial of Testosterone Gel HRT in Hypogonadal Men, Computer Retrieval of Information on Scientific Projects (downloaded 2/19/02)	
	633.	Dobs et al. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. <i>Current Med. Res. and Opns.</i> 20(5):729-738 (2004).	
	634.	Dobs et al., Pharmacokinetic Characteristics, Efficacy and Safety of Buccal Testosterone in Hypogonadal Males: A Pilot Study, <i>J. Clinical Endocrinology & Metabolism</i> 83:33-39 (1998)	
	635.	DOBS, Androgen Therapy in AIDS Wasting, <i>Bailliere's Clinical Endocrinology and Metabolism</i> , Vol. 12, No. 3, pp. 379-390 (October 1998).	
	636.	Dobs, A.S. Endocrine Disorders In Men Infected with Human Immunodeficiency Virus. <i>Am. J. of Med.</i> 84: 611-616 (March 1988).	
	637.	DOBS, et al., An Open Label Phase III Study of Fortigel (Testosterone) 2% Gels in Hypogonadal Males, <i>ASA Poster</i> (2009)	
	638.	Dobs, et al., Pharmacokinetics, Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men, <i>J Clin Endocrinol Metab.</i> 1999 Oct;84(10):3469-78.	
	639.	Donahoe, M., J. Mancino, J. Constatino, H. Lebow, and R M. Rogers. The effect of an aggressive nutritional support regimen on body composition in patients with severe COPD and weight loss. <i>Am. J. Respir. Crit Care Med.</i> 149(4):A3-A13 (1994).	
	640.	DOREN, Basic Principles of Hormone Replacement Therapy in the Postmenopause, <i>Ther. Umsch</i> Vo. 57 (No. 10). pp. 628-634 (October 2000): [Abstract].	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	641.	Dosik et al., Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream, 0.05% in subjects with healthy skin. (Clinical report). Journal of drugs in Dermatology. June 1, 2007. Exhibit to the Declaration by Norman Weiner filed 10-13-2009 in U.S. Ser. No. 11/549083.	
	642.	Douchi, et al., Serum Androgen Levels and Muscle Mass in Women with Polycystic Ovary Syndrome, Obstetrics & Gynecology, Vol. 94, No.3, pp. 337-340 (1999).	
	643.	DOUGLAS, et al., Effect of Exogenous Testosterone Replacement on Prostate-Specific Antigen and Prostate-Specific Membrane Antigen Levels in Hypogonadal Men, J. of Surg. Oncology, Vol. 59, pp. 246-250 (1995).	
	644.	Dr. N's Menopause & Hysterectomy Resource Page, http://www.menopausehysterectomy.com/methods.htm (accessed 6/22/2000).	
	645.	Drafta, et al., The Effects of Endocrine Therapy on Plasma Steroids in Prostatic Carcinoma Patients, Endocrinologie, Jul.-Sep. 1984; 22(3): 191-7.	
	646.	Drake, et al., Associations Between Circulating Sex Steroid Hormones and Cognition in Normal Elderly Women, Neurology, Feb. 2000; 54(3): 599-603.	
	647.	Drobac et al., A workshop on pubertal hormone replacement options in the United States, Journal of Pediatric Endocrinology and Metabolism, 19(1):55-64 (2006).	
	648.	DUCHARME, Male Menopause: The Real Thing?, PN/Paraplegia News, November 2002.	
	649.	Duncan PW, Weiner DK, Chandler J, Studenski S: Functional reach: a new clinical measure of balance. J Geron 45:M192-7, 1990.	
	650.	Earthman, C. P., J. R. Matthie, P. M. Reid, L T. Harper, E. Ravussin, and W. H. Howell A comparison of bioimpedance methods for detection of body cell mass change in H1V infection. J. Appl. Physiol 88: 944-956 (2000).	
	651.	ECHIKSON, Solvay CEO's Positive Outlook Breaks with Usual Caution, Dow Jones News Service, June 6, 2002.	
	652.	EDELSTEIN, et al., The Latest Option and Future Agents for Treating Male Hypogonadism, Expert Opin. Pharmacother., Vol. 8(17), pp. 2991-3008 (2007).	
	653.	Ehrenfeld, T. Health: A Loving Feeling, Newsweek (November 11, 2002).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	654.	ENDO 99: Testosterone Patch Effective for Diminished Sexual Function in Surgically Menopausal Women, Doctor's Guide to the Internet, www.docguide.com (Jun. 15, 1999).	
	655.	Engelen, M. P. K. J., A. M. W. J. Schols, W. C. Baker, G. J. Wesseling, and E. F. M. Wouters. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. <i>Eur. Respir. J.</i> 7: 1793-1797 (1994).	
	656.	ENGLISH, et al., Low-Dose Transdermal Testosterone Therapy Improves Angina Threshold in Men with Chronic Stable Angina: A Randomized, Double-Blind, Placebo-Controlled Study, <i>Circulation</i> , Vol. 102, pp. 1906-1911 (2000).	
	657.	ENGLISH, et al., Men with Coronary Artery Disease Have Lower Levels of Androgens than Men with Normal Coronary Angiograms, <i>European Heart J.</i> , Vol. 21, pp. 890-894 (2000).	
	658.	ENGLISH, et al., Testosterone Acts as Coronary Vasodilator by a Calcium Antagonistic Action, <i>J. of Endocrinological Investigation</i> , Vol. 25, pp. 455-458 (2002).	
	659.	Eriksson, et al., Serum Levels of Androgens are Higher in Women with Premenstrual Irritability and Dysphoria Than in Controls, <i>Psychoneuroendocrinology</i> , Vol. 17, Nos. 2-3, pp. 195-204 (May-July 1992).	
	660.	Ernesti, et al., Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture, <i>Skin Pharmacol</i> , 1992; 5(3): 146-153.	
	661.	Escoffier et al., Age-related mechanical properties of human skin: an invivo study, the Society for Dermatology, Inc. 353 (1989).	
	662.	Esposito, J Rights to Market: Marketing Presence in Oncology, <i>Med Ad News</i> (West Trenton, NJ), October 2002.	
	663.	EstroGel ® 0.06% (estradiol gel), 500123, 3E Rev 3/2004, pages 1-16	
	664.	Estrogel, www.netdoktor.dk/medicin/Fakta/Estrogel (Downloaded Jun. 26, 2001).	
	665.	Events Calendar: Events for the week of Dec. 13-19 – Sportmart: 'Time Out for	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		Men's Health, St. Paul Pioneer Press, December 13, 2002.
	666.	Ewing, et al., Dihydrotestosterone Concentration of Beagle Prostatic Tissue: Effect of Age and Hyperplasia, Endocrinology, Dec. 1983; 113(6): 2004-9.
	667.	Experimental Abbott drug halts spread of prostate cancer. Chicago Tribune, June 5, 2001.
	668.	Exton, et al., Cardiovascular and Endocrine Alterations after Masturbation-Induced Orgasm in Women, Psychosom Med, May-Jun. 1999; 61(3): 280-9.
	669.	FABBRI, et al., Testosterone Treatment to Mimic Hormone Physiology in Androgen Replacement Therapy: A View on Testosterone Gel and Other Preparation Available, Expert Opin. Biol. Ther., Vol. 7(7), pp. 1093-1106 (2007).
	670.	FAHMY, et al., Is the Measurement of Serum Testosterone Routinely Indicated in Men with Erectile Dysfunction?, BJU Intl., Vol. 84, pp. 482-484 (1999).
	671.	Fahrner et al., Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG), International Journal Of Sports Medicine, Vol. 19, No.1, pp. 12-15 (January 1998). [Abstract]
	672.	Farmer et al. Race and sex differences in hip fracture incidence. Am J. Public Health 74:1374 (1984).
	673.	FDA Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products- General Considerations, March 2003.
	674.	FDA Guidance for Industry, Developing Products for Weight Management (Draft Guidance), February 2007.
	675.	FDA Guidance for Industry, Statistical Approaches to Establishing Bioequivalence, January 2001.
	676.	FDA press release, Testosterone Gel Safety Concerns Prompt FDA to Require Label Changes, Medication Guide , May 7, 2009.
	677.	Fedorak et al., A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis, Am. J. Physiol, 269:G210-218 (1995).
	678.	FEIGL, et al., Design of the Prostate Cancer Prevention Trial (PCPT), Controlled Clinical Trials, Vol. 16, pp. 150-163 (1995).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	679.	FELDMAN, et al., Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study, The J. of Urology, Vol. 151, pp. 54-61 (January 1994).	
	680.	Feldmann et al. Percutaneous Penetration of 14C Hydrocortisone in Man. Archives of Dermatology. 94:649-651 (1966)	
	681.	Female Sexual Dysfunction and Andropause Could be Advisory Cmte. Topics, The Pink Sheet (Chevy Chase, MD), March 18, 2002.	
	682.	Female Testosterone in Phase II, Pharmaceutical Business News, Vol. 12 (No.279), pg. 17 (November 8, 1996).	
	683.	FERENCHICK, Are Androgenic Steroids Thrombogenic?, The New England Journal of Medicine, p.476 (February 15, 1990).	
	684.	Ferreira, I. M., I. T. Verreschi, L. E. Nery, R S. Goldstein, N. Zamel, D. Brooks, and J. R Jardim. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 114: 19-28 (1998).	
	685.	Fiet J et al. Percutaneous absorption of 5a-dihydrotestosterone in man. I. Plasma androgen and gonadotropin levels in normal adult men after percutaneous administration of 5a-dihydrotestosterone. Int J. Androl 5:586 (1982).	
	686.	Findlay, et al., Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone, J Clin Endocrinol Metab, Feb. 1989; 68(2): 369-373.	
	687.	Finkelstein JK et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 106:354 (1987).	
	688.	Finkelstein JS, Klibanski A, Neer RM et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69 ; 69:776-783.	
	689.	First Phase of Testosterone TDS Trial Successful. Press release. 3/5/04.	
	690.	Floter, et al., Administration of Testosterone Undecanoate in Postmenopausal Women: Effects on Androgens, Estradiol, and Gonadotrophins., Menopause, Jul.- Aug. 2000; 7(4): 251-6.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	691.	Flynn MA et al. Total body potassium in aging humans: longitudinal study. Am J. Clin. Nutr. 50:713 (1989).	
	692.	Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198.	
	693.	Forbes GB. et al. Age and sex trends in lean body mass calculated from 40K measurements: with a note on theoretical basis for the procedure. Ann NY Acad Sci 110:225 (1963).	
	694.	Fournier et al., Value of a Percutaneous Estrogen Solution in Stopping Lactation, Rev. Fr. Gynecol. Obstet., Vol. 85, No. 12, pp. 715-719 (December 1990). [Abstract]	
	695.	FOWLER, et al., The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone, The J. of Urology, Vol. 126, pp. 372-375 (September 1981).	
	696.	Francis RM et al. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxy vitamin D, calcium malabsorption and low bone formation. Bone 7:261 (1986).	
	697.	Franklin, et al., Precocious Puberty Secondary to Topical Testosterone Exposure, Journal of Pediatric Endocrinology & Metabolism, Vol. 16(1), pp. 107-110 (2003).	
	698.	FRANSEN, et al., Excess Mortality or Institutionalization After Hip Fracture: Men Are at Greater Risk than Women, JAGS, Vol. 50, pp.685-690 (2002).	
	699.	Free Health Screenings Offered Saturday for Men, The Tampa Tribune, November 8, 2002.	
	700.	Freidl KE et al. High density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 39:69-74 (1990).	
	701.	Friday, July 5 – Men's Health, Arizona Republic (Phoenix, AZ), July 5, 2002.	
	702.	Friedl KE et al. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J. Clin. Endocrinol. Metab. 68:971 (1989).	
	703.	FUGL-MEYER, et al., On Life Satisfaction in Male Erectile Dysfunction, Intl. J. of	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		Impotence Research, Vol. 9, pp. 141-148 (1997).
	704.	Fukayama S. et al. Direct modulation by androgens of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH related protein. Endocrinology 125:1789 (1989).
	705.	Furuyama et al., Radioimmunoassay for Plasma Testosterone, Steroids, Vol. 16, No.4, pp. 415-428 (1970). [Abstract]
	706.	Gaidano et al., Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty, Clinical Chimica Acta, Vol. 100, No.2, pp. 91-97 (January 15, 1980).
	707.	Gallagher JC. et al. Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin. Orth. Rel.Res. 150:163 (1980).
	708.	GALLAGHER, et al., Androgens Contribute to the Stimulation of Cancellous Bone Formation by Ovarian Hormones in Female Rats, The American Physiological Society, pp. E407-E412 (1996).
	709.	Gann et al., Prospective Study of Sex Hormone Levels and Risk of Prostate Cancer, Journal of National Cancer Institute, Vol. 88, No. 16, pp. 1118-1126 (August 21, 1996). [Abstract]
	710.	Garban et al., Restoration of Normal Adult Penile Erectile Response in Aged Rats by Long-Term Treatment with Androgens, Biology of Reproduction, Vol. 53, pp. 1365-72 (1995).
	711.	Garnett et al., A Cross-Sectional Study of the Effects of Long-Term Percutaneous Hormone Replacement Therapy on Bone Density, Obstetrics & Gynecology, Vol. 78, No.6, pp. 1002-1007 (December 1991).
	712.	Garnett et al., The Effects of Plasma Estradiol Levels on Increases in Vertebral and Femoral Bone Density Following Therapy with Estradiol and Estradiol with Testosterone Implants, Obstetrics and Gynecology. Vol. 79, No.6, pp. 968-972 (June 1992).
	713.	GEARON, Dealing with Male Menopause, DiscoveryHealth.com (January 2, 2002).
	714.	Gefael, Graeme's Testosterone Page, www.voyager.co.nz (May 12, 2000).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	715.	Geist S. H., Androgen therapy in the human female, <i>J. Clin. Endocrinol.</i> 1941; 1:154-161	
	716.	Gelfand et al., Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941-1996. <i>Clinical Therapeutics, Excerpta Medica</i> , Princeton, NJ, US vol. 19, no. 3, 1997, pages 383-404.	
	717.	Geller, Basis for Hormonal Management of Advanced Prostate Cancer, <i>Cancer</i> , Feb. 1, 1993; 71(3 Suppl): 1039-45.	
	718.	Geller, et al., DHT in Prostate Cancer Tissue--a Guide to Management and Therapy, <i>Prostate</i> , 1985; 6(1):19-25.	
	719.	Geller, Nonsurgical Treatment of Prostatic Hyperplasia, <i>Cancer</i> , Jul. 1, 1992; 70(1 Suppl): 339-45.	
	720.	Geller, Pathogenesis and Medical Treatment of Benign Prostatic Hyperplasia, <i>Prostate Suppl</i> , 1989; 2:95-104.	
	721.	Gennaro R. Alfonso, <i>Remington Farmacia</i> , 19th Edition, Panamericana. Spain. 1998. p.2326-2327	
	722.	Gennaro, <i>Remington: The Science and Practice of Pharmacy</i> , 20th Edition, Chapter 44, "penetration enhancers,: pp. 842-843 (2000).	
	723.	Gennaro, <i>Remington: The Science and Practice of Pharmacy</i> , 20th Edition, Chapter 57, Drug Absorption, Action, and Disposition, (2003).	
	724.	GENNARO, ET AL., <i>Remington's Pharmaceutical Sciences</i> , Eighteenth Edition, pp. 1305, 1314-1315 (1990).	
	725.	Genuth et al., Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. <i>Diabetes</i> . 2005 Nov;54(11):3103-11.	
	726.	Gerrity MS, Gaylord S. Williams ME. Short version of the timed manual performance test. Development, reliability and validity. <i>Med Care</i> 1993;31(7):617-628.	
	727.	GERSTENBLUTH, Prostate-Specific Antigen Changes in Hypogonadal Men Treated with Testosterone Replacement, <i>J. of Andrology</i> , Vol. 23, No. 6, pp. 922-	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		926 (November/December 2002).	
	728.	Gertner, J.M., I-70, Hypogonadism is Uncommon in Men with Aids-Associated Wasting. 38th Annual ICAAC, Abstracts: 384	
	729.	Get it Checked! Radio: Audio News Release. Mens Health Network: Jun. 10-16 (2002?).	
	730.	Ghosh et al., Methods of Enhancement of Transdermal Drug Delivery: Part I, Physical and Biochemical Approaches, Pharmaceutical Technology, pp. 73-90 (March 1993).	
	731.	Ghosh et al., Methods of Enhancement of Transdermal Drug Delivery: Part IIA, Chemical Permeation Enhancers, Pharmaceutical Technology, pp. 62-90 (April 1993).	
	732.	Ghosh et al., Methods of Enhancement of Transdermal Drug Delivery: Part IIB, Chemical Permeation Enhancers, Pharmaceutical Technology, pp. 68-76 (May 1993).	
	733.	Ghusn et al. Evaluation and Treatment of Androgen Deficiency in Males. The Endocrinologist 1(6):399-408 (1991)	
	734.	Goggin, et al., The Relationship of Mood, Endocrine, and Sexual Disorders in Human Immunodeficiency Virus Positive (HIV+) Women: an Exploratory Study, Psychosom Med, Jan.-Feb. 1998; 60(1): 11-6.	
	735.	Goldberg-Cettina et al., Enhanced transdermal delivery of estradiol in vitro using binary vehicles of isopropyl myristate and short-chain alkanols, Int'l J. Pharmaceutics (1995);114:237-245	
	736.	Gonzalez-Sagrado, et al., Reference Values and Methods Comparison of a New Testosterone Assay on the AxSYM System, Clin Biochem, Apr. 2000; 33(3): 175-9.	
	737.	Gonzalo IT et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002 Aug;87(8):3562-72.	
	738.	Good, et al., Bone Mineral Density and Body Composition in Lean Women with Polycystic Ovary Syndrome, Fertil Steril, Jul. 1999; 72(1): 21-5.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	739.	Goodman & Gilman, Pharmacological Basis of Therapeutics, Ninth Edition (McGraw-Hill, New York, 1996), page 8	
	740.	Goodman, et al., Action of Skin Permeation Enhancers Azone, Oleic Acid and Decylmethyl Sulphoxide: Permeation and DSC Studies. J Pharm Pharmacol 38(Supply): 71P, 1986.	
	741.	Gooren L J. G. and Polderman K. H., Safety aspects of androgens. In Testosterone: Action, Deficiency, Substitution. E. Nieschlag and H M. Behre, editors, Springer-Verlag, Heidelberg, p. 136 (1990).	
	742.	Gooren, Androgen levels and sex function in testosterone-treated hypogonadal men, Archives of Sexual Behavior 16(6):463-473 (1987).	
	743.	Gooren, Human male sexual functions do not require aromatization of testosterone: a study using tamoxifen, testolactone, and dihydrotestosterone, Arch. Sex. Behav. 14(6):539-48 (1985).	
	744.	Gooren, A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate, J Androl. 1994 May-Jun;15(3):212-5.	
	745.	Gordon C L, et al., Relation between image-based assessment of distal radius trabecular structure and compressive strength, Canad. Assoc. Radiol. J., 49:390-7 (1998).	
	746.	Gosker, H. R., E. F. M. Wouters, G. J. van der Vusse, and A. M. W. J. Schols. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am. J. Clin. Nutr. 71: 1033-1047 (2000).	
	747.	Gouchie, et al., The Relationship Between Testosterone Levels and Cognitive Ability Patterns, Psychoneuroendocrinology, Vol. 16, No.4, pp. 323-334 (1991).	
	748.	GOULD, Duncan, A Novel Metered-Dose 2% Testosterone Gel Treatment for Male Hypogonadism, JMHG, Vol. 4(4), pp. 419-427 (2007).	
	749.	Graeme's Testosterone Page, http://www.voyager.co.nz/~gtuck/graeme/ (5/12/2000)	
	750.	Granger CV, Cotter AC, Hamilton BB, Fiedler RC, Hens MM: Functional assessment scales: a study of persons with multiple sclerosis. Arch Phys Med Rehab 71:870-5, 1990.	
	751.	GRAVHOLT, ET AL., Reduced Androgen Levels in Adult Turner Syndrome: Influence of Female Sex Steroids and Growth Hormone Status, Clinical Endocrinology, Vol. 50(6), p. 791-800. (January 22, 1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	752.	Gray A, Feldman HA, McKinlay JB, Longcope C: Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73:1016-25, 1991.
	753.	Gray A. et al. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J. Clin Epidemiol 44:671 (1991).
	754.	Greendale, et al., Endogenous Sex Steroids and Bone Mineral Density in Older Women and Men: the Rancho Bernardo Study, J Bone Miner Res, Nov. 1997; 12(11): 1833-43.
	755.	Greenspan SL, et al. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 104:777-82 (1986).
	756.	GREGORY, et al., A Mechanism for Androgen Receptor-mediated Prostate Cancer Recurrence After Androgen Deprivation Therapy, Cancer Research, Vol. 61, pp. 4315-4319 (June 1, 2001).
	757.	GREGORY, et al., Androgen Receptor Expression in Androgen-independent Prostate Cancer Is Associated with Increased Expression of Androgen-regulated Genes, Cancer Research, Vol. 58, pp. 5718-5724 (December 15, 1998).
	758.	Griggs RC et al. Effect of testosterone on muscle mass and muscle protein synthesis. J. Appl Physiol 66:498 (1989).
	759.	GRIGNON, et al., College of American Pathologists Conference XXVI on Clinical Relevance of Prognostic Markers in Solid Tumors: Report of the Prostate Cancer Working Group, Arch. Pathol. Lab. Med., Vol. 119, pp. 1122-1126 (December 1995).
	760.	Grinspoon, et al, Body Composition and Endocrine Function in Women with Acquired Immunodeficiency Syndrome Wasting, J. Clin Endocrinol Metab, May 1997; 82(5): 1332-7.
	761.	GRINSPOON, et al., Effects of Androgen Administration in Men with the AIDS Wasting Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial, Ann. Intern. Med., Vol. 129, pp. 18-26 (1998).
	762.	GRINSPOON, Scientific Project: AIDS Wasting in Women - Anabolic Effects of Testosterone (2001). [Abstract].

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	763.	Grober ED, et al., Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men, Int J Impot Res. 2008 Mar-Apr;20(2):213-7. Epub 2007 Sep 27.	
	764.	Gruber, et al., Effect of Percutaneous Androgen Replacement Therapy on Body Composition and Body Weight in Postmenopausal Women, Maturitas, Vol. 29, pp. 253-259 (June 1998).	
	765.	GUAY, et al., Testosterone Treatment in Hypogonadal Men: Prostate-Specific Antigen Level and Risk of Prostate Cancer, Endocrine Practice, Vol. 6, No. 2, pp. 132-138 (March/April 2000).	
	766.	Guideline on Clinical Evaluation of Medical Products Used in Weight Control-Addendum on weight control in children. European Medicines Agency. November 15, 2007.	
	767.	GUNAWARDENA, et al., Testosterone Is a Potential Augmentor of Antioxidant-induced Apoptosis in Human Prostate Cancer Cells, Cancer Detection and Prevention, Vol. 26, pp. 105-113 (2002).	
	768.	Guralnik JM, Simonsick EM, Ferrucci L et al. A short physical performance battery assessing lower extremity function: Association with self-regulated disability and predictors of mortality and nursing home admission. J Gerontol Med Sci 1994;49:M85-M94.	
	769.	Guzick, et al., Sex, Hormones, and Hysterectomies, The New England Journal Of Medicine, Vol. 343, No. 10, pp. 730-731 (September 7, 2000).	
	770.	Gwin et al., The effect of topical pilocarpine on intraocular pressure and pupil size in the normotensive and glaucomatous beagle. Investigative Ophthalmology and Visual Science 16:1143-1148 (1977). Exhibit to the Declaration by Norman Weiner filed 10-13-2009 in U.S. Ser. No. 11/549083.	
	771.	HADIGAN, Scientific Project: AIDS Wasting in Women: Anabolic Effects of Testosterone Treatment Only (2001). [Abstract].	
	772.	Hagenfeldt Y, Linde K, Sjoberg HE, Zumkeller W, Arver S: Testosterone increases serum 1,25-dihydroxy vitamin D and insulin-like growth factor-1 in hypogonadal men. Int J Androl 15:93-102, 1992.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	773.	HAJJAR, et al., Outcomes of Long-Term Testosterone Replacement in Older Hypogonadal Males: A Retrospective Analysis, J. of Clinical Endocrinology and Metabolism, Vol. 82, No. 11, pp. 3793-3796 (1997).
	774.	Hak, Elisabeth A., Authors Response: Low Levels of Endogenous Androgens Increase the Risk of Atherosclerosis in Elderly Men-Further Supportive data. J Clin Endocrinol Metab 88(3): 1404(2003)
	775.	HAK, et al., Low Levels of Endogenous Androgens Increase the Risk of Atherosclerosis in Elderly Men: The Rotterdam Study, The J. of Endocrinology & Metabolism, Vol. 87, No. 8, pp. 3632-3639 (2002).
	776.	HALL, et al., A Randomized Trial of Testosterone Therapy in Males with Rheumatoid Arthritis, Brit. J. of Rheumatology, Vol. 35, pp. 568-573 (1996).
	777.	Hameed, A. et al. Delivery of testosterone replacement therapy. Curr Opin in Invest Drugs 2003. 4(1):1213-1219.
	778.	Handelsman, et al., Pharmacokinetics and Pharmacodynamics of Testosterone Pellets in Man, Journal of Clinical Endocrinology and Metabolism, vol. 70, No. 1., pp. 216-222 (1990).
	779.	HANKE, et al., Effect of Testosterone on Plaque Development and Androgen Receptor Expression in the Arterial Vessel Wall, Circulation, Vol. 103, No. 10, pp. 1382-1385 (March 13, 2001).
	780.	Hansen, Nanette et al., Transcript of Early Today, (NBC television broadcast July 31, 2002).
	781.	Hanson DA et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen crosslinked n-telopeptides in urine. J. Bone Min Res 7:1251 (1992).
	782.	Hardy, et al., Endocrine Assessment of Impotence--Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin, Postgrad Med J (1994) 70, 836-837.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	783.	Harman SM. et al. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. <i>J. Clin Endocrinol. Metab.</i> 51:35 (1980).
	784.	Harman SM. et al. Reproductive hormones in aging men. II. Basal pituitary gonadotropins and gonadotropin responses to luteinizing hormone releasing hormone. <i>J. Clin. Endocrinol. Metab.</i> 54:547 (1982).
	785.	Hatch et al. Hirsutism: implications, etiology and management. <i>Am. J. Obstet. Gynec.</i> 140: 815-830 (1981).
	786.	HECHT, Ask Dr. Hecht, New York Daily News, April 22, 2002.
	787.	Heikkila, et al., Serum Androgen-Anabolic Hormones and the Risk of Rheumatoid Arthritis, <i>Ann Rheum Dis</i> , May 1998; 57(5): 281-5.
	788.	Heiss, et al., Associations of Body Fat Distribution, Circulating Sex Hormones Bone Density in Postmenopausal Women, <i>J Clin Endocrinol Metab</i> , May 1995; 80(5): 1591-6.
	789.	Hendrick, Bill, Over the Hill? , Atlanta Journal-Constitution, Healthy Living, September 17, 2002
	790.	Hengge, U. R., M. Baumann, R. Maleba, N. H. Brockmeyer, and M. Goos. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. <i>Br. J. Nutr.</i> 75: 129-138 (1996).
	791.	Hermens, WA. Delivery of hormones: some new concepts. <i>Pharm. Weekbl Sci.</i> 14(4A):253-7. 1992.
	792.	Herschberg AD., A new treatment of climacteric disorders, <i>Gynecol Prat.</i> 1965;16:433-42. (Article in French)
	793.	Heymsfield SB et al. Dual photon absorptiometry: comparison of bone mineral and soft tissue mass measurements in vivo with established methods. <i>Ann J. Clin. Nutr.</i> 49:1283 (1989).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	794.	HILL, et al., Analysis of Relations Between Serum Levels of Epitestosterone, Estradiol, Testosterone, IGF-1 and Prostatic Specific Antigen in Men with Benign Prostatic Hyperplasia in Carcinoma of the Prostate, <i>Physiol. Res.</i> , Vol. 49 (Suppl. 1), pp. S113-S118 (2000).	
	795.	HIV Wasting Syndrome, www.thebody.com (May 1997).	
	796.	HIV Wasting Treatment: Nandrolone Decanoate, www.hivinsite.ucsf.edu (Aug. 1, 1995).	
	797.	HIV/AIDS Clinical Trials in the New Orleans Area, ACTG 329, www.tmc.tulane.edu (Downloaded Oct. 8, 1998).	
	798.	Hobbs CJ, Plymate SR, Rosen CJ, Adler RA: Testosterone administration increases insulin-like growth factor-1 levels in normal men. <i>J Clin Endocrinol Metab</i> 77:776-9, 1993.	
	799.	Hochhaus, et al., A Selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids, <i>Biomed. Chrom.</i> , 6:283-286 (1992).	
	800.	HOFFMAN, et al., Is Low Serum Free Testosterone a Marker for High Grade Prostate Cancer?, <i>J. Urology</i> , Vol. 163, pp. 824-827 (March 2000).	
	801.	Holman et al., 10-year follow-up of intensive glucose control in type 2 diabetes. <i>New England Journal of Medicine</i> 359(15):1577-1589.	
	802.	Holownia, et al., A Clinical Evaluation of a Direct Radioimmunoassay of Testosterone; <i>Clin Chim Acta</i> , Jan. 31, 1993; 214(1): 31-43.	
	803.	Hormone Therapy, BioSante Pharmaceuticals. Downloaded on 10/02.	
	804.	Howland, The Other Hormone Replacement Therapy: Testosterone in Menopausal Women, <i>HealthGate</i> , www.bewell.com (Aug. 7, 2000).	
	805.	HSIEH, et al., Risk Factors for Prostate Cancer: A Case-Control Study in Greece, <i>Int. J. Cancer</i> , Vol. 80, pp. 699-703 (1999).	
	806.	Fertility Industry News; Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men. August 19, 1998. http://staging.inciid.org/fertnews/androgel.html (Androgel)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		<u>Press Release 08-19-1998)</u>	
	807.	Humberstone et al. Comparison of pharmacokinetics and tolerability following application of an Estraderm 50(RM) patch or a novel Estradiol Metered-Dose Transdermal Spray (MTDS(RM)). Poster, presented at the NAMS 2002 Estradiol (2002).	
	808.	Humberstone et al. Elevation of serum testosterone levels in oophorectomized women following application of a novel Metered-Dose Transdermal Spray (MTDS(RM)). Poster.	
	809.	Humberstone et al. Pharmacokinetics of estradiol after application of an Estradiol Metered-Dose Transdermal System (MDTS(RM)): Linearity and effect of washing the application site. Poster, Acrux Drug Delivery Solutions.	
	810.	Husband Crabby, Sluggish, WebMD.com (May 6, 2002).	
	811.	Hwang S N, et al., Probability-based structural parameters from three-dimensional nuclear magnetic resonance images as predictors of trabecular bone strength., Med. Phys., 24:1255-61 (1997)	
	812.	Annex 1 filed in AU01286995, Hydroalcoholic gel according to the invention improves the efficacy of phosphodiesterase type 5 inhibitors in phosphodiesterase type 5 inhibitors Non-Responders.	
	813.	Annex 2 filed in PL366037, Hydroalcoholic Testosterone gel according to the invention improves the efficacy of phosphodiesterase type 5 inhibitors in men with erectile dysfunction not responding to phosphodiesterase type 5 inhibitors.	
	814.	Hydrocortisone (hydrocortisone cream 2.5%, and hydrocortisone ointment 2.5%). RxList.com. http://www.rxlist.com/hydrocortisone-drug.htm . Pages 1-2. Downloaded on 10/13/2009. Exhibit to the Declaration by Norman Weiner filed 10-13-2009 in U.S. Ser. No 11/549083.	
	815.	Idson, et al., Percutaneous Absorption Enhancers, D&CI, pp. 30-33 (July 1985).	
	816.	Impotence Treatments, Impotence World Association, http://www.imootenceworld.org/treatment.htm (2000).	
Examiner Signature		Date Considered	

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	817.	Industry News: Mens Health Effort, M M R/MASS Market Retailers (New York, NY), September 23, 2002.	
	818.	Information on TestoCreme® from www.testocreme.com. Downloaded on 10/21/02.	
	819.	Internet information on Bentley Pharmaceuticals, research.businessweek.com (October 21, 2002).	
	820.	Iqbal, et al., Binding of Testosterone and Oestradiol to Sex Hormone Binding Globulin, Human Serum Albumin and Other Plasma Proteins: Evidence for Non-Specific Binding of Oestradiol to Sex Hormone Binding Globulin, Clinical Science, Vol. 64, No. 3, pp. 307-314 (March 1983).	
	821.	Isaacs, et al., Etiology and Disease Process of Benign Prostatic Hyperplasia, Prostate, Suppl 2:33-50 (1989).	
	822.	Isaacs, Etiology of Benign Prostatic Hyperplasia, Eur Urol, 1994; 25 Suppl 1:6-9.	
	823.	ISAIA, et al., Effect of Testosterone on Bone in Hypogonadal Males, Maturitas, Vol. 15, pp. 47-51 (1992).	
	824.	Isidori et al.,Erectil dysfunction. Recenti Prog. Med.,1999, Jul-Aug; 90(7-8):396-402.	
	825.	Itoh et al., The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level, Nippon Naibunpi Gakkai Zasshi, Vol. 67, No.1, pp. 23-32 (January 20, 1991). [Abstract]	
	826.	Jackson JA et al. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J. Clin Endocrinol. Metab. 65:53 (1987).	
	827.	Jackson JA, Riggs MW, Spiekerman AM: Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 304:4-8, 1992.	
	828.	Jackson S A, et al., Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos), Osteoporosis Int., 11:680-7 (2000)	
	829.	Jaffa et al., Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab. 2008 May;93(5):1893-900.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/829,618
Filing Date	April 20, 2004
Inventor(s)	Dudley et al.
Art Unit	1627
Examiner Name	Jean-Louis, Samira
Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		Epub 2008 Mar 4.
	830.	Jaffe, et al., Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men, Horm. Res., Vol. 41, pp. 215-217 (1994)
	831.	JAIN, et al., Testosterone Supplementation for Erectile Dysfunction: Results of a Meta-Analysis, The J. of Urology, Vol. 164, pp. 371-375 (August 2000).
	832.	James JS. San Francisco area: testosterone replacement study, injection vs. patch. AIDS Treat News. 1995 Oct 20(233):7-8.
	833.	Janowsky JS et al. Testosterone administration enhances spatial cognition in older men. Soc for Neurosci Ann Meeting, New Orleans, LA (1991).
	834.	JANOWSKY, et al., Sex Steroids Modify Working Memory, J. of Cognitive Neuroscience, Vol. 12, No. 3, pp. 407-414 (2000).
	835.	JANOWSKY, et al., Testosterone Influences Spatial Cognition in Older Men, Behavioral Neuroscience, Vol. 108, No. 2, pp. 325-332 (1994).
	836.	Jarkander-Rolff, et al., Transdermal Application of A Testosterone Gel--A Pharmacokinetic Study. Menopause, Vol. 4(4): 251.
	837.	Jarkander-Rolff, M, et al. Treatment with percutaneous testosterone gel in women with sexual arousal disorder. Abstract.
	838.	Javanbakht, et al., Pharmacokinetics of a Novel Testosterone Matrix Transdermal System in Healthy, Premenopausal Women and Women Infected with the Human Immunodeficiency Virus, Journal of Clinical Endocrinology and Metabolism, Vol. 85, No.7, pp. 2395-2401 (July 2000).
	839.	Jenkins et al., Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 2003 Mar;26(3):810-8.
	840.	Jiang Y, et al., Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure., J. Bone Miner. Res., 18:1932-41 (2003)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	841.	JIN, et al., Effects of Androgen Deficiency and Replacement on Prostate Zonal Volumes, Clinical Endocrinology, Vol. 54, pp. 437-445 (2001).	
	842.	Jockenhovel, et al., Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men, Clinical Endocrinology, Vol. 45, pp. 61-71 (1996).	
	843.	Johnson L. Spermatogenesis and aging in the human. J. Androl 7:331 (1986).	
	844.	JONES, et al., Placebo Controlled Study on the Effects of Transdermal Testosterone Gel in Hypogonadal Men with Type II Diabetes (T2D) or Metabolic Syndrome (MS) in Diabetic Control and Insulin Sensitivity: The TIMES 2 Study, P3-422, Endo Society 2008	
	845.	JONES, et al., Pulmonary Vasodilatory Action of Testosterone: Evidence of Calcium Antagonistic Action, J. Cardiovasc. Pharmacol., Vol 39, No. 6, pp. 814-823 (June 2002).	
	846.	Jones, R. et al. Low Levels of Endogenous Androgens Increase the Risk of Atherosclerosis in Elderly Men: Further Supportive Data. J Clin Endocrinol Metab 88(3): 1403-1404(2003)	
	847.	JORDAN, Allergy and Topical Irritation Associated With Transdermal Testosterone Administration: A Comparison of Scrotal and Nonscrotal Transdermal Systems, American Journal of Contact Dermatitis. Vol. 8 (No. 2), pp. 108-113 (June 1997).	
	848.	JOSEPH, et al., Relationship of Serum Sex-Steroid Hormones and Prostate Volume in African American Men, The Prostate, Vol. 53, pp. 322-329 (2002).	
	849.	JUENEMANN, et al., Androgen Deficiency in Prostate Carcinoma- and BPH-Patients?, 193.	
	850.	Kalantaridou, et al., Transdermal Testosterone Replacement for Young Women with Spontaneous Premature Ovarian Failure: A Pilot Study, No. 2322, www.abstracts-on-1 (Downloaded Aug. 7, 2000).	
	851.	KALMAN, Future Pharmacy: What's the T Team Up to?, Muscular Development (Setauken, NY), September 2002.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	852.	KANG, et al., Effect of Oral Administration of Tesosterone on Brachial Arterial Vasoreactivity in Men with Coronary Artery Disease, The Amer. J. of Cardiology, Vol. 89, pp. 862-864 (April 1, 2002).	
	853.	Kanis J A, et al., The components of excess mortality after hip fracture, Bone, 32:468-73 (2003)	
	854.	Kao, et al., Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture, J Pharmacol Exp Ther, May 1987; 241(2): 482-487.	
	855.	Karr, et al., Induction of Benign Prostatic Hypertrophy in Baboons, Urology, Mar. 1984; 23(3): 276-89.	
	856.	Kasper, et al., Development, Progression, and Androgen-Dependence of Prostate Tumors in Probasin-Large T Antigen Transgenic Mice: a Model for Prostate Cancer, Lab Invest, Mar. 1998; 78(3): 319-333.	
	857.	Kasperk CH et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 124:1576 (1989).	
	858.	Katznelson L, et al., Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism, J. Clin. Endocrinol. Metab., 4358-4365 (1996)	
	859.	KATZNELSON, Therapeutic Role of Androgens in the Treatment of Osteoporosis in Men, Bailliere's Clinical Endocrinology and Metabolism, Vol. 12, No. 3:453-470 (October 1998).	
	860.	Kaufman JM, et al. Safety and efficacy of a testosterone (T) gel in a geriatric population. Abstract #1104 at the 97th Annual Meeting of the American Urological Association, May 25-30, 2002, Orlando, FL.	
	861.	Kaufman, Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation, International Journal of Impotence Research, Vol. 12, Supplement 3, p. S75 (B9) (September 2000).	
	862.	KAUFMAN, et al., Background for Studies on the Treatment of Male Osteoporosis: State of the Art, Ann. Rheum. Dis., Vol. 59, pp. 765-772 (2000).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	863.	KAUFMAN, et al., Declining Gonadal Function in Elderly Men, <i>Bailliere's Clinical Endocrinology and Metabolism</i> , Vol. 11, No. 2, pp. 289-307 (July 1997).
	864.	Kellie S E, et al., Sex-specific and race-specific hip fracture rates, <i>Am J. Public Health</i> , 80:326-8 (1990).
	865.	Kelly PJ et al. Dietary calcium, sex hormones, and bone mineral density in men. <i>Br. Med. J.</i> 300:1361-4 (1990)
	866.	KENNY, et al., Determinants of Bone Density in Healthy Older Men With Low Testosterone Levels, <i>J. of Gerontology</i> , Vol. 55A, No. 9, pp. M492-M497 (2000).
	867.	KERR, Hormone Therapy a Risk for Men, Too: Testosterone Perils May Go Up With Age, <i>Newsday</i> (Melville, NY), December 17, 2002.
	868.	Keyrus Biopharma, Clinical Study Report, Double-blind, placebo-controlled, randomised study of the effects of co-administering testosterone with a PDE V inhibitor in ED patients non-responders to PDE V inhibitors alone, September 25, 2008.
	869.	Khan, et al., Radioimmunoassay for Human Testosterone-Estradiol Binding Globulin, <i>J. Clinical Endocrinology and Metabolism</i> , Vol. 54, pp. 705-710 (1982).
	870.	Khosla S. et al., Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen, <i>J Clin Endocrinol Metab.</i> 1998;83(7): 2266-74.
	871.	KHOSLA, Oestrogen, Bones, and Men: When Testosterone Just Isn't Enough, <i>Clinical Endocrinology</i> , Vol. 56, pp. 291-293 (2002).
	872.	Kim et al. Formulation of a reservoir-type testosterone transdermal delivery system. <i>International Journal of Pharmaceutics</i> . 219:51-9 (2001).
	873.	Kim et al., Skin permeation of testosterone and its easier derivatives in rats. <i>Journal of Pharmacy and Pharmacology</i> . 2000 April; 52 (4) 369-75
	874.	Kim, DD et al. Mutual hairless rat skin permeation-enhancing effect of ethanol/water system and oleic acid. <i>J. Pharm. Sci.</i> 85(11): 1191-1195 (1996)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	875.	KIRN, Testosterone Gel Promising in Hypoglandal Men (Benefits Seen at 29 Months), Family Practice News, November 1, 2002.	
	876.	KIRN, Testosterone Gel's Benefits Sustained at 29 Months, Internal Medicine News (Rockville, MD), September 15, 2002.	
	877.	Kirschner, et al., Androgen-Estrogen Metabolism in Women with Upper Body Versus Lower Body Obesity, Journal Of Clinical Endocrinology And Metabolism, Vol. 70, No.2, pp. 473-479 (February 1990).	
	878.	KIRSCHNER, et al., Androgen Production and Metabolism in Normal and Virilized Women, Metabolism, Vol. 21 (7), pp. 667-688, (July 22, 1972).	
	879.	Klein et al., Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care. 2003 May;26(5):1439-48.	
	880.	Klinicheskaya endokrinologiya pod. Red. Prof. N.T. Starkovoy, M. Medicina, 1991, p 426	
	881.	Klose et al. Enhanced Percutaneous Penetration of Ethinyl Estradiol using Across(RM) Enhancers in Spray Formulations. Poster, Acrux Drug Delivery Solutions.	
	882.	Klugo et al., Response of micropenis to topical testosterone and gonadotropin. J. Urol. 119(5):667-8 (May, 1978).	
	883.	Knussmann, et al., Relations Between Sex Hormone Levels and Sexual Behavior in Men, Archives of Sexual Behavior, vol. 15, No. 5, p. 429-45 (1986).	
	884.	Koenig HG, Meador KG, Cohen HJ, Blazer DG: Self-rated depression scales and screening for major depression in the older hospitalized patient with medical illness. J Am Geriatr Soc 36:699-706, 1988.	
	885.	KOLATA, Male Hormone Therapy Popular but Untested, N.Y. Times, August 19, 2002.	
	886.	KONG, et al., Testosterone Therapy in HIV Wasting Syndrome: Systematic Review	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		and Meta-Analysis, The Lancet Infectious Diseases, Vol. 2, pp. 692-699 (November 2002).	
	887.	Karbonits et al. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J. Clinical Endocrinology and Metabolism 89(5): 2039-2043 (2004).	
	888.	Korenman SG et al. Secondary hypogonadism in older men: its relation to impotence. J. Clin Endocrinol Metab. 71:963 (1990).	
	889.	Korenman, et al., Androgen Therapy of Hypogonadal Men with Transscrotal Testosterone Systems, Am J Med, Sep. 1987; 83(3): 471-478.	
	890.	Kraemer, et al., Orgasmic Frequency and Plasma Testosterone Levels in Normal Human Males, Archives of Sexual Behavior, vol. 5, No. 2, p. 125 (1976).	
	891.	Krahe, et al., Risk Factors for Decreased Bone Density in Premenopausal Women, Braz J Med Biol Res, Sep. 1997; 30(9): 1061-6.	
	892.	Krotkiewski M et al. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J. Clin. Invest 72:1150 (1983).	
	893.	KRUMHOLTZ, et al., Prostate-Specific Antigen Cutoff of 2.6 ng/mL for Prostate Cancer Screening is Associated with Favorable Pathologic Tumor Features, Urology, Vol. 60, pp. 469-474 (2002).	
	894.	Kuhn, et al., Gynecomastia: Effect of Prolonged Treatment with Dihydrotestosterone by the Percutaneous Route, Presse Medicine, Vol. 12, No. 1, pp. 21-25 (January 8, 1983). [Abstract]	
	895.	Kuhn, et al., Effects of 10 Days Administration of Percutaneous Dihydrotestosterone on the Pituitary-Testicular Axis in Normal Men, J Clin Endocrinol Metab, Feb. 1984; 58(2): 231-5.	
	896.	Kuhn, et al., Traitement Androgenique Percutane des Hypogonadismes Masculins. Efficacite Comparee de la Testosterone et de la Dihydrotestosterone: Etude de 40 Observations, Contraception-Fertilite-Sexualite, vol. 14, No. 11, pp 1031-1036 (1986).	
	897.	KUHNERT, et al., Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial, European Journal of	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Endocrinology, Vol. 153, pp. 317-326 (2005).	
	898.	Kunz, et al., Virilization of Young Children After Topical Androgen Use by Their Parents, Pediatrics, Vol. 114(1), pp. 282-284 (2004).	
	899.	Kydonieus et al. Transdermal Delivery of Drugs Volume II. Drug and Cosmetic Industry, pp. 57-62 (1987).	
	900.	KYPRIANOU, et al., Quantal Relationship Between Prostatic Dihydrotestosterone and Prostatic Cell Content: Critical Threshold Concept, The Prostate, Vol. 11, pp. 41-50 (1987).	
	901.	La Sexualite . . . , L'Androgel, Le Gel Miracle, www.aci-multimedia.net/feminin/androgel (Downloaded May 9, 2001).	
	902.	Labrie, et al., Physiological Changes in Dehydroepiandrosterone are not Reflected by Serum Levels of Active Androgens and Estrogens but of their Metabolites: Introcrinology, J Clin Endocrinol Metab, Aug. 1997; 82(8): 2403-2409.	
	903.	Lacayo, Are You Man Enough?, Time Europe, www.Time.com , vol. 155, No. 16 (Apr. 24, 2000).	
	904.	Lachin et al., Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes. 2008 Apr; 57(4):995-1001. Epub 2008 Jan 25.	
	905.	Lagiou, et al., Serum Steroids in Relation to Benign Prostatic Hyperplasia, Oncology, Vol. 54, No.6, pp. 497-501 (November-December 1997).	
	906.	LAMMERS, et al., Combination Therapy for Erectile Dysfunction: A Randomized, Double Blind, Unblended Active-Controlled, Cross-Over Study of the Pharmacodynamics and Safety of Combined Oral Formulations of Apomorphine Hydrochloride, Phentolamine Mesylate and Papaverine Hydrochloride in Men with Moderate to Severe Erectile Dysfunction, Intl. J. of Impotence Research, Vol. 14, pp. 54-60 (2002).	
	907.	Langtry, et al., Sildenafil: A Review of its Use in Erectile Dysfunction, Drugs, Vol. 57, No.6, pp. 967-989 (June 1999).	
	908.	Lanman BM et al. The role of human patch testing in a product development program. Joint Conference on Cosmetic Sciences, The Toilets Goods Association (currently the Cosmetic, Toiletry and Fragrance Association), Washington D.C.,	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		April 21-23, 1968.
	909.	Larsen and H. Bundgaard, Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamidines, N-sulfonylsulfonimides and sulfonylureas as possible prodrug derivatives, Int. J. Pharmaceutics, 37:87-95 (1987).
	910.	Larsen et al., Int. J. Pharmaceutics, 47, 103 (1988)
	911.	Lawrence, J. Husband Crabby, Sluggish? MSN.com (May 6, 2002)
	912.	Lee KK, et al., A simple self-report diary for assessing psychosexual function in hypogonadal men, J Androl. 2003 Sep-Oct;24(5):688-98.
	913.	Lee, Men's Health: Testosterone Gel Study Demonstrates Safety and Efficacy up to 42 Months in Men with Low Testosterone, Health & Medicine Week (Atlanta, GA), August 5, 2002.
	914.	LEE, New Gel Treatment Proven and FDA Approved for Effective Treatment of Low Testosterone, 50+ Senior News (Bellport, NY), December 2002.
	915.	LEGRO, ET AL., Role of Androgens in the Growth of Endometrial Carcinoma: An in Vivo Animal Model, American Journal of Obstetrics and Gynecology, Vol. 184 (No.3), p: 303-308, (2001).
	916.	Leiblum, et al., Vaginal Atrophy in the Postmenopausal Woman. The Important Sexual Activity and Hormones, JAMA, Apr. 22-29, 1983;249(16): 2195-8.
	917.	LEIFKE, et al., Age-Related Changes of Serum Sex Hormones, Insulin-like Growth Factor-1 and Sex-hormone Binding Globulin Levels in Men: Cross-sectional Data from a Healthy Male Cohort, Clinical Endocrinology, Vol. 53, pp. 689-695 (2000).
	918.	Leifke, et al., Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Verbal Body Area and Paraspinal Muscle Area in Hypogonadal Men, European Journal of Endocrinology (1998) 138 51-58.
	919.	LEIGH, Antidote for Middle Age Met with Joy, Skepticism, San Mateo County Times, November 25, 2002.
	920.	LEIGH, Doctors Wary of Testosterone Drug Despite FDA's Approval, The Argus

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		(Fremont, CA), November 25, 2002.
	921.	LEIGH, Some Doctors Question Use of Testosterone Gel: Despite FDA's Approval, Ointment for Men Might Increase Risk of Prostate Cancer, Alameda Times-Star (Oakland, CA), November 25, 2002.
	922.	Leinonen, et al., Serum Sex Hormone Binding Globulin and Testosterone Binding After Estradiol Administration, Castration, and Their Combination in Men with Prostatic Carcinoma, Invest Urol, Jul. 1979; 17(1): 24-27.
	923.	LEMON, Testosterone Promises Renewed Vigor: Hormone Replacement Credited with Boosting Energy in Aging Men, MSNBC.com (November 7, 2002).
	924.	Lesher EL, Berryhill J: Validation of the geriatric depression scale-short form among inpatients. J Clin Psycho140:256-60, 1994.
	925.	Letters to the Editor, J. Clin. Endocrinol. Metab., Vol. 88, No. 3, pp. 1402-1405 (March 2003).
	926.	Leucuta et al., abstract of Clujul Medical, 1983 ;56(4) :371-376
	927.	Leuprorelin/testosterone – First Report of Heart Transplant Rejection: 3 Case Reports, Reactions, Vol. 27, No. 912 (July 2002).
	928.	LEVY, Manopause: Experts Discuss Treatments for Testosterone Deficiencies in Older Men, Journal Inquirer (Manchester, CT), August 26, 2002.
	929.	Lewis, et al., Proceedings: Age-Related Changes in Serum 5alpha-Dihydrotestosterone and Testosterone in Normal Men, Journal Of Endocrinology, Vol. 67, No.2, PQ. 15P (November 1975).
	930.	Lewis, et al, Serum 5.alpha.-Dihydrotestosterone and Testosterone Changes with Age in Man, Acta Endocrinologica, 82 (1976) 444-448.
	931.	Liao, J., Androgen Action: Molecular Mechanism and Medical Application, Formos Med. Assoc., Vol. 93, No.9, pp. 741-751 (September 1994).
	932.	LIEBERHERR, et al., Androgens Increase Intracellular Calcium Concentration and Inositol 1,4,5-Triphosphate and Diacylglycerol Formation Via a Pertussis Toxin-sensitive G-protein, The J. of Biological Chemistry, Vol. 269, No. 10, pp. 7217-7223

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		(March 11, 1994).
	933.	LIGNIERES, Effect of High Dihydrotestosterone Plasma Levels on Prostate of Aged Men.
	934.	Lin, S. et al. Transdermal testosterone delivery: comparison between scrotal and nonscrotal delivery systems. Pharm Dev and Tech. 4(3): 405-414 (1999)
	935.	LINET, et al., Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile Dysfunction, The New England J. of Medicine, Vol. 334, No. 14, pp. 873-877 (April 4, 1996).
	936.	LING, et al., Testosterone (T) Enhances Apoptosis-Related Damage in Human Vascular Endothelial Cells, Endocrinology, Vol. 143, No. 3, pp. 1119-1125 (2002).
	937.	Liu, et al. Impact of Assay Parameters on the Accuracy of Free PSA Test: Souce and Stability of Calibrator, Calibration Curve Fitting, and Level of Total PSA in the Serum. J Clinical Laboratory Analysis 12:304-309 (1998).
	938.	LO, et al., Reproductive Function in Human Immunodeficiency virus Infection, The J. of Clinical Endocrinology & Metabolism, Vol. 86, No. 6, pp. 2338-2343 (2001).
	939.	Lobo R. A., Chapter 20: Androgen excess in Infertility, Contraception and Reproductive Endocrinology, Third Edition. D R Mishell, V. Davajan and R. Lobo, Editors. Blackwell Scientific Publications, Boston. pp 422-446, 1991
	940.	Loftsson T. et al. Cyclodextrins as Co-Enhancers in Dermal and Transdermal Drug Delivery, Pharmazie, Vol. 2, pp. 137-139 (1998)
	941.	London Rubber Industries Ltd's Patent, Reports of Patent, Design, and Trade Mark Cases, No. 2, p. 31 (1968).
	942.	Longcope, et al., Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men, Journal Of Clinical Endocrinology And Metabolism, Vol. 71, No.6, pp. 1442-1446 (December 1990).
	943.	Longstreth, et al., Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment, Unimed Pharmaceuticals (October 31, 2000).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	944.	Lopes-Virella et al., Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008 Oct;31(10):2006-12. Epub 2008 Jul 15.	
	945.	LOUIE, Transdermal Testosterone Replacement to Improve Women's Sexual Functioning, Canadian Family Physician p. 1571-1573 (August 22 2001).	
	946.	Lucas, Finasteride Cream in Hirsutism, Endocrine Practice, 7(1):5-10 (2001)	
	947.	Lugg et al., The Role of Nitric Oxide in Erectile Function, J. Andrology, Vol. 16, pp. 2-4, (1995).	
	948.	Luster, B. Sex Sells: But Buyers Should Beware of Natural Supplements that Haven't Been Tested and May Have Dangerous Side Effects, The Courier-Journal (Louisville, KY), March 4, 2002.	
	949.	Ly et al., A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Transdermal Dihydrotestosterone Gel on Muscular Strength, Mobility, and Quality of Life in Older Men with Partial Androgen Deficiency, The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No.9, pp. 4078-4088 (2001).	
	950.	MACLENNAN, ET AL., Hormone Replacement Therapies in Women at Risk of Cardiovascular Disease and Osteoporosis in South Australia in 1997, Medical Journal of Australia, Vol: 170 (No. 11), p. 524-527, (June 7 1999).	
	951.	MacroChem Accelerates Development of Top For Impotence, www.psllgroup.com (April 10, 1997).	
	952.	MacroChem Accelerates Development of Top For Impotence, www.psllgroup.com (Apr. 10, 1997).	
	953.	Macrochem announces initiation of next clinical trial of Opteron, first testosterone cream for male hypogonadism. Macrochem Press Release. 12/8/04.	
	954.	MacroChem Awarded U.S. Patent Covering Transdermal Hormone Replacement Incorporating Proprietary SEPA® Technology and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone, http://www.mchm.com/press/pr24.asp (October 21, 1999).	
	955.	Macrochem. SEPA enhanced testosterone for topical applications: Macrochem	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		investigational topical treatment for testosterone deficiency. Press Release. 12/8/04.	
	956.	Macrochem. Macrochem announces initiation of clinical trial of Opteron, first absorption-enhanced topical cream to treat testosterone deficiency. Press release. 12/16/03	
	957.	Macrochem. MCHM begins dose study for testosterone cream. Press Release. 12/16/2003.	
	958.	Magoha, East Afr. Med. J. (1997) vol.74(10) pp 642-644 , East Afr. Med. J. (1997) vol.74(10) pp 642-644	
	959.	Mahabadi V, et al., Combined transdermal testosterone gel and the progestin nesterone suppresses serum gonadotropins in men, J Clin Endocrinol Metab. 2009 Jul;94(7):2313-20. Epub 2009 Apr 14.	
	960.	Maibach, et al., The Effect of DMSO on Percutaneous Penetration of Hydrocortisone and Testosterone in Man, Annals New York Academy of Sciences, pp. 423-427.	
	961.	Majumdar S, et al., Correlation of trabecular bone structure with age, bone mineral density, and osteoporotic status: in vivo studies in the distal radius using high resolution magnetic resonance imaging, J. Bone Miner. Res., 12:111-8 (1997)	
	962.	Male Hormone Patch Approved, Nuphann, http://www.nuoharm.com/malehorm.htm .	
	963.	Male hypogonadism, Merck Index, pp. 1-6 (June 2007)	
	964.	Man, et al., Optimization of Physiological Lipid Mixtures for Barrier Repair, J Invest Dermatol, May 1996; 106(5): 1096-1101.	
	965.	Manopause: Experts Seeking Treatments for Middle-Age Male Testosterone Deficiency, The Patriot Ledger (Quincy, MA), July 9, 2002.	
	966.	Manos, FDA Approves Gel to Treat Low Testosterone Levels, www.testocreme.com . Downloaded on 5/09/01.	
	967.	Mantzoros, et al, Contribution of Dihydrotestosterone to Male Sexual Behaviour, British Medical Journal, No. 6990, vol. 310, pp 1289-1291 (May 20, 1995).	
	968.	MANTZOROS, et al., Insulin-like Growth Factor 1 in Relation to Prostate Cancer and Benign Prostatic Hyperplasia, Brit. J. of Cancer, Vol. 76, No. 9, pp. 1115-1118	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		(1997).	
	969.	Mantzoros, et al., Leptin Concentrations in the Polycystic Ovary Syndrome, <i>J Clin Endocrinol Metab</i> , Jun. 1997; 82(6): 1687-91.	
	970.	Mantzoros, et al., Serum Steroids in Relation to Benign Prostatic Hyperplasia, <i>Oncology</i> , Nov.-Dec. 1997; 54(6):497-501.	
	971.	MARBURY et al., Evaluation of the Pharmacokinetic Profiles of the New Testosterone Topical Gel Formulation, <i>Testim(TM)</i> , Compared to AndroGel(R), <i>Biopharm. Drug Dispos.</i> , 24:115-120 (2003).	
	972.	Marin, et al., Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues, <i>European Journal of Medicine</i> , Vol. 1, NO.6, pp. 329-336 (October 1992).	
	973.	Marin, et al., Androgen-dependent Nitric Oxide Release in Rat Penis Correlates with Levels of Constitutive Nitric Oxide Synthase Isoenzymes, <i>Biology of Reproduction</i> , Vol. 61, pp. 1012-1016 (1999).	
	974.	MARIN, et al., Androgen Treatment of Abdominally Obese Men, <i>Obesity Research</i> , Vol. 1(4), pp. 245-251 (1993).	
	975.	MARIN, et al., The Effects of Testosterone Treatment on Body Composition and Metabolism in Middle-Aged Obese Men, <i>Intl. J. of Obesity</i> , Vol. 16, pp. 991-997 (1992).	
	976.	MARKS, et al., Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism – A Randomized Controlled Trial, <i>JAMA</i> , Vol. 296(19), pp. 2351-2361 (2006).	
	977.	Marzulli FN. Photoirritation (Phototoxicity, Phototoxic Dermatitis) in <i>Dermatotoxicology</i> , 5th Ed., Eds. Marzulli et al., Washington D.C. 231-237 (1996). Rich JB, Brandt J. Lesh K, Dobs AS. The effect of testosterone on cognition in hypogonadal men. ICE the endocrine society page 734 #OR58-6 (1996)	
	978.	Masi, Sex Hormones and Rheumatoid Arthritis: Cause or Effect Relationships in a Complex Pathophysiology?, <i>Clin Exp Rheumatol</i> , Mar.-Apr. 1995; 13(2): 227-40.	
	979.	Masters, et al., Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol, <i>Clinical Chemistry</i> , Vol. 35, No.6, pp. 979-984 (June 1989).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	980.	Mather, et al., Free Plasma Testosterone Levels During the Normal Menstrual Cycle, Journal of Endocrinol. Invest., Vol. 8, No.5, pp. 437-41 (October 1985).	
	981.	Matsumoto A.M., Hormonal therapy of male hypogonadism. Endocrinology and Metabolism Clinics of North America, 23(4):857-875 (1994).	
	982.	Mazer N et al., Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men, J Sex Med. 2005 Mar;2(2):213-26.	
	983.	Mazer, et al., Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men, Journal of Controlled Release, Vol. 19, pp. 347-361 (1992).	
	984.	Mazer, New Clinical Applications of Transdermal Testosterone Delivery in Men and Women, J Controlled Release, Mar. 1, 2000; 65(1-2): 303-15.	
	985.	MAZESE, et al., Influence of Age and Body Weight on Spine and Femur Bone Density in U.S. White Men, J. of Bone and Mineral Research, Vol. 5, No. 6; pp 645-52 (1990).	
	986.	MCCARTHY, et al., Ventricular Thrombosis and Systemic Embolism in Bodybuilders: Etiology and Management, Ann. Thorac. Surg., Vol. 70, pp. 658-660 (2000).	
	987.	McClellan, et al., Transdermal Testosterone. ADIS New Drug Profile--Drugs, Feb. 1998 55(2): 253-258.	
	988.	McClure et al., Hypogonadal impotence treated by transdermal testosterone. Urology 37(3):224-228 (1991).	
	989.	MCCOOK, Testosterone Boost May Help Some with Parkinson's, ReutersHealth.com (November 26, 2002).	
	990.	McCoy, et al., A Longitudinal Study of the Effects of Menopause on Sexuality, Maturitas, Sep. 1985; 7(3): 203-10.	
	991.	MCDONNELL, et al., A Survey of 2851 Patients with Hemochromatosis: Symptoms and Response to Treatment, The Am. J. Med., Vol. 106, No. 6, pp. 619-624 (June 1999).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	992.	McGuire M. Instant History: The Week, Chicago Tribune, December 1, 2002.	
	993.	McHorney CA, et al., The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs, Med Care. 1993 Mar;31(3):247-63.	
	994.	McLoed, et al., A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. Gastroenterol., 106:405-413 (1994).	
	995.	MCMAHON, et al., Treatment of Intracorporeal Injection Nonresponse with Sildenafil Alone or in Combination with Triple Agent Intracorporeal Injection Therapy, The J. of Urology, Vol. 162, pp. 1992-1998 (December 1999).	
	996.	Mean, et al., Study on the Binding of Dihydrotestosterone, Testosterone and Oestradiol Sex Hormone Binding Globulin, Clin Chim Acta, Oct. 1, 1977; 80(1): 171-180.	
	997.	Meier DE et al. Marked decline in male vertebral bone mineral content with age: association with free testosterone level. Clin. Res 32:705 (1984) [Abstract].	
	998.	Meier DE et al. Marked disparity between trabecular and cortical bone loss with age in healthy men. Ann. Int. Med. 101:605 (1984).	
	999.	Meikle, Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 49(2):191 (1997)	
	1000.	Meikle, et al., Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism, Pharmacology Biology and Clinical Applications of Androgens, Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.).	
	1001.	Meikle, et al., Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men, J Clin Endocrinol Metab, Mar. 1992; 74(3): 623-628.	
	1002.	Meikle, et al., Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradiol and Sex-Hormone-Binding Globulin, Metabolism, Jan. 1982; 31(1): 6-9.	
	1003.	Meikle, et al., Familial Prostatic Cancer Risk and Low Testosterone, J Clin Endocrinol Metab, Jun. 1982; 54(6): 1104-8.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	1004.	Meikle, et al., Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site--A Clinical Research Center Study, Journal of Clinical Endocrinology and Metabolism, vol. 81, No. 5,
	1005.	Meilahn, et al., Association of Sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in Postmenopausal Women, American Journal of Epidemiology, Vol. 143 (2) p. 159-166 (1996).
	1006.	Men's Health Screenings, The Washington Post, June 11, 2002.
	1007.	Mendel, Rates of Dissociation of Sex Steroid Hormones from Human Sex Hormone-Binding Globulin: a Reassessment, J Steroid Biochem Mol Biol, Oct. 1990; 37(2): 251-255.
	1008.	MENDENHALL, Custom Fit: Compounding Pharmacies Tailor Hormone Replacement Therapies to Individual Women, Pittsburgh Post-Gazette, May 28, 2002.
	1009.	Meneely GR. et al. Analysis of factors affecting body composition determined from potassium content in 915 normal Subjects. Ann NY Acad Sci 110:271 (1963).
	1010.	Menopause and Testosterone, www.womenshealth.com (Downloaded Aug. 7, 2000).
	1011.	MERHI, et al., Postmenopausal virilization after spousal use of topical androgens, Fertility and Sterility, Vol. 87(4), pp. 976.e13-e15 (2007).
	1012.	Mermall, et al., Temporal (Circadian) and Functional Relationship between Pro Specific Antigen and Testosterone in Healthy Men, Urology, Jul. 1995; 46(1): 45-53.
	1013.	MESSING, et al., Immediate Hormonal Therapy Compared with Observation After Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer, N. Engl. J. Med., Vol. 34, No. 1, pp. 1781-1788 (December 9, 1999).
	1014.	Methyltestosterone 1-2MG, QUESTION NO. 1151236.012. "Medi-Hut Clarifies Syntest Formula." Business Wire (accessed 4/16/2002).
	1015.	Methyltestosterone, http://www.mesomorphosis.com/steroid-profiles/methyltestosterone.htm , April 15, 2002,

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1016.	Methyltestosterone, http://www.rxlist.com/cgi/generic3/methyltes_ids.htm , April 15, 2002, 2 pages.	
	1017.	METTLIN, et al., Characteristics of Prostate Cancer Detected in the American Cancer Society-National Prostate Cancer Detection Project, The J. of Urol., Vol. 152, pp. 1737-1740 (November 1994).	
	1018.	Miekle AW et al. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. BJU Int. 2004 Apr. 93(6): 789-95.	
	1019.	Miller, Benign Prostatic Hyperplasia: Nutritional and Botanical Therapeutic Options, Alt Med. Rev., (Vol. 1, pp. 18-25 (1996). [Abstract]	
	1020.	Miller, et al., Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study, Journal of Clinical Endocrinology and Metabolism, Vol. 83, No.8, pp. 2717-25 (1998).	
	1021.	Miller, et al., Androgen Deficiency in Women with Hypopituitarism, The Journal of Clinical Endocrinology & Metabolism, vol. 86, No. 2, pp. 561-567 (2001).	
	1022.	MILLER, M et al. Contemporary Use Of Complexed PSA And Calculated Percent Free PSA For Early Detection Of Prostate Cancer: Impact Of Changing Disease Demographics. UROLOGY 57:1105-1111 (2001)	
	1023.	Minoxidil. Wikipedia. http://en.wikipedia.org/wiki/Minoxidil . Pages 1-3. Downloaded on 10/13/2009. Exhibit to the Declaration by Norman Weiner filed 10-13-2009 in U.S. Ser. No. 11/549083.	
	1024.	Misra, et al., Biphasic Testosterone Delivery Profile Observed With Two Different Transdermal Formulations. Pharmaceutical Research, vol. 14, No. 9, pp. 1264-1268 (1997).	
	1025.	MITCHELL, et al., Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men, The J. of Clinical Endocrinology and Metabolism, Vol. 86, No. 2, pp. 724-731 (2001).	
	1026.	Mitchell, et al., Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive, Clin Endocrinol (Oxf), May 1995; 42(5): 501-507.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1027.	MOFFAT, et al., Longitudinal Assessment of Serum Free Testosterone Concentration Predicts Memory Performance and Cognitive Status in Elderly Men, The J. of Clin. Endocrinology & Metabolism, Vol. 87, No. 11, pp. 5001-5007 (2002).	
	1028.	Mollgaard, et al., Permeation of Estradiol Through the Skin - Effect of Vehicles, International Journal of Pharmaceutics, Vol. 15, pp. 185-197 (1983).	
	1029.	Moller, et al., Sex Hormone-Binding Globulin Mediates Prostate Androgen Receptor Action via a Novel Signaling Pathway, Endocrinology, Jan. 1998; 139(1):213-8.	
	1030.	Mollgaard, et al., Vehicle Effect on Topical Drug Delivery, Acta Pharm. Suec., vol. 20, pp. 433-442 (1983).	
	1031.	MONATH, et al., Physiologic Variations of Serum Testosterone Within the Normal Range Do Not Affect Serum Prostate-Specific Antigen, Urology 46(1): 58-61 (1995).	
	1032.	MONGA, et al., Patient Satisfaction with Testosterone Supplementation for the Treatment of Erectile Dysfunction, Arch. Of Andrology, Vol. 48, pp. 433-442 (2002).	
	1033.	Monnier et al., Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999 Apr;48(4):870-80.	
	1034.	Mooney, Anabolic Steroids For AIDS Therapy: Differences Between Analogs, No. 1, www.digiweb.com. (Jul. 1998).	
	1035.	Mooney, Frequency of Administration--Testosterone & Nandrolone, vol. 1, No. 4, www.medibolics.com (Downloaded Oct. 8, 1998).	
	1036.	Mooradian, et al., Biological Actions of Androgens, Endocrine Reviews, vol. 8, No. 1, pp. 1-28 (1987).	
	1037.	Morgan et al. An Ergonomic and Performance Evaluation of a Metered-Dose Transdermal Spray (MDTS(RM)) in Women of Postmenopausal Age. Poster, Acrux Drug Delivery Solutions.	
	1038.	Morgan et al. Photostabilization of Estradiol by Padimate O or Octyl Salicylate When Added to a Transdermal S[ray as Dermal Penetration Enhancing Excipients.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Poster, Acrux Drug Delivery Solutions.	
	1039.	MORGAN et al., 'Enhanced Skin Permeation of Sex Hormones with Novel Topical Spray Vehicles, J. Pharm. Science (1998) Vol. 87 No. 10, PP. 1213-1218.	
	1040.	MORGAN et al., Enhanced Transdermal Delivery of Sex Hormones in Swine with a Novel Topical Aerosol, J. Pharm. Science (1998) Vol. 87 No. 10, pp. 1219-1225.	
	1041.	Morgentaler A, Response to: Efficacy of changing testosterone gel preparations (AndroGel or Testim) among suboptimally responsive hypogonadal men, Int J Impot Res. 2008 May-Jun;20(3):331; author reply 332.	
	1042.	Morgentaler, A. Transcript of CBS-TV Interview with the Early Show, (CBS television broadcast August 30, 2002).	
	1043.	MORGENTALER, et al., Occult Prostate Cancer in Men with Low Serum Testosterone Levels, Vol. 276, No. 23, pp. 1904-1906 (December, 18 1996).	
	1044.	MORGENTALER, et al., Letters to the Editor, Testosterone's Uses The New Yorker, August 19 & 26, 2002.	
	1045.	Morley JE. Charlton E. Patrick P. et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism, 2000;49(9):1239-1242.	
	1046.	MORLEY, Testosterone Treatment in Older Men: Effects on the Prostate, Endocr. Pract., Vol. 6, No. 2, pp. 218-221 (2000).	
	1047.	Morley, et al., Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy, J. Lab. Clin. Med., Vol. 135, No.5, pp. 370-378 (May 2000).	
	1048.	Morley, et al., Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men, Metabolism, vol. 46, No. 4 (Apr. 1997), pp. 410-413.	
	1049.	Morley, J. E., H. M. Perry, F. E. Kaiser, and et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J. Am. Geriatr. 41: 149-152 (1993).	
	1050.	Morris, et al., Marital Sex Frequency and Midcycle Female Testosterone, Arch Sex	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Behav, Feb. 1987; 16(1):27-37.	
	1051.	Morrison and Boyd Organic Chemistry, 3rd Edition, Boston, US (1973), pages 36-7	
	1052.	Morrison, Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women, Psychopharmacology Bulletin, Vol. 33, No.2, pp. 293-296 (1997).	
	1053.	Mother Molly's Guide for Living: Daddy, Too. Post-Messenger (New Glarus, WI), August 7, 2002.	
	1054.	MUKHERJEE, et al., Testosterone Attenuates Expression of Vascular Cell Adhesion Molecule-1 by Conversion to Estradiol by Aromatase in Endothelial Cells: Implications in Atherosclerosis, PNAS, Vol. 99, No. 6, pp. 4055-4060 (March 19, 2002).	
	1055.	Mulhall, et al. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urology 63:348-353, 2004.	
	1056.	Muller et al., Testosterontherapie des Hypogonadismus, Schweizerische Arztezeitung, Vol. 81, No. 46, pgs. 2589-2593 (2000).	
	1057.	Mulligan, K., V. W. Tai, and M. Schambelan. Use of growth hormone and other anabolic agents in AIDS wasting. JPEN J. Parenter. Enteral Nutr. 23: S202-S209 (1999).	
	1058.	Mussoline M E, et al., Risk factors for hip fracture in white men: the NHANES I Epidemiologic Follow-up Study. J. Bone Miner. Res. 13: 918-24 (1998).	
	1059.	MYDLO, et al., Initial Results Utilizing Combination Therapy for Patients with a Suboptimal Response to Either Alprostadil or Sildenafil Monotherapy, Eur. Urol., Vol. 38, pp. 30-34 (2000).	
	1060.	MYDLO, et al., Results from Different Patient Populations Using Combined Therapy with Alprostadil and Sildenafil: Predictors of Satisfaction, BJU Intl., Vol. 86, pp. 469-473 (2000).	
	1061.	Myers, et al., Effects of Estrogen, Androgen, and Progestin on Sexual Psychophysiology and Behavior in Postmenopausal Women, Journal of Clinical	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Endocrinology And Metabolism, Vol. 70, No.4, pp. 1124-1131 (April 1990).	
	1062.	Mylonakis, et al., Clin. Infect. Dis., 2001, 33, p. 857-864	
	1063.	N.N. AIDS ALERT, American health consultants, June 1999	
	1064.	NAGELBERG, et al., Cerebrovascular Accident Associated with Testosterone Therapy in a 21-year-old Hypogonadal Man, N. Engl. J. Med., Vol. 314, No. 10, pp. 649-650 (March 6, 1986).	
	1065.	Nakhla, et al, Stimulation of Prostate Cancer Growth by Androgens and Estrogens Through the Intermediacy of Sex Hormone-Binding Globulin, Endocrinology, Vol. 137, No. 10, pp. 4126-4129 (October 1996).	
	1066.	Nankin HR et al. The aging Leydig cell III. Gonadotropin stimulation in men. J. Androl 2:181 (1981).	
	1067.	Nankin, et al., Daytime Titers of Testosterone, LH, Estrone, Estradiol, and Testosterone-Binding Protein: Acute Effects of LH and LH-Releasing Hormone in Men, Journal of Clinical Endocrinology Metabolism, Vol. 41, pp. 271-81 (1975). [Abstract]	
	1068.	Nankin, et al., Decreased Bioavailable Testosterone in Aging Normal and Impotent Men, J Clin Endocrinol Metab, Dec. 1986; 63(6):1418-1420.	
	1069.	NAPS, Hey Men, It's Time for a Health Tune-Up, Newspaper: Matte Release	
	1070.	Nathorst-Boos, J, et al. reatment with percutaneous gel in women with sexual arousal disorder - effects on quality of life. Abstract.	
	1071.	Navarro, et al., Salivary Testosterone in Postmenopausal Women with Rheumatoid Arthritis, J Rheumatol, Jun. 1998; 25(6): 1059-62.	
	1072.	Need, et al., Double-Blind Placebo-Controlled Trial of Treatment of Osteoporosis with the Anabolic Nandrolone Decanoate, Osteoporosis Int. Supplement 1: S218-222 (1993).	
	1073.	Need, et al., Effects of Nandrolone Therapy on Forearm Bone, www.medmedia.com (Downloaded Oct. 8, 1998).	
	1074.	NEHRA, et al., Rationale for Combination Therapy of Intraurethral Prostaglandin E ₁ and Sildenafil in the Salvage of Erectile Dysfunction Patients Desiring Noninvasive	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Therapy, Intl. J. of Impotence Research, Vol. 14, Suppl. 1, pp. S38-S42 (2002).	
	1075.	Neugarten BL, Havigurst RJ, Tobin SS. The measurement of life satisfaction. J Gerontol 16:134-43, 1961.	
	1076.	Nevalainen, et al., Hormone Regulation of Human Prostate in Organ Culture, Cancer Res, Nov. 1, 1993; 53(21):5199-207.	
	1077.	Never Too Buff, Time Europe, www.time.com, vol. 155, No. 16 (Apr. 24, 2000).	
	1078.	New Drug Application for Testosterone Gel Accepted For Review by FDA Represents First NDA with Bentley's Proprietary CPE-215 Technology, Business Wire (March 6, 2002).	
	1079.	New Treatment Approved for Low Testosterone, Not Born Yesterday (La Canada Flintridge, CA), December 2002.	
	1080.	Ng. Martin et al., Prospective Study of Effect of Androgens on Serum Inflammatory Markers in Men, Arterioscler. Thromb. Vasc. Biol., Vol. 22, pp. 1136-1141 (2002).	
	1081.	Nieschlag E. et al. Reproductive functions in young fathers and grandfathers. J. Clin. Endocrinol. Metab. 55:876 (1982).	
	1082.	Nieschlag et al., Testosterone: Action, Deficiency, Substitution, Chapters 1, 6-16 (1999).	
	1083.	NIESCHLAG, Eberhard, Testosterone Treatment Comes of Age: New Options for Hypogonadal Men, Clinical Endocrinology, Vol. 65, pp. 275-281 (2006).	
	1084.	NIESCHLAG, et al. eds., Testosterone: Action – Deficiency – Substitution (2d ed.), pp.335-337.	
	1085.	Nilas, et al., Bone Mass and its Relationship to Age and the Menopause, J Clin Endocrinol Metab, Oct. 1987; 65(4): 697-702.	
	1086.	Nishimura, Y., M. Tsutsumi, H. T. Tsunenari, H. Maeda, and M. Yokoyama. Relationship between respiratory muscle strength and lean body mass in men with COPD. Chest 107: 1232-1236 (1995).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1087.	NOVELLI, et al., Pharmacogenetics of Human Androgens and Prostatic Diseases, Pharmacogenomics, Vol. 2, No. 1, pp. 65-72 (2001).	
	1088.	Noveon, Formulating Hydroalcoholic Gels with Carbopol Polymers, Noveon TDS-255, December 1999.	
	1089.	Noveon, Neutralizing Carbopol and Pemulen Polymers in Aqueous and Hydroalcoholic Systems, Commercial Brochure TDS-237 (October 1998) by Noveon Inc. of Cleveland, Ohio.	
	1090.	O'Carrol & Bancroft, Testosterone Therapy for Low Sexual Interest and Erectile Dysfunction in Men: A Controlled Study, Brit. J. Psychiatry 145:146-151 (1984).	
	1091.	O'Connor, Managing Menopause - Part 2: What Are The Choices in Treatment? Medicine Today, Vol. 2 (No.2), p. 30-39, (February 22, 2001).	
	1092.	Oden Z M, et al., The effect of trabecular structure on DXA-based predictions of bovine bone failure. Calcif. Tissue Int., 63:67-73 (1998).	
	1093.	OKUN, et al., Beneficial Effects of Testosterone Replacement for the Nonmotor Symptoms of Parkinson Disease, Arch. Neurol., Vol. 59, pp. 1750-1753 (November 2002)	
	1094.	OKUN, et al., Refractory Nonmotor Symptoms in Male Patients with Parkinson Disease Due to Testosterone Deficiency: A Common Unrecognized Comorbidity, Arch. Neurol., Vol. 59, pp. 807-811 (May 2002).	
	1095.	O'Neill T W, et al., The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J. Bone Miner. Res., 11:1010-8 (1996).	
	1096.	Openbrier, D. R., M. M. Irwin, R. M. Rogers, G. P. Gottlieb, J. H. Daubner, D. H. Van Theil and B. E. Pennock. Nutritional status and lung function in patients with emphysema and chronic bronchitis. Chest 83: 11-22 (1983).	
	1097.	OPPERMANN, Testosterone Replacement Carries Definite Risks for Men, Chicago Daily Herald, June 3, 2002.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1098.	Orwell ES et al. The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men. <i>J. Clin. Endocrinol. Metab.</i> 70:1202 (1990).	
	1099.	Orwoll ES et al. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. <i>Ann. Int. Med.</i> 112:29 (1990).	
	1100.	Orwoll, E. S., Oviatt, S., Biddle, J., and Janowsky, J. Transdermal testosterone supplementation in normal older men. <i>Proc. 74th Endocr. Soc. Meetings</i> , San Antonio, TX. 6-24-1992 (1992).	
	1101.	Osborne et al., Skin Penetration Enhancers Cited in Technical Literature, <i>Pharmaceutical Technology</i> , pp. 58, 60, 62, 64 and 66, November 1997.	
	1102.	Ostrenga, et al., Significance of Vehicle Composition I: Relationship Between Topical Vehicle Composition, Skin Penetrability, and Clinical Efficacy, <i>Journal of Pharmaceutical Sciences</i> , vol. 60, No. 8, pp. 1175-1179 (Aug. 1971).	
	1103.	Ostrenga, et al., Significance of Vehicle Composition II: Prediction of Optimal Vehicle Composition, <i>Journal of Pharmaceutical Sciences</i> , vol. 60, No. 8, pp. 1180-1183 (Aug. 1971).	
	1104.	Pabla D, Zia H, A comparative permeation/release study of different testosterone gel formulations, <i>Drug Deliv.</i> 2007 Aug;14(6):389-96.	
	1105.	Package insert for Estrogel, (March 2004)	
	1106.	Padova, et al., Pubarche Induction with Testosterone Treatment in Women with Panhypopituitarism, <i>Fertil Steril</i> , Feb. 1996; 65(2): 437-9.	
	1107.	Page ST et al., Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist, <i>J Clin Endocrinol Metab.</i> 2006 Nov;91(11):4374-80. <i>Epub 2006 Aug 29.</i>	
	1108.	PANNEK, et al., The Role of PSA and Percent Free PSA for Staging and Prognosis Prediction in Clinically Localized Prostate Cancer, <i>Seminars in Urologic Oncology</i> , Vol. 16, No. 3, pp. 100-105 (August 1998).	
	1109.	Parfitt A M, Implications of architecture for the pathogenesis and prevention of vertebral fracture. <i>Bone</i> , 13:S41-7 (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1110.	Parfitt A M, et al., Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. <i>J. Clin. Invest.</i> , 72:1396-409 (1983)	
	1111.	Park, et al., Effects of Androgens on the Expression of Nitric Oxide Synthase mRNAs in Rat Corpora Cavemosum, <i>BJU Int'l</i> Vol. 83, pp. 327-33 (1999).	
	1112.	Parker, et al., Experience with Transdermal Testosterone Replacement in Hypogonadal Men, <i>Clinical Endocrinology (OXF)</i> , Vol. 50, pp. 57-62 (1999).	
	1113.	Patch Ups Women's Sex Drive. ABCNEWS.com: http://abcnews.go.com/sections/living/DailyNews/testosterone990615.html	
	1114.	Pedersen, et al., Relationship Between Sex Hormones, Body Composition and Metabolic Risk Parameters in Premenopausal Women, <i>Eur J Endocrinol</i> , Aug. 1995; 133(2): 200-6.	
	1115.	PENA, Topical Drug Delivery Formulations, ed. Osborne and Amann, Vol. 42, pp. 381-388 (1990).	
	1116.	Penson, et al., Androgen and Pituitary Control of Penile Nitric Oxide Synthase and Erectile Function In the Rat, <i>Biology of Reproduction</i> , Vol. 55, pp.567-74 (1996).	
	1117.	PERCUTACRINE STRONG ANDROGENIC Testosterone Percutacrine Androgenique Forte from VIDAL dictionary (1985).	
	1118.	PERES, Clinical Trials to Test Efficacy of Testosterone-Replacement Therapy for Men, <i>Knight-Ridder Tribune Business News</i> , November 29, 2002.	
	1119.	PERES, Hormones Now a Men's Issue, <i>Chicago Tribune</i> , November 29, 2002.	
	1120.	PERES, Replacement Hormones New Issue for Men, <i>Pittsburgh Post-Gazette</i> , January 5, 2003.	
	1121.	PERES, Researchers Consider Benefits of Male Hormone Replacement, <i>Houston Chronicle</i> , January 3, 2002.	
	1122.	Perez CA, I love my Androgel, <i>Posit Aware</i> . 2003 Nov-Dec;14(6):42-3.	
	1123.	PERRY, et al., Osteoporosis in Men: Are We Ready to Diagnose and Treat?, <i>Curr. Rheumatol. Res.</i> , Vol. 3, No. 3, pp. 240-244 (June 2001).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1124.	Persky, et al., The Relation of Plasma Androgen Levels to Sexual Behaviors and Attitudes of Women, Psychosomatic Medicine, Vol. 44, No.4, pp. 305-319 (September 1982).	
	1125.	Persky, et al., Plasma Testosterone Level and Sexual Behavior of Couples. Arch Sex Behav, May 1978; 7(3): 157-73.	
	1126.	Petra, The Plasma Sex Steroid Binding Protein (SBP or SHBG): A Critical Review of Recent Developments of the Structure, Molecular Biology, and Function, J. Steroid Biochem. Mol. Biol. Vol. 40, pp. 735-53 (1991).	
	1127.	Petrangeli, et al., Effects of Two Different Medical Treatments on Dihydrotestosterone Content and Androgen Receptors in Human Benign Prostatic Hyperplasia. J Steroid Biochem, 1988; 30(1-6): 395-9.	
	1128.	Petrow, The Dihydrotestosterone (DHT) Hypothesis of Prostate Cancer and its Therapeutic Implications. Prostate, 1986; 9(4): 343-61.	
	1129.	PFEILSCHIFTER, et al., Osteoporosis Due to Cancer Treatment: Pathogenesis and Management, J. of Clin. Oncology, Vol. 18, No. 7, pp. 1570-1593 (April 2000).	
	1130.	Pharmaceutical additive encyclopedia 2000 (in Japanese)	
	1131.	Phillips GB, Pinkernell BH, Jinh TY: The association of hypotestosteronemia with coronary artery disease in men. Arteriosclerosis & Thrombosis 14:701-6, 1994.	
	1132.	Phillips L et al. A comparison of rabbit and human skin response to certain irritants. Toxicol. Appl. Pharmacol. 21, 369-82 (1972)	
	1133.	PILEPICH, et al., Androgen Deprivation with Radiation Therapy Compared with Radiation Therapy Alone for Locally Advanced Prostatic Carcinoma: A Randomized Comparative Trial of the Radiation Therapy Oncology Group, Urology, Vol. 45, No. 4, pp. 616-623 (April 1995).	
	1134.	Pirke KM et al. Age related changes in free plasma testosterone, dihydrotestosterone and oestradiol. Acta Endocrinol. 80: 171 (1975).	
	1135.	Pirke, et al., Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males,	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		ACTA Endocrinologica (COPENH), Vol. 74, No.4, pp. 792-800 (December 1973).	
	1136.	Place, et al., Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadian Pattern of Testosterone. Ann NY Acad Sci, 1991; 618:441-9.	
	1137.	PLYMATE, et al., Androgens, Lipids, and Cardiovascular Risk, Annals of Internal Medicine, Vol. 117, No. 10, pp. 871-872 (November 15, 1992).	
	1138.	Plymate, et al., Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men. J Androl, Sep.-Oct. 1989; 10(5): 366-71.	
	1139.	Plymate, et al., Effects of Sex Hormone Binding Globulin (SHBG) on Human Prostatic Carcinoma. J Steroid Biochem Mol Biol, 1991; 40(4-6): 833-839.	
	1140.	Pollard et al., Dihydrotestosterone does not induce prostate adenocarcinoma in L-W rats, Prostate 10:325-331 (1987).	
	1141.	POLSY, et al., HIV-Associated Wasting in the HAART Era: Guidelines for Assessment, Diagnosis, and Treatment, AIDS Patient Care and STDs, Vol. 15, No. 8, pp. 411-423 (2001).	
	1142.	POOR, et al., Determinants of Reduced Survival Following Hip Fractures in Men, Clinical Orthopaedics and Related Research, No. 319, pp. 260-265 (October 1995).	
	1143.	POPE JR., et al., Testosterone Gel Supplementation for Men with Refractory Depression: A Randomized, Placebo-Controlled Trial. Am. J. Psychiatry, 160(1): 105-111 (2003).	
	1144.	Porche DJ. Treatment review. Testosterone (Testoderm). J Assoc Nurses AIDS Care. 1995 Jul-Aug;6(4):43-5.	
	1145.	PORTER, et al., Humoral Mechanisms in Prostate Cancer: A Role for FSH, Urologic Oncology, Vol. 6, pp. 131-138 (2001).	
	1146.	POSTMA, et al., Effects of Testosterone Administration on Selective Aspects of Object-Location Memory in Healthy Young Women, Psychoneuroendocrinology, Vol. 25, pp. 563-575 (2000).	
	1147.	POTEAT, et al., Appropriateness of Prostate-Specific Antigen Testing, Am. J. Clin. Pathol., Vol. 113, pp. 421-428 (2000).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1148.	PREIDT, Testosterone: Shot in the Arm for What Ails Aging Males, HealthScoutNews.com (August 5, 2002).	
	1149.	Prince RL et al. Prevention of postmenopausal osteoporosis: A comparative study of exercise, calcium supplementation and hormone-replacement therapy. N Engl J. Med 325:1189 (1991).	
	1150.	Procter & Gamble, TheraTech Plan Testosterone Patch For Use by Women. The Wall Street Journal, pg. B6 (December 4, 1997)	
	1151.	Product information - Testoderm TTS, Physicians' Desk Reference, Alza pp. 517-520 (1999).	
	1152.	Prospectus - Cellegy Pharmaceuticals, Inc., OPPENHEIMER & CO., pp. 1-4, 20821-28 (it is 21-28 on 10/153468) (1997).	
	1153.	Quincey et al., THE METABOLISM OF [1,2-3H]17{alpha}-METHYLTESTOSTERONE IN HUMAN SUBJECTS J. Endocrinol. 37(1):37-35 (1967)	
	1154.	RABKIN, et al., Testosterone Therapy for Human Immunodeficiency Virus-Positive Men With and Without Hypogonadism, J. Clin. Psychopharmacol., Vol. 19, No. 1, pp. 19-27 (February 1999).	
	1155.	RABKIN, et al., Treatment of Depression in HIV+ Men: Literature Review and Report of an Ongoing Study of Testosterone Replacement Therapy, Ann. Behav. Med., Vol. 18, No. 1, pp. 24-29 (1996).	
	1156.	Rabkin, J et al. A double -blind, Placebo-Controlled Trial of Testosterone Therapy for HIV-Positive Men With Hypogonadal Symptoms. Arch Gen Psychiatry 57: 141-147 (Feb 2000)	
	1157.	Radio: Public Service Announcement: Transcripts for Advertisements: Low Testosterone in Men, An Easily Diagnosed and Treated Condition. PSA. :15, :30, :60 Versions.	
	1158.	Raisz, et al., Comparison of the Effects of Estrogen Alone and Estrogen Plus Androgen on Biochemical Markers of Bone Formation and Resorption in	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		Postmenopausal Women, Journal Of Clinical Endocrinology And Metabolism, Vol. 81, No.1, pp. 37-43 (January 1996).
	1159.	Rako, Testosterone Deficiency: a Key Factor in the Increased Cardiovascular Risk to Women Following Hysterectomy or with Natural Aging? J Womens Health, Sep. 1998; 7(7): 825-9.
	1160.	Ramzy, P. I., S. E. Wolf, and D. N. Herndon. Current status of anabolic hormone administration in human burn injury. JPEN J. Parenter. Enteral Nutr. 23: S190-S194 (1999).
	1161.	Raudaskoski, et al., Sex-Hormone Binding Globulin As An Indicator of the Hepatic Impacts of Continuous Combined Hormone Replacement Regimens, Maturitas, Vol. 29 (No.1), p. 87-92, (January 22, 1998).
	1162.	RAY Fox et al., Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation, J. of Bone and Mineral Research, Vol. 12, No. 1, pp. 24-35 (1997).
	1163.	RAY, et al., ISATT Series 2007, Men's Health Information (Presentation)
	1164.	REBORA, Baldness and Coronary Artery Disease: The Dermatologic Point of View of a Controversial Issue, Arch Dermatol. 137:943-947 (2001)
	1165.	Reed RL et al. The relationship ,between muscle mass and muscle strength in the elderly. J. Am Ger Soc 39:555 (1991).
	1166.	Registr lekarstvennykh trav Rossii. Enziklopediya lekarstv. M., RLS-2000 , 1999, p. 831-969
	1167.	REHM, Testosterone and Andropause, National Public Radio The Diane Rehm Show Online (August 14, 2002).
	1168.	Reichardt, J. Prostatic Steroid 5 α -Reductase, an Androgen Metabolic Gene. Mayo Clin Proc. 75(suppl):S36-S39 (2000)
	1169.	Reilly et al., Androgenic Regulation of NO Availability in Rat Penile Erection, 18 J. Andrology 110 (1997): 110-115.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1170.	Research & Education Institute at Harbor-UCLA Medical Center, Testosterone Gel (AndroGel(R)) Study Demonstrates Safety and Efficacy Persists Up to 42 Months in Men with Low Testosterone, Yahoo!Finance.com (June 20, 2002).	
	1171.	Retin-A (tretinoin) Cream; Retin-A (tretinoin) Gel; Retin-A (tretinoin) Liquid. Daily Med. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3734 . Pages 1-13. Downloaded on 10/13/2009. Exhibit to the Declaration by Norman Weiner filed 10-13-2009 in 11/549083.	
	1172.	Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. NEJM. 2000. 342:381-9.	
	1173.	Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. Am J Ophthalmol. 2000 May;129(5):704-5.	
	1174.	Retnakaran et al., Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006 Jun;55(6):1832-9.	
	1175.	Reynolds, Do women with impaired sexual function following oophorectomy benefit from transdermal testosterone at a physiologic dose? The Journal of Family Practice, Vol. 49 (No. 12n), pg. 1075 (December 2000)	
	1176.	Rheology Modifiers Handbook, 2000, page 81-88, published by William Andrew Publishing.	
	1177.	RHODEN, et al., The Relationship of Serum Testosterone to Erectile Function in Normal Aging Men, The J. of Urol., Vol. 167, pp. 1745-1748 (April 2002).	
	1178.	Richmond et al., Male pubertal development and the role of androgen therapy, Nature Clinical Practice Endocrinology and Metabolism, 3(4):338-344 (2007).	
	1179.	RIETSCHEL, et al., Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral Therapy, Clinical Infectious Diseases, Vol. 31, pp. 1240-1244 (2000).	
	1180.	RIGGS, et al., A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		Contributes to Bone Loss in Aging Men, J. of Bone and Mineral Research, Vol. 13, No. 5, pp. 763-773 (1998).
	1181.	Riggs, Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel, Unimed News Release, pp. 1-2 (Mar. 31, 1997).
	1182.	Ringham, et al., Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel In Hypogonadal Men, Unimed Pharmaceuticals (October 31, 2000).
	1183.	ROBERTS, More Men Take Testosterone, CBS-TV CBS Morning News Online (August 25, 2002).
	1184.	ROBERTS, et al., PSA Doubling Time as a Predictor of Clinical Progression After Biochemical Failure Following Radical Prostatectomy for Prostate Cancer, Mayo Clin. Proc., Vol. 76, pp. 576-581 (2001).
	1185.	Rodriguez, Study of Drug to Preserve Lean Muscle Mass Recruiting Patients, ALPA 9701: Study Recruiting Patients, www.apla.org (Downloaded Oct. 8, 1998).
	1186.	Rogol A.D., New facets of androgen replacement therapy during childhood and adolescence. Expert Opinion on Pharmacotherapy, 6(8):1319-1336 (2005).
	1187.	Rogol, Nature clinical practice endocrinology and metabolism vol. 3, no. 4, April 2007, pages 338-344.
	1188.	Rogol, Pubertal androgen therapy in boys. Pediatr. Endocrinol. Rev., 2005, March; 2(3):383-90.
	1189.	ROLF, et al., Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation, Clinical Endocrinology, Vol. 56, pp. 637-641 (2002).
	1190.	ROLF, et al., Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men, European Journal of Endocrinology, Vol. 146, pp. 673-679 (2002).
	1191.	ROSANO et al., Acute Anti-Ischemic Effect of Testosterone in Men with Coronary Artery Disease, Circulation, Vol. 99, No. 13, pp. 1666-1670 (April 6, 1999).
	1192.	Rosano, et al., Antianginal and Lipid Lowering Effect of Chronic Oral Androgen Supplementation in Elderly Male Patients with Coronary Heart Disease, JACC,

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Abstract No. 835-4 (Feb. 2001).	
	1193.	ROSEN, et al., The International Index of Erectile Function (IIEF): A Multidimensional Scale for Assessment of Erectile Dysfunction, Urology, Vol. 49, pp. 822-830 (1997).	
	1194.	Rosenthal BD, et al., Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone, Urology. 2006 Mar;67(3):571-4.	
	1195.	Rosner et al., Sex Hormone-Binding Globulin Mediates Steroid Hormone Signal Transduction at the Plasma Membrane, J. Steroid Biochem. Mol. Biol. Vol. 69:481-5 (1999)	
	1196.	ROUBENOFF, et al., Role of Cytokines and Testosterone in Regulating Lean Body Mass and Resting Energy Expenditure in HIV-infected Men, Am. J. Physiol. Endocrinol. Metab., Vol. 283, pp. E138-E145 (2002).	
	1197.	Rouru, et al., Serum Leptin Concentrations in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab, Jun. 1997; 82(6): 1697-700.	
	1198.	Rousseau, et al, Inhibition of Steroid-Protein Interactions by Dicyclohexane Derivatives. J Steroid Biochem, vol. 31, No. 4B, pp 691-697 (1988).	
	1199.	ROWE et al., Handbook of Pharmaceutical Excipients, 2d ed. (1994).	
	1200.	Rubens RM et al. Further studies on Leydig cell function in old age. J. Clin. Endocrinol. Metab. 39:40 (1974).	
	1201.	Rudman D, Drinka PJ, Wilson CR, Mattson DE, Scherrman F, Cuisinier MC, Schults S: Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men. Clin Endocrinol 40:653-61, 1994.	
	1202.	Saad F, et al., A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate, J Androl. 2008 Jan-Feb;29(1):102-5. Epub 2007 Oct 3.	
	1203.	Saad F, et al., Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome, Andrologia. 2008 Feb;40(1):44-8.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1204.	Saeedi M et al., A randomized, double-blind, controlled trial of testosterone gel treatment versus vehicle control on the facial hair of young men with beta-thalassemia major, <i>J Dermatolog Treat.</i> 2007;18(5):271-4.	
	1205.	Salehian et al. Pharmacokinetics, bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate - a clinical research center study. <i>J. Clin. Endocrinol. Metab.</i> 80: 3567-75 (1995).	
	1206.	Sanctis et al. Clinical experience using the Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. <i>J. Ped. Endocrinol. Metab.</i> 11, Supp. 3, 891-900 (1998) (abstract only).	
	1207.	Sands, et al., Exogenous Androgens in Postmenopausal Women, <i>Am J Med</i> , Jan. 16, 1995; 98(1A): 76S-79S.	
	1208.	Santavirta S et al. Determinants of osteoporotic thoracic vertebral fracture. Screening of 57,000 Finnish women and men. <i>Acta Orthop Scand</i> 63:198 (1992).	
	1209.	SANTUS G C ET AL. Transdermal enhancer patent literature JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B. V. AMSTERDAM, NL, vol. 25, no. 1 /2 , 27 May 1993, DD. 1-20.	
	1210.	SARREL P ET AL: ESTROGEN AND ESTROGEN-ANDROGEN REPLACEMENT IN POSTMENOPAUSAL WOMEN DISSATISFIED WITH ESTROGEN-ONLY THERAPY SEXUAL BEHAVIOR AND NEUROENDOCRINE RESPONSES JOURNAL OF REPRODUCTIVE MEDICINE, JOURNAL OF REPRODUCTIVE MEDICINE, INC., CHICAGO, US, vol. 43, no. 10, October 1998 (1998-10), pages 847-856.	
	1211.	Sasagawa I, Adachi M, Sawamura T et al. Serum levels of total and free testosterone in men undergoing hemodialysis. <i>Arch Androl</i> 1998;40(20):153-158.	
	1212.	Sattler FR, Jaque SV, Schroeder ET, Olson C, Dube MP, Martinez C, Briggs W, Horton R, Azen S: Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with Human Immunodeficiency Virus. <i>J Clin Endocrinol Metab</i> 84:1268-76, 1999.	
	1213.	Savvas, et al., Increase in Bone Mass after One Year of Percutaneous Oestradiol and Testosterone Implants in Post-Menopausal Women Who Have Previously Received	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Long-Term Oral Oestrogens, British Journal of Obstetrics Gynecology, Vol. 99, No.9, pp. 757-760 (September 1992).	
	1214.	SCHAEFER et al., Skin Barrier, Principles of Percutaneous Absorption, ed. Kager, pp. 164-171 (1996).	
	1215.	SCHAISON et al., Testosterone,; Percutaneous dihydrotestosterone treatment, Ch. 15, pp. 423-435 (1999)	
	1216.	Schaison G, Nahoul K, Couz B) Percutaneous dihydrotestosterone (DHT) treatment. Testosterone: Action. Deficiency and Substitution E. Nieschlag, H.M. Behre (Eds.). Springer-Verlag, New York, pp. 155-164 (1990).	
	1217.	Schaison, et al., On the Role of Dihydrotestosterone in Regulating Luteinizing Hormone Secretion in Man, J Clin Endocrinol Metab, Nov. 1980; 51(5): 1133-1137.	
	1218.	SCHATZL, et al., Endocrine Patterns in Patients with Benign and Malignant Prostatic Diseases, The Prostate, Vol. 44, pp. 219-224 (2000).	
	1219.	SCHATZL, et al., High-Grade Prostate Cancer is Associated With Low Serum Testosterone Levels, The Prostate, Vol. 47, pp. 52-58 (2001).	
	1220.	Schering AG Business: Reproductive, Metabolic. Biocentury Part II, Belmont, CA (July 8, 2002)	
	1221.	SCHIAVI, RC, et al., Effect of Testosterone Administration on Sexual Behavior and Mood in Men with Erectile Dysfunction. Arch. Sex Behav., 1997 June, 26(3):231-41, abstract PMID 9146812 [online].	
	1222.	Schols, A. M., P. B. Soeters, R. Mostert, R. J. Pluymers, and E. F. Wouters. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am. J. Respir. Crit Care Med. 152: 1268-1214 (1995).	
	1223.	SCHOOR, M., Livening Up Libidos: Testosterone Patches Can Help Revive Women's Sex Drive, www.abcnews.com, September 6, 2000.	
	1224.	Schottner, et al., Lignans Interfering with 5 alph-Dihydrotestosterone Binding to Human Sex Hormone-Binding Globulin, J Natl Prod, Jan. 1988; 61(1): 119-121.	
	1225.	Schreiner-Engel, et al., Low Sexual Desire in Women: the Role of Reproductive Hormones, Hormones and Behavior, Vol. 23, No.2, pp. 221-234 (June 1989).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1226.	Schreiner-Engel, et al., Sexual Arousal and the Menstrual Cycle, Psychosom Med Jun. 1981; 43(3): 199-214.	
	1227.	Schluthesis, D et al. Pilot study of the transdermal application of testosterone gel to the penile skin for the treatment of hypogonadotropic men with erectile dysfunction Abstract. World J Urol 18: 431-435 (2000)	
	1228.	Schurmeyer, et al., Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men, International Journal of Andrology, Vol. 7, pp. 181-187.	
	1229.	Schustack A, Meshiaj D, Waiss Z, Gottlob L. L. Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis anemia: a follow up of up to 8 years in 16 patients. Clin Nephrol 1985; 23(6):303-306.	
	1230.	Schwartz RS et al. Abrass 1B J. Geront 6:M181 (1990).	
	1231.	Scott JD et al., Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men, HIV Clin Trials. 2007 Nov-Dec;8(6):412-20.	
	1232.	Seeman E, et al. Risk factors for spinal osteoporosis in men. Am J. Med 75:977 (1983).	
	1233.	Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression . Journal of Affective Disorder 4H: 157-161 (1998)	
	1234.	Seidman, et al. J Clin Psychiatry 2001 ;62:406-412	
	1235.	SEPA Testosterone Transdermal Gel Receives Application By FDA, Doctor's Guide Global Edition, http://pslgroup.com/dg/123aa.htm (January 15, 1997).	
	1236.	SEPA Testosterone Transdermal Gel Receives IND Application by FDA, Doctor's Guide Global Edition, http://pslgroup.com/dg/123aa.htm (January 15, 1997).	
	1237.	Sexual Dysfunction in the Male - Sexual Arousal Disorder, The Merck Manual, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1238.	Shabsigh R, et al. Testosterone replacement therapy with testosterone gel 1% converts sildenafil non-responders to responders in men with hypogonadism and erectile dysfunction who failed prior sildenafil therapy. Abstract #954 at the 98th Annual Meeting of the American Urological Association, April 26-May 1, 2003, Chicago, IL	
	1239.	Shabsigh R, et al., Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone, J Urol. 2008 May;179(5 Suppl):S97-S102.	
	1240.	SHABSIGH, Recent Developments in Male Sexual Dysfunction, pp. 196-200	
	1241.	SHABSIGH, The Effects of Testosterone on the Cavernous Tissue and Erectile Dysfunction, World J. of Urol., Vol. 15, pp. 21-26 (1997).	
	1242.	SHABSIGH, et al., Intracavernous Alprostadil Alfadex (Edex/Viridal) is Effective and Safe in Patients with Erectile Dysfunction After Failing Sildenafil (Viagra), Urology, Vol. 55, pp. 477-480 (2000).	
	1243.	Shanbhag, et al., The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma, J Steroid Biochem, Feb. 1986; 24(2): 549-555.	
	1244.	Shaneyfelt et al., Hormonal Predictors of Prostate Cancer: A Meta-Analysis, Journal of Clinical Oncology, Vol. 18, No.4, pp. 847-853, 2000.	
	1245.	Shapiro et al. Testosterone and Other Anabolic Steroids as Cardiovascular Drugs, Am. J. of Therapeutics, vol. 6, no. 3 May 1999, pages 167-174	
	1246.	Sheffield-Moore M, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DN, Wolfe RR, Ferrando AA: Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 84:2705-11, 1999.	
	1247.	Sheikh VI, Yesavage VA: Geriatric Depression scale (GDS): recent evidence and development of a shorter version. Clinical Gerontology: A Guide to Assessment and intervention. New York: Haworth Press, 1986, 165-74.	
	1248.	Sherwin B. B. and Gelfand M. M., Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause, Am. J. Obstet.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Gynecol. 1985; 151:153-160.	
	1249.	Sherwin, Affective Changes with Estrogen and Androgen Replacement Therapy in Surgically Menopausal Women, Journal Of Affective Disorders, Vol. 14, pp. 177-187 (1988).	
	1250.	Sherwin, Estrogen and/or Androgen Replacement Therapy and Cognitive Functioning in Surgically Menopausal Women, Psychoneuroendocrinology, Vol. 13, NO.4, PP. 345-357 (March 1988).	
	1251.	Sherwin, Sex Hormones and Psychological Functioning in Postmenopausal Women, Experimental Gerontology, Vol. 29, Nos. 3&4, pp. 423-430 (May- August 1994).	
	1252.	Sherwin, et al., Androgen Enhances Sexual Motivation in Females: a Prospective Crossover Study of Sex Steroid Administration in the Surgical Menopause, Psychosom Med, Jul.-Aug. 1985; 47(4): 339-51.	
	1253.	Sherwin, et al., Postmenopausal Estrogen and Androgen Replacement and Lipoprotein Lipid Concentrations, Am J Obstet Gynecol, Feb. 1987; 156(2): 414-9.	
	1254.	Sherwin, et al., The Role of Androgen in the Maintenance of Sexual Functioning in Oophorectomized Women, Psychosomatic Medicine, 49: 397-409 (1987).	
	1255.	SHIBASAKA, Effect of Testosterone Replacement Therapy on Serum PSA in Patients with Klinefelter Syndrome, Archives of Andrology, Vol. 47, pp. 173-176 (2001).	
	1256.	Shifren, et al, Transdermal Testosterone Treatment in Women with Impaired Sexual Function After Oophorectomy, The New England Journal Of Medicine, Vol. 343, No. 10, pp. 682-688 (September 7,2000). [Abstract]	
	1257.	Shifren, et al., Do women with impaired sexual function following oophorectomy benefit from transdermal testosterone at a physiologic dose? The Journal of Family Practice, Vol. 49 (No. 12), pp. 1148 (December 2000)	
	1258.	SHIMIZU, et al., Androgen-Induced Production of Colony-Stimulating Factor (CSF) and Colony-Inhibitory Factor (CIF) in the Submandibular Gland in Female Mice, Journal of Pharmacobi-Dyn., Vol. 12 (6), pp. 352-356, (January 22,1989).	
	1259.	Shirai, et al., Effects of Testosterone, Dihydrotestosterone and Estrogen on 3,2'-Dimethyl-4-Aminobiphenyl-Induced Rat Prostate Carcinogenesis, Int J Cancer, Apr. 15, 1994; 57(2):224-8.	
	1260.	SHOULS, ET AL., Contact Allergy to Testosterone in an Androgen Patch: Control of Symptoms by Pre-Application of Topical Corticosteroid, Contact Dermatitis, p.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		124-125, (August 22, 2001).	
	1261.	Shuster et al., The influence of age and sex on skin thickness, skin collagen and density. British Journal of Dermatology 93:639 (1975).	
	1262.	Sidh, et al., Adenocarcinoma of Prostate: Role of 17beta-Estradiol and 5alpha-Dihydrotestosterone Binding Proteins, Urology, Jun. 1979; 13(6): 597-603.	
	1263.	Signorello, et al., Serum Steroids in Relation to Prostate Cancer Risk in a Case-Control Study (Greece), Cancer Causes Control, Jul. 1997; 8(4): 632-636.	
	1264.	SIMMS, Use of Male Sex Hormone is Growing, Wisconsin State Journal (July 29, 2002).	
	1265.	Simon et al., Androgen Therapy Improves Insulin Sensitivity and Decreases Leptin Level in Healthy Adult Men with Low Plasma Total Testosterone , Diabetes Care, Vol. 24, No. 12, pgs. 2149-2151 (December 2001)	
	1266.	Simon HB, On call. My wife and I are both 62 and healthy. She started taking Prempro during her menopause eight years ago but has now decided to stop the hormones. I began taking DHEA five years ago, but I switched to AndroGel when my doctor gave me a prescription last year. Should I stay on AndroGel, go back to DHEA, or stop hormones? Harv Mens Health Watch. 2003 Jan;7(6):8.	
	1267.	SIMON, et al., Association Between Plasma Total Testosterone and Cardiovascular Risk Factors in Healthy Adult Men: The Telecom Study, J. of Clin. Endocrinology and Metabolism, Vol. 82, No. 2, pp. 682-685 (1997).	
	1268.	SIMON, ET AL., Safety Profile: Transdermal Testosterone Treatment of Women After Oophorectomy, Obstetrics & Gynecology, Vol. 97 (Suppl. 4), DD. 10S-11S (April 2001),	
	1269.	Simon, et al., Percutaneous Absorption of 17 Beta-Estradiol in Ovariectomized Rhesus Monkeys: Skin and Serum Pharmacokinetics. Fertility and Sterility, vol. 53, No. 3, pp. 561-565 (Mar. 1990).	
	1270.	Simon, et al., The Absorption of Oral Micronized Progesterone: The Effect of Food, Dose Proportionality, and Comparison With Intramuscular Progesterone. Fertility and Sterility, vol. 60, No. 1, pp. 26-33 (Jul. 1993).	
	1271.	Sinaki M et al. Relationship between bone mineral density of spine and strength of back extensors in healthy postmenopausal women. Mayo Clin Proc 61:116 (1986).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1272.	Sinaki M. Exercise and osteoporosis. Arch Phy Med Rehab 70:220 (1989).	
	1273.	SINGH, et al., Pharmacokinetics of a Transdermal Testosterone System in Men with End Stage Renal Disease Receiving Maintenance Hemodialysis and Healthy Hypogonadal Men, The J. of Clinical Endocrinology & Metabolism, Vol. 86, No. 6, pp. 2437-2445 (2001).	
	1274.	SINGH, et al., The Effects of Varying Doses of T on Insulin Sensitivity, Plasma Lipids, Apolipoproteins, and C-Reactive Protein in Healthy Young Men, The J. of Clin. Endocrinology & Metabolism, Vol. 87, No. 1, pp. 136-143 (2002).	
	1275.	Sinha-Hikim et al., The Use of a Sensitive Equilibrium Dialysis Method for the Measurement of Free Testosterone Levels in Healthy, Cycling Women and in HIV-Infected Women, J. CLINICAL ENDOCRINOLOGY & METABOLISM 83:1312-18. (1998)	
	1276.	Sinkula et al., Rationale for design of biologically reversible drug derivatives: prodrugs. J. Pharm. Sci., 64:181-210 (1975).	
	1277.	Sitruk-Ware, Percutaneous and Transdermal Oestrogen Replacement Therapy, Annals of Medicine, Vol. 25, pp. 77-82 (1993).	
	1278.	Skakkebaek, et al., Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study, Clinical Endocrinology (1981) 14, 49-61.	
	1279.	SLATER, ET AL., Pharmacokinetics of Testosterone After Percutaneous Gel or Buccal Administration Fertility and Sterility, Vol. 76 (No.1), D. 32-37 (July 22 2001).	
	1280.	Slayden SM., Risks of menopausal androgen supplementation, Semin Reprod Endocrinol. 1998;16(2):145-52.	
	1281.	SMERDELY, et al., Predictors of Bone Mass in Healthy Older Men in the Community, MJA, Vol. 173, pp. 183-186 (August 21, 2000).	
	1282.	SMILEY, Male Menopause, National Public Radio The Tavis Smiley Show Online (August 13, 2002).	
	1283.	SMITH, et al., The Nature of Prostate Cancer Detected Through Prostate Specific Antigen Based Screening, The J. of Urol., Vol. 152, pp. 1732-1736 (November	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		1994).
	1284.	SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available, International Association of Physicians in AIDS Care, http://www.iapac.org/clinmgt/compnews/sb061297.html (June 12, 1997).
	1285.	Snitker T. The Nation Takes a 'Time Out for Men's Health' – Free Health Screenings for Men Across the U.S., WCNC-TV (NBC) Online (June 11, 2002).
	1286.	Snow-Harter C et al. Muscle strength as a predictor of bone mineral density in young women. J. Bone Miner Res 5:589 (1990).
	1287.	Snyder ET AL. Effect of testosterone treatment on body composition and muscle strength in, men over 65 years of age. J Clin Endocrinol Metab 84:2647-53, 1999.
	1288.	Snyder et al. Treatment of Male Hypogonadism with Testosterone Enanthate. J. Clinical Endocrinology and Metabolism 51(5): 1335-9 (1980).
	1289.	Snyder et al., Effects of Testosterone Replacement in Hypogonadal Men, J. Clin. Endocrinol. Metab., 85:2670-7 (2000)
	1290.	SNYDER, Effects of Age on Testicular Function and Consequences of Testosterone Treatment, The J. of Clinical Endocrinology & Metabolism, Vol. 86, No. 6, pp. 2369-2372 (2001).
	1291.	Snyder, et al., Effect of Testosterone Treatment of Bone Mineral Density in Men Over 65 Years of Age, The Journal of Clinical Endocrinology and Metabolism, vol. 84, No. 6, pp. 1966-1972 (1999).
	1292.	Sobel, S. Clinical Considerations of Transdermal Drugs. Chapter 24, pp. 431-436. Topical Drug Bioavailability, Bioequivalence, and Penetration (eds. Shah, VP and Maibach, HI).1993.
	1293.	Solvay Eyes Acquisitions, Confirms FY Double-Digit Growth, Dow Jones News Service, July 31, 2002.
	1294.	SOLVAY PHARMACEUTICALS; AndroGel1%, Online, December 2000, pp. 1-2.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1295.	Solvay Pharmaceuticals, Estratest Prescribing and Safety Information and Patient Information (2005).	
	1296.	Southren A. L., et al., Further study of factors-affecting the metabolic clearance rate of testosterone in man, J. Clin. Endocrinol. Metab. 1968; 28:1105-1112	
	1297.	Spark et al., Dihydrotestosterone gel: a novel androgen for AIDS wasting syndrome. 79th Annual Meeting of the Endocrine Society (Abstract) 1997.	
	1298.	Sparrow D et al. The influence of age, alcohol consumption, and body build on gonadal function in men. J. Clin. Endocrinol. Metab. 51: 508 (1980).	
	1299.	SPECTOR, et al., Free and Serum Testosterone Levels in 276 Males: A Comparative Study of Rheumatoid Arthritis, Ankylosing Spondylitis and Healthy Controls, Clinical Rheumatology, Vol. 8, No. 1, pp. 37-41 (1989).	
	1300.	SPECTOR, et al., Low Free Testosterone Levels in Rheumatoid Arthritis, Annals of the Rheumatic Diseases, Vol. 47, pp. 65-68 (1988).	
	1301.	STAFFORD, et al., Androgen Deficiency and Bone Mineral Density in Men with Rheumatoid Arthritis, The J. of Rheumatology, Vol. 27, No. 12, pp. 2786-2790 (2000).	
	1302.	Stahl, et al., Effects of Tamoxifen on the Levels of Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), Prolactin (PRL), 17 beta-oestradiol (E2), Total and Free Testosterone (T) and Total and Free Dihydrotestosterone (DHT) in blood of Patients	
	1303.	Stanley HL et al. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men. J. Am Ger Soc 39:766 (1991).	
	1304.	Stearns EL et al. Declining testicular function with age, hormonal and clinical correlates. Am J. Med 57:761 (1974).	
	1305.	Stehli, et al., Info . . . , Info . . . , Info . . . --Androgel, www.mageos.ifrance.com/nade38/androgel (Downloaded May 9, 2001).	
	1306.	Steidle et al. AA2500 Testosterone Gel Normalizes Androgen Levels in Aging	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		Males with Improvements in Body Composition and Sexual Function. J. Clinical Endocrinology & Metabolism 88(6):2673-2681 (2003).	
	1307.	Stepan JJ et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J. Clin Endocrinol. Metab. 69:528 (1989).	
	1308.	STEPHAN, et al., Prostate-Specific Antigen, Its Molecular Forms, and Other Kallikrein Markers for Detection of Prostate Cancer, Urology, Vol. 59, pp. 2-8 (2002).	
	1309.	STEPHENSON, As Genes Differ, So Should Interventions for Cancer, JAMA, Vol. 285, No. 14, pp. 1829-1830 (April 11, 2001).	
	1310.	Sternbach, Age-Associated Testosterone Decline in Men: Clinical Issues for Psychiatry. Am. J. Psychiatry (1998) vol 155(10), pp 1310-1318.	
	1311.	Stineman MG, Shea JA, Jette A, Tassoni CJ, Ottenbacher KJ, Fiedler R, Granger CV: The functional independence measure: tests of scaling assumptions, structure, and reliability across 20 diverse; impairment categories. Arch Phys Med Rehab 77:1101-8, 1996.	
	1312.	Stomati, et al., Effects of Hormonal Replacement Therapy on Plasma Sex Hormone-Binding Globulin, Androgen and Insulin-Like Growth Factor-1 Levels in Postmenopausal Women, Journal of Endocrinological Investigation, Vol. 19 (No.8), p. 535-541, (January 22, 1996).	
	1313.	STOMATI, ET AL., Endocrine, Neuroendocrine and Behavioral Effects of Oral Dehydroepiandrosterone Sulfate Supplementation in Postmenopausal Women, Gynecological Endocrinology, Vol. 13 (No. 1), p.134 15-25, (January 22, 1999).	
	1314.	Strategy for Change: Pharmaceuticals Represent a Major Direction of Solvay's Growth Strategy and the Objective is to Have the Pharmaceutical Business Grow More Rapidly, Med Ad News (West Trenton, NJ), September 2002.	
	1315.	STRAUB, et al., Involvement of the Hypothalamic-Pituitary-Adrenal/Gonadal Axis and the Peripheral Nervous System in Rheumatoid Arthritis: Viewpoint Based on a Systemic Pathogenetic Role, Arthritis & Rheumatism, Vol. 44, No. 3, pp. 493-507	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		(March 2001).
	1316.	STRAWFORD, et al., Effects of Nandrolone Decanoate Therapy in Borderline Hypogonadal Men with HIV-Associated Weight Loss, J. of AIDS and Human Retrovirology, Vol. 20, pp. 137-146 (1999).
	1317.	Studd, et al., The Relationship Between Plasma Estradiol and the Increase in Bone Density in Postmenopausal Women After Treatment with Subcutaneous Hormone Implants, American Journal Of Obstetrics And Gynecology, Vol. 163, No.5 (Part 1), pp. 1474-1479 (November 1990).
	1318.	Stuenkel, et al, Sublingual Administration of Testosterone-Hydroxypropyl-.beta.-Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men, Journal of Clinical Endocrinology and Metabolism, vol. 72, No. 5, pp. 1054-1059 (1991).
	1319.	Sturdee, D. W., et al. Br. J. Obstet. Gynecol. (1997) 104:109-115
	1320.	Styne, D., Puberty, Basic and Clinical Endocrinology, 6th Edition, Greenspan F S and Gardner D G, ed. McGraw-Hill, New York, 2001.
	1321.	Suchner, U., M. M. Rothkopf, G. Stanislaus, D. H. Elwyn, V. Kvetan, and J. Askanazi. Growth hormone and pulmonary disease - Metabolic effects in patients receiving parenteral nutrition. Arch. Intern. Med. 150: 1225-1230 (1990).
	1322.	Suenderhauf et al., Therapy of menopausal syndrome with a combination of ovocyclin and perandren. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, vol. 32, no. 22, 31 May 1952 (1952-05-31), pages 589-590.
	1323.	SURBER et al., Optimization of Topical Therapy: Partitioning of Drugs into Stratum Corneum, Pharmaceutical Res., Vol. 7(12), pp. 1320-1324 (1990)
	1324.	SUSMAN, 'Male Menopause' Therapy Hotly Debated, The Palm Beach Post, August 28, 2002.
	1325.	SVETEC, et al., The Effect of Parenteral Testosterone Replacement on Prostate Specific Antigen in Hypogonadal Men with Erectile Dysfunction, The J. of Urol., Vol. 158, pp. 1775-1777 (November 1997).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1326.	Swerdloff RS et al. Androgen replacement therapy. In Current Therapy in Endocrinology and Metabolism (4th edition), Bardin C.W. (Ed) Decker, Philadelphia pp. 255 (1991).	
	1327.	Swerdloff RS, et al. Transdermal testosterone (T) gel is efficacious and safe in older compared to young men. Poster presentation #P2-648 at the 84th Annual Meeting of the Endocrine Society, June 19-22, 2002, San Francisco, CA.	
	1328.	Tan KC et al. Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. Clin Endocrinol (Oxf). 51(6):765-9 (1999).	
	1329.	TANGREDI, ET AL., Hypertension as a Complication of Topical Testosterone Therapy. The Annals of Pharmacotherapy, Vol. 35 (No. 10), p. 1205-1207 (October 22 2001).	
	1330.	TDS Delivers Testosterone safely and effectively. Press release. 10/1/04.	
	1331.	TEICHERT, A Man's Pain: Age-Related Testosterone Loss in Men, Coined by One Doctor as Mano-Pause, Fuels Medical Debate, The Montgomery Journal (Rockville, MD), July 9, 2002.	
	1332.	TEICHERT, Manopause: Experts Seeking Treatments for Middle-Age Male Testosterone Deficiency, Sacramento Bee, May 19, 2002.	
	1333.	TENNANT, PSA Levels, IPPS Scores Normal: Transdermal Testosterone Gel Safe Over Long Term, Urology Times (Cleveland, OH), October 2002.	
	1334.	Tenover JL: Testosterone and the aging male. J Androl 18:103-106, 1997.	
	1335.	Tenover JS et al. Serum bioactive and immunoreactive follicle-stimulating hormone levels and the response to clomiphene in healthy young and elderly men. J. Clin. Endocrinol. Metab. 64:1103 (1987).	
	1336.	Tenover JS. Effects of testosterone supplementation in the aging male. J. Clin Endocrinol. Metab. 75:1092-1098 (1992).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1337.	Tenover, et al., Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men. <i>J Gerontol</i> , Nov. 1988; 43(6): M163-9.	
	1338.	Tenover, et al., The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate, <i>J Clin Endocrinol Metab</i> , Dec. 1987; 65(6): 1118-1126.	
	1339.	Testim 1% (Testosterone Gel) CIII.	
	1340.	Testim 1% (Testosterone Gel), Physician Desk Reference, pp. 711-713 (2004).	
	1341.	TestoCreme - A Natural Transdermal Testosterone Replacement Therapy, www.testocreme.com .	
	1342.	Testocreme - No Shots, No Pills, No Patches, www.testocreme.com (Downloaded 7/10/00).	
	1343.	Testocreme Transdermal Testosterone Is New, Preventive Medicine Clinic Of Monterey, http://www.wellnessmd.com/testo.html .	
	1344.	Testosterone Aids Post-Menopausal Women, BBC News Online: Health, www.bbc.co.uk . (Jun. 14, 1999).	
	1345.	Testosterone Gel May Help Men with Low Sex Drive, WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/0814-tgel/ (August 14, 1997).	
	1346.	Testosterone Gel May Help Men with Low Sex Drive, WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/0814-tgel/ (August 14, 1997)	
	1347.	Testosterone gel plus Sildenafil Improves Sexual Performance in Sildenafil Non-Responders , filed in Australian counterpart AU2001286995.	
	1348.	Testosterone Patch Treats Sexual Dysfunction in Women, Biomedical Technology Information Service Vol. 23 (No. 21), pp. 244 (December 1996).	
	1349.	Testosterone Patch Trial for Women with AIDS, Pharmaceutical Business News. Vol. 12 (No. 275), pg. 19 (September 14 1996).	
	1350.	Testosterone Replacement Therapy: Effective Treatments Are Available, MayoClinic.com (February 26, 2002).	
	1351.	Testosterone Therapy--for Women?, Health News, www.onhealth.com (May 7, 1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1352.	Testosterone Undecanoate - Schering AG. Drugs RD. 2004; 5(6):368-9.	
	1353.	Testosterone's Role in the Female Sex Drive, USA Today News, www.usatoday.com (Apr. 8, 1996).	
	1354.	Testosterone-Topical Fortigel – Cellegy: Fortigel Tostrex, BioDrugs, Vol. 17(4), pp. 299-300 (2003) (No authors listed).	
	1355.	The Male Body: A Physician's Guide to What Every Man Should Know About His Sexual Health. CBS-TV The Early Show Online:Eye On Health (Aug. 30, 2002)	
	1356.	The Nation Takes a 'Time Out for Men's Health' – Free Health Screenings for Men Across the U.S., Yahoo!Finance.com (June 11, 2002).	
	1357.	The Testosterone Source, http://www.testosteronesource.com (1998)	
	1358.	THOMPSON, Hey Guys, If You Have Your Health..., HealthScoutNews, http://www.healthscoutnews.com/view.cfm?id=507614 (June 12, 2002).	
	1359.	THOMPSON, et al., Effect of Intravenous Testosterone on Myocardial Ischemia in Men with Coronary Artery Disease, Am. Heart J., Vol. 143, pp. 249-256 (2002).	
	1360.	Time Out for Men's Health, The Weekly Planet (Tampa, FL), November 4, 2004.	
	1361.	Tirassa, et al., High-Dose Anabolic Androgenic Steroids Modulate Concentrations of Nerve Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain, Journal of Neuroscience Research, vol. 47, No. 2, pp. 198-207 (Jan. 15, 1997).	
	1362.	Tostran 2% Gel Medicinal Guide, available at http://emc.medicines.org.uk/printfriendlydocument.aspx?documentid=19702&companyid .	
	1363.	Toutiou E, et al. Enhanced Delivery of Drugs Into and Across the Skin by E ethosomal Carriers, Drug Development Research, Vol. 50 pp. 406-415 (2000)	
	1364.	Toutiou E, et al. E ethosomes - Novel Vesicular Carriers for Enhanced Delivery: Characterization and Skin Penetration Properties, Journal of Controlled Release, Vol. 65 pp. 403-418 (2000)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1365.	Traish et al., Effects of Castration and Androgen Replacement on Erectile Function in a Rabbit Model, <i>Endocrinology</i> 140:1861 (1999)	
	1366.	Transdermal Technologies Profile. Available at pharmalicensing.com/company/dc/2252 . (12/16/04).	
	1367.	Transdermal Testosterone, Cellegy Pharmaceuticals, www.Cellegy.com . Downloaded on 10/21/02.	
	1368.	Transpharma Medical, Product Applications: Testosterone, www.transpharma-medical.com/product_apps_testosterone.html (downloaded 12/16/2004).	
	1369.	TRBOVICH, Drug Development & Biotechnology Companies, The Wall Street Transcript (New York, NY), February 4, 2002, at 18-24.	
	1370.	Trials for the Treatment of Wasting, AIDS Treatment Data Network, www.aidsinfo.org (Downloaded Oct. 8, 1998).	
	1371.	Tsai et al., Effect of Barrier Disruption by Acetone Treatment on the Permeability of Compounds with Various Lipophilicities: Implications for the Permeability of Compromised Skin, <i>Journal of Pharmaceutical Sciences</i> , Vol. 90, pp. 1242-1254, 2001.	
	1372.	Tsai, et al., Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors, <i>J Pharm Sci</i> , Jun. 1996; 85(6): 643-648.	
	1373.	Tsouras, Effects of Age on Testicular Function, <i>Endocrinology and Metabolism Clinics</i> , vol. 16, No. 4, p. 1045-1059 (Dec. 1987).	
	1374.	Tuiten, et al., Time Course of Effects of Testosterone Administration on Sexual Arousal in Women, <i>Arch Gen Psychiatry</i> , Feb. 2000; 57(2): 149-53.	
	1375.	TULLER, Competitors to Viagra Get Ready to Rumble, <i>N.Y. Times</i> , September 23, 2002.	
	1376.	Tutten, et al., Discrepancies Between Genital Responses and Subjective Sexual Function during Testosterone Substitution in Women with Hypothalamic Amenorrhea, <i>Psychosom Med</i> , May-Jun. 1996; 58(3): 234-41.	
	1377.	TYMCHUK, et al., Role of Testosterone, Estradiol, and Insulin in Diet- and Exercise-Induced Reductions in Serum-Stimulated Prostate Cancel Cell Growth in	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		Vitro, Nutrition and Cancer, Vol. 42, No.1, pp. 112-116 (2002).
	1378.	UK PROSPECTIVE DIABETES STUDY GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) THE LANCET, vol. 352, 12 September 1998 (1998-09-12), pages 854-865.
	1379.	UK PROSPECTIVE DIABETES STUDY GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33) THE LANCET, vol. 352, 12 September 1998 (1998-09-12), pages 837-53.
	1380.	Ulrich D, et al., The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone Bone, 25:55-60 (1999).
	1381.	Unimed Pharmaceuticals' AndroGel Shows Solid Promise for Men, Fertility Industry News, www.INCIID.com (Aug. 19, 1998).
	1382.	Unimed pharmaceuticals initiates phase III geriatric hypogonadism study in elderly men: Broad US patent covering DHT delivery for androgen therapy is issued. Unimed News Release, September 10, 1997.
	1383.	Urban RJ, Bodenbough YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A: Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 269:E820-6, 1995.
	1384.	Urman B., et al., Elevated serum testosterone, hirsutism and virilism associated with combined androgen-estrogen hormone replacement therapy, Obstet. Gynecol., 1991; 77:595-598.
	1385.	USP Drug Information--Anabolic Steroids (Systemic), MayoClinic, www.mayohealth.org (Downloaded Oct. 8, 1998).
	1386.	Valero-Politi, et al., Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men, Clinica Chimica Acta, Vol.271, No.1, pp. 57-71 (March 9,1998).
	1387.	Valero-Politi, et al., Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men, Eur J Clin Chem Clin Biochem, Jun. 1996; 34(6): 455-462.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	1388.	Van Den Beld AW, Huhtaniemi IT, Pettersson KSL, Pols HAP, Grobbee DE, De Jong FH, Lamberts SWJ: Luteinizing hormone and different genetic variants, as indicators of frailty in healthy elderly men. <i>J Clin Endocrinol Metab</i> 84:1334-9, 1999.
	1389.	Van Gaal, et al., Sex Hormones, Body Fat Distribution, Resting Metabolic Rate and Glucose-Induced Thermogenesis in Premenopausal Obese Women, <i>Int J Obes Relat Metab Disord</i> , May 1994; 18(5): 333-8.
	1390.	van Honk, et al., Correlations Among Salivary Testosterone, Mood, and Selective Attention to Threat in Humans. <i>Horm Behav</i> . Aug. 1999; 36(1): 17-24.
	1391.	Van Scott et al., Typerkeratinization, Corneocyte Cohesion, and Alpha Hydroxy Acids, <i>J. Am Acad Dermatol</i> 11:867-879 (1984).
	1392.	Vaubourdolle, et al., Effect of Dihydrotestosterone on the Rate of Ethanol Elimination in Healthy Men. <i>Alcohol Clin. Exp. Res.</i> , vol. 15, No. 2, pp. 238-240 (Mar. 1991).
	1393.	Vedi S, et al., Effects of hormone replacement therapy on cancellous bone microstructure in postmenopausal women. <i>Bone</i> , 19:69-72 (1996).
	1394.	Veldhuis JD et al. Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging in men. <i>J. Clin. Endocrinol. Metab.</i> 75:707-713 (1992).
	1395.	Veldhuis, et al., Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men, <i>The Journal of Clinical Endocrinology & Metabolism</i> , vol. 86, No. 2, pp. 529-535. (200
	1396.	Vergel, Anabolic Steroids: A Practical Guide, CRIA Update, vol. 7, No. 3 (Summer 1998).
	1397.	Vermeulen A et al. Testosterone secretion and metabolism in male senescence. <i>J. Clin. Endocrinol. Metab.</i> 34:730 (1972).
	1398.	Vermeulen A. Androgens in aging male. <i>J. Clin. Endocrinol. Metab.</i> 73:221 (1991).
	1399.	Vermeulen A. Nyctohemeral growth hormone profiles in young and aged men: correlation with somatomedin-C levels. <i>J. Clin. Endocrinol. Metab.</i> 64:884 (1987).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	1400.	Vermeulen, et al., Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins, <i>Maturitas</i> , Vol. 7, pp. 281-287 (1985).
	1401.	Vetter et al., Quantitative Determination of Isostearic Acid Isomers in Skin Creams by GC-MS-SIM, <i>Chromatographia</i> 2009, 70, July (No. 1/2). pp: 157-164.
	1402.	Viagra and Testocreme Together, www.testocreme.com (downloaded 2/28/02).
	1403.	Vijayakumar, et al., Results of a Study to Correlate Serum Prostate Specific antigen Reproductive Hormone Levels in Patients with Localized Prostate Cancer. <i>J Natl Med Assoc</i> , Nov. 1995; 87(11): 813-9.
	1404.	Vogel W, Klaiber EL, Broverman DM. Roles of gonadal steroid hormones in psychiatric depression in men and women. <i>Prog. Neuro-Psychopharmacol</i> 2: 487-503 (1978)
	1405.	Voigt, et al., The Role of Tissue Steroids in Benign Hyperplasia and Prostate Cancer, <i>Urologe [A]</i> , Nov. 1987; 26(6):349-57.
	1406.	WAGNER, et al., A Comparative Analysis of Standard and Alternative Antidepressants in the Treatments of Human Immunodeficiency Virus Patients, <i>Comprehensive Psychiatry</i> , Vol. 37, No. 6, pp. 402-408 (November/December 1996).
	1407.	WAGNER, et al., Exercise as a Mediator of Psychological and Nutritional Effects of Testosterone Therapy in HIV+ Men, <i>Official Journal of the American College of Sports Medicine</i> , pp. 811-817 (1998).
	1408.	WAGNER, et al., Testosterone as a Treatment for Fatigue in HIV+ Men, <i>Gen. Hospital Psychiatry</i> , Vol. 20, pp. 209-213 (1998).
	1409.	Walters, Penetration Enhancers and Their Use in Transdermal Therapeutic Systems, pp. 202-227 (1990).
	1410.	WANDELL, et al., Assessing Sexual Functioning in Patients with Chronic Disorders by Using a Generic Health-Related Quality of Life Questionnaire, <i>Quality of Life Research</i> , Vol. 9, pp. 1081-1092 (2001).
	1411.	Wang C, et al. Does pretreatment testosterone affect responsiveness to long term transdermal testosterone gel (Androgel) in hypogonadal men. Poster presentation

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
		#P2-166 at the 85th Annual Meeting of the Endocrine Society, June 19-22, 2003, Philadelphia, PA.	
	1412.	Wang C, et al. Long term efficacy and safety of transdermal testosterone gel (AndroGel) in hypogonadal men. Poster presentation #P2-646 at the 84th Annual Meeting of the Endocrine Society, June 19-22, 2002, San Francisco, CA.	
	1413.	Wang et al., Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean, and Fat Mass, and Bone Mineral Density in Hypogonadal Men , J. Clin. Endocrinol. Metab., Vol. 85, No.5, pgs. 2085-2098 (May 2004).	
	1414.	Wang et al., Male Reproductive Function, Kluwer Acad. Publ. (May 1999). Table of Contents.	
	1415.	Wang J. et al. Body fat from body density: underwater weighing vs dual-photon absorptiometry. Am J. Physiol 256:E829 (1989).	
	1416.	Wang, et al., Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men, Clinical Endocrinology, Vol. 54, pp. 1-13 (2001). [Abstract]	
	1417.	Wang, et al., Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men, Clinical Science: Reproduction (Male)-Prostate, Male Reproduction Poster Session, No. 2348 , Board 579 (June 22, 2000).	
	1418.	Wang, et al., Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone, Journal Of Clinical Endocrinology And Metabolism, Vol. 53, No.5, pp. 1021-1024 (November 1981).	
	1419.	Wang, et al., Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men, Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, The Endo Society No. 1360 ENDO 2000) (June 24, 2000).	
	1420.	WANG, et al., Effects of Transdermal Testosterone Gel on Bone Turnover Markers WANG Bone Mineral Density in Hypogonadal Men, Clinical Endocrinology, Vol. 54, pp. 739-750 (2001). [Abstract]	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/829,618
	Filing Date	April 20, 2004
	Inventor(s)	Dudley et al.
	Art Unit	1627
	Examiner Name	Jean-Louis, Samira
	Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	1421.	Wang, et al., Pharmacokinetics Of Transdermal Testosterone Gel In Hypogonadal Men, Abstract P2-51, 80th Annual Meeting of the Endocrine Society, New Orleans, Louisiana, June 1998 (ENDO '98)
	1422.	WANG, ET AL., 'New Androgen Formulations, The Endocrine Society, No. 167 (ENDO 2000),
	1423.	Wang, et al., Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men--A Clinical Research Center Study, J Clin Endocrinol Metab. 1996 Oct;81(10):3654-62.
	1424.	Wang, et al., Testosterone Replacement Therapy Improves Mood in Hypogonadal Men--A Clinical Research Center Study, Journal of Clinical Endocrinology and Metabolism, vol. 81, No. 10, pp. 3578-3583 (1996).
	1425.	Warner BA et al. Effects of aging and illness on the pituitary testicular axis in men: qualitative as well as quantitative changes in luteinizing hormone. J. Clin. Endocrinol. Metab. 60:263-268 (1985).
	1426.	Warnock JK, et al., Female hypoactive sexual desire disorder due to androgen deficiency: clinical and psychometric issues, Psychopharmacol Bull. 1997;33(4):761-6.
	1427.	Watts, et al. Comparison of Oral Estrogens and Estrogens Plus Androgen on Mineral Density, Menopausal Symptoms, and Lipid-Lipoprotein Profiles in Surgical Menopause, Obstet Gynecol, Apr. 1995; 85(4):529-37.
	1428.	WEBB, et al., Effect of Acute Testosterone on Myocardial Ischemia in Men with Coronary Artery Disease, Am. J. of Cardiol., Vol. 83, No. 3, pp. 437-439, A9 (February 1, 1999).
	1429.	WEBB, et al., Effects of Testosterone on Coronary Vasomotor Regulation in Men with Coronary Heart Disease, Circulation, Vol. 100, pp. 1690-1696 (1999).
	1430.	Weekend datebook: Nov 14-17 – Time Out for Men's Health, The Seattle Times, November 14, 2002.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1431.	Weinbauer et al., Pharmacokinetics and Pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ACTA Endocrinologica (COPENH) 122(4):432-444 (1990).	
	1432.	Weiner DK, Bongiorni DR, Studenski SA, Duncan PW, Kochersberger GG: Does functional reach improve with rehabilitation? Arch Phys Med Rehabil 74:796-800, 1993.	
	1433.	Weiner DK, Duncan PW, Chandler J, Studenski SA: Functional reach: a marker of physical frailty. J Amer Geriatr Soc 40:203-7, 1991.	
	1434.	Weinstein et al., Topical methotrexate therapy for psoriasis. Arch Dermatol. 1989; 125(2):227-230. Exhibit to the Declaration by Norman Weiner filed 10-13-2009 in U.S. Ser. No. 11/549083.	
	1435.	Weissberger AJ, Ho KKY: Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization. J Clin Endocrinol Metab 76:1407-1412, 1993.	
	1436.	Westaby et al., LIVER DAMAGE FROM LONG-TERM METHYLTESTOSTERONE, The Lancet, Volume 310, Issue 8032, Pages 261-263	
	1437.	Wheeler, M D, Endocrinol and Metab Clin N. Am., 20(1):1-14 (1991)	
	1438.	Whittaker, J. S., C. F. Ryan, P.A. Buckley, and J. D. Road. The effects of refeeding on peripheral and respiratory muscle function in malnourished chronic obstructive pulmonary disease patients. Am. Rev. Respir. Dis. 142: 283-288 (1990).	
	1439.	Willemse, et al., No Change in Plasma Free Testosterone Ratio and Plasma Sex Hormone-Binding Globulin Concentration During hCG Stimulation, Journal Of Clinical Endocrinology And Metabolism, Vol. 58, No.6, pp. 1193-1196 (June 1984).	
	1440.	Wilson JD, Androgen abuse by athletes. Endocr Rev 9:181 (1988).	
	1441.	Wilson, D.O., R. M. Rogers, and R. M. Hoffinan. Nutrition and chronic lung disease. Am. Rev. Respir. Dis. 132: 1347-1365 (1999).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/829,618
Filing Date	April 20, 2004
Inventor(s)	Dudley et al.
Art Unit	1627
Examiner Name	Jean-Louis, Samira
Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	1442.	WILSON, ET AL., Use of Topical Corticosteroid Pretreatment to Reduce the Incidence and Severity of Skin Reactions Associated with Testosterone Transdermal Therapy, Clinical Therapeutics Vol. 20 (No.2), p. 299-306, (January 22 1998).
	1443.	Wilson, The Pathogenesis of Benign Prostatic Hyperplasia, Am J Med, May 1980; 68(5): 745-56.
	1444.	Winters SJ et al. Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. J. Clin Endocrinol. Metab. 55:560 (1982).
	1445.	WINTERS, Current Status of Testosterone Replacement Therapy in Men, Arch. Fam. Med., Vol. 8, pp. 257-263 (1999).
	1446.	WINTERS, et al., LH, Non-SHBC Tesosterone and Estradiol Levels During Testosterone Replacement of Hypogonadal Men: Further Evidence that Steroid Negative Feedback Increases as Men Grow Older, Journal of Andrology, December 3, 2009 (Published-Ahead-of-Print).
	1447.	WINTERS, et al., Pituitary-Testicular Function in Men with Testicular Failure Treated with a 2% Testosterone Gel: Further Evidence that Increased Testosterone Negative Feedback Contributes to the Gonadotropin Disturbances as Men Grow Older, P3-639, Endo Society 2008.
	1448.	WINTERS, et al., Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence That Ageing Enhances Testosterone Negative Feedback. The Testoderm Study Group, Clinical Endocrinology (OXF), Vol. 47, No. 3, pp. 317-322 (September 1997).
	1449.	Winters, The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men; Metabolism, Nov. 1984; 33(11): 1052-1059.
	1450.	WITTERT, et al., Androgen Deficiency in Aging Men, The Endocrine Society, No 126 (ENDO 2000)
	1451.	WOLF, et al., Testosterone and Cognition in Elderly Men: A Single Testosterone Injection Blocks the Practice Effect in Verbal Fluency, But Has No Effect on Spatial or Verbal Memory, Biol. Psychiatry, Vol. 47, pp. 650-654 (2000).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
	1452.	WOLK, et al., Insulin-like Growth Factor 1 and Prostate Cancer Risk: A Population-Based, Case-Control Study, J. of the Natl. Cancer Inst., Vol. 90, No. 12, pp. 911-915 (June 17, 1998).
	1453.	Women and HIV, Women and HIV Discussion Paper, pp. 1-12 (1/98).
	1454.	Women's Hormones: Testosterone, the Other Female Hormone, Harvard Women's Health Watch, September 2002, at 4-5.
	1455.	Wong TK et al. Bone mass response to testosterone replacement in hypogonadal men. J. Bone and Min Res Suppl 1. Abstract 1092 (1989).
	1456.	Woodford, et al., Optimization of Bioavailability of Topical Steroids: Thermodynamic Control, The Journal of Investigative Dermatology, vol. 79, No. 6, pp. 388-391 (Dec. 1982).
	1457.	Worboys, et al., Testosterone Therapy improves endothelium - dependent and endothelium - independent vasodilation in postmenopausal women on established hormone replacement therapy, The Endocrine Society (ENDO 2000)
	1458.	World Health Organization. Guidelines for the use of androgens in men. World Health Organization: Geneva (1992).
	1459.	WOZNICKI, Feature: Doctors Debate Hormones for Men, United Press International, August 8, 2002.
	1460.	Wu SZ, Weng XZ: Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chinese Med J 106:415-8, 1993.
	1461.	YAFFE, et al., Sex Hormones and Cognitive Function in Older Men, JAGS, Vol. 50, pp. 707-712 (2002).
	1462.	Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37-49, 1983.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	April 20, 2004
		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.	
	1463.	Yesavage JA, Davidson J. Widrow L, Berger PA. Plasma testosterone levels, depression, sexuality and age. Biological Psychiatry 20: 199-225 (1985)	
	1464.	Your health and Well-Being, SF-36v2™ survey © 1996, 2000 by Quality Metric Incorporated and Medical Outcomes Trust. 6 pages.	
	1465.	Yu Z et al. DeMonS--a new deconvolution method for estimating drug absorbed at different time intervals and/or drug disposition model parameters using a monotonic cubic spline. Biopharm Drug Dispos. 1997 Aug;18(6):475-87.	
	1466.	YU, et al., Sexual Development in a Two-Year-Old-Boy Induced by Topical Exposure to Testosterone, Pediatrics, Vol. 104(2), pp. 1-2 (1999).	
	1467.	Yu, et al., Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men, Journal of Clinical Pharmacology, Vol. 37, pp. 1139-1145 (1997).	
	1468.	Yu, et al., Transdermal Testosterone Administration in Hypogonadal Men:Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application, Journal of Clinical Pharmacology, Vol. 37, pp. 1129-1138 (1997).	
	1469.	ZAGARS, et al., Serum Testosterone – A Significant Determinant of Metastatic Relapse for Irradiated Localized Prostate Cancer, Urology, Vol. 49, No. 3, pp. 327-334 (1997).	
	1470.	Zartarian, et al., Comparative Evaluation of the Acceptability of a New Estradiol Gel TX11323(A) and a Reference Gel, J. Gynecol. Obstet. Biol. Reprod. (Paris), Vo. 25, No.5, pp. 451-456 (1996). [Abstract]	
	1471.	Zatz JL et al. Topical Protective and Cosmetic Products. Transdermal and Topical Drug Delivery Systems. Eds. Ghosh et al. Interpharm Press Inc., Illinois 1997.	
	1472.	Zeginiadou, et al., NonLinear Binding of Sex Steroids to Albumin and Sex Hormone Binding Globulin, Eur J Drug Metab Pharmacokinet, Jul. 1997; 22(3): 229-235.	
	1473.	Zetterberg C et al. Epidemiology of hip fractures in Goteborg, Sweden, 1940-1983. Clin Orth Rel Res 191:43 (1984).	
	1474.	ZHANG, et al., Association Between Prostate Cancer and Serum Testosterone	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	10/829,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 20, 2004
(Use as many sheets as necessary)		Inventor(s)	Dudley et al.
		Art Unit	1627
		Examiner Name	Jean-Louis, Samira
		Attorney Docket Number	003168.1043

Exam. Initial.	No.	Include name of Author, Title, Date, Pertinent Pages, Etc.
		Levels, The Prostate, Vol. 53, pp. 179-182 (2002).
	1475.	Zhao H et al. The effects of pressure-sensitive adhesives and solubilizers on the skin permeation of testosterone from a matrix-type transdermal delivery system. Drug Dev Ind Pharm. 2002 Oct;28(9):1125-31.
	1476.	Ziegler, T. R., C. F. Estivariz, C. R. Jonas, L. H. Gu, D. P. Jones, and L. M. Leader. Interactions between nutrients and peptide growth factors in intestinal growth, repair, and function. JPEN J. Parenter. Enteral Nutr. 23: S174-S183 (1999).
	1477.	Zimulti (rimonabant), NDA 21-888, Briefing Information for FDA Advisory Committee Meeting. May 10, 2007.
	1478.	Zmuda, et al., Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men, Metabolism, Vol. 45, No.8, pp. 935-939 (August 1996).
	1479.	Zonagen Product Pipeline, www.zonagen.com/html/product_pipeline.htm (downloaded 12/17/2004).
	1480.	Zonagen reports initial findings comparing Androxal to Androgel form from US Phase I/II safety and efficacy study in men with low testosterone. Press release. 7/15/04
	1481.	Zumoff B. et al. Age variation of the 24-hour mean plasma concentrations of androgens, estrogens and gonadotropins in normal adult men. J. Clin. Endocrinol. Metab. 54:534 (1982).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:698355.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.